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Abstract 
 
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum that spans 
simple steatosis, through steatohepatitis (NASH) to fibrosis and ultimately cirrhosis. 
NAFLD is characterised by substantial inter-patient variation in rate of progression 
and disease outcome: whilst up to 25% of the general population are at risk of 
progressive disease, only a minority experience associated liver-related morbidity. 
Inter-patient genetic variation and environment determine severity and progression of 
NAFLD. This thesis reports a series of studies examining the association of genetic 
variations in two genes patatin-like phospholipase domain-containing 3 (PNPLA3, 
rs738409 c.444 C>G, p.I148M) and transmembrane 6 superfamily member 2, 
(TM6SF2, rs58542926 c.449 C>T, p.E167K) with severity of NAFLD and risk of 
NAFLD-associated hepatocellular carcinoma (HCC).  
Addressing first the role of PNPLA3, I demonstrate that the rs738409 variant is 
associated with steatosis, steatohepatitis and fibrosis in the largest histologically 
characterised NAFLD cohort of European-Caucasian descent (n=1,005) studied to 
date. Subsequently, adopting a case-control analyses in a cohort of 100 consecutive 
Northern European Caucasian patients with NAFLD-associated HCC arising and a 
cohort of patients with histologically characterised NAFLD, I demonstrate that 
carriage of the rs738409 minor (G) allele is significantly associated with increased 
risk of developing NAFLD-associated HCC, independent of potential confounding 
factors including gender, age at diagnosis, presence of advanced fibrosis/cirrhosis, 
T2DM and BMI.  
During my studies, a genome-wide association study identified a SNP in TM6SF2 as 
a modifier of hepatic triglyceride accumulation measured by MR Spectroscopy. It was 
therefore pertinent to determine whether this variant also affected risk of 
steatohepatitis or fibrosis in NAFLD. Using the aforementioned cohorts, I 
demonstrate for the first time that, in addition to its association with steatosis, the 
rs58542926 SNP is significantly associated with stage of fibrosis in NAFLD. In 
contrast to PNPLA3 however, no association with NAFLD-HCC was found.  
In conclusion, the current thesis confirms the association of PNPLA3 with NAFLD 
severity and provides new evidence of its association with HCC risk. In addition, it 
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demonstrates for the first time that TM6SF2 is associated with NAFLD-fibrosis 
severity. These studies provide important new insights into NAFLD pathogenesis and 
mandate further functional study.  
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1.1 NAFLD 
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver 
dysfunction worldwide (Angulo, 2007; Yilmaz, 2012). It is estimated that one 
third of the population in Western countries is afflicted by NAFLD (Day, 2010), 
and the prevalence is increasing owing to its close association with metabolic 
syndrome (central obesity, insulin resistance/type 2 diabetes mellitus (T2DM), 
dyslipidaemia, hypertension and thus with cardiovascular disease (CVD)) 
(Sanyal and American Gastroenterological, 2002; Anstee et al., 2013b). 
NAFLD represents a spectrum of liver disease that ranges from steatosis to 
more progressive forms of non-alcoholic steatohepatitis (NASH), fibrosis, 
cirrhosis, and ultimately hepatocellular carcinoma (HCC) and liver failure 
without a history of excess alcohol consumption (Anstee et al., 2011b).  
Observations on fatty degeneration in the liver was first described by Thomas 
Addison in 1836 (Addison, 1836). A “fatty liver hepatitis” was first described by 
Adler and Schaffner more than three decades ago, discovering that the 
histopathological patterns of non-alcoholic patients resembled those of 
alcoholics (Adler and Schaffner, 1979). However, it was Ludwig that originally 
coined the term non-alcoholic steatohepatitis ‘’NASH’’ one year later (Ludwig 
et al., 1980) whilst describing a small group of 20 patients with fatty liver 
disease of unknown cause. The majority of these patients were obese and 
had comorbidities including hyperlipidaemia and diabetes. Their liver biopsy 
specimens were characterized by lobular hepatitis, focal necrosis with mixed 
inflammatory infiltrates and Mallory bodies, the most common histological 
feature of alcohol-induced liver disease (Ludwig et al., 1980). In line with the 
resemblance of histopathology between the two diseases, several other terms 
as pseudo-alcoholic liver disease, alcohol-like hepatitis, diabetic hepatitis, 
non-alcoholic Laennec’s disease and steatonecrosis had been adopted to 
refer to this entity prior to the umbrella term NAFLD which was first introduced 
in 1986 (Schaffner and Thaler, 1986; Sheth et al., 1997). Ever since then, 
both clinical and research interest in NAFLD has increased, with 
investigations encompassing heritability, diagnosis and natural history, the 
association with the metabolic syndrome, underlying mechanisms, and 
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developing possible pharmaceutical treatments (Dietrich and Hellerbrand, 
2014). 
 
1.2 Epidemiology 
The prevalence of NAFLD has risen rapidly due to prevalent lifestyle habits of 
diets enriched in fat and carbohydrates and sedentary behaviour, which have 
changed profoundly over the past few decades (Angulo, 2007; Ratziu et al., 
2010). However, accurate estimates of NAFLD/NASH prevalence remain 
challenging as the numbers vary greatly by the population studied (different 
ethnicities, genders, and comorbidities), and the sensitivity of the diagnostic 
methods employed (radiology or histology). Nevertheless, studies performed 
so far provide some information on the global trend of the NAFLD epidemic. A 
recent meta-analysis that included twenty-one population-based studies 
(Europe: 6, East Asia: 7, South Asia: 5, and 3 in Middle East) has 
demonstrated that the pooled worldwide prevalence of NAFLD is 24.24% and 
was significantly correlated to economic status (Zhu et al., 2015). When taking 
regions/ethnicity into account, the numbers changed slightly: Western 
countries have a higher incidence rate of NAFLD with 20-30% of the 
population affected (Day, 2010; Masarone et al., 2014) compared to a rate of 
5-18% in Asia (Masarone et al., 2014). Using proton magnetic resonance 
spectroscopy (1H-MRS) to assess hepatic steatosis in a multi-ethnic 
population from The Dallas Heart Study, 33.6% of 2349 US individuals were 
found to have NAFLD. Once again, an ethnicity effect was seen: the 
frequency of hepatic steatosis showed a distinct variation between Hispanics 
(45%), Caucasians (33%), and African Americans (17%) (Browning et al., 
2004b; Szczepaniak et al., 2005). As liver biopsy remains the diagnostic gold 
standard to reliably assess the degree of severity of NAFLD, histological 
studies in apparently healthy, prospective living liver donors indicate that the 
prevalence of NAFLD was 12–18% in Europe (Browning et al., 2004b; 
Nadalin et al., 2005) and 27–38% in the USA (Ryan et al., 2002; Browning et 
al., 2004b; Tran et al., 2006). Estimates increase further when populations 
with known risk factors are targeted. For instance, NAFLD was found in 91% 
of obese patients (body mass index (BMI) ≥30 kg/m2), 67% of overweight 
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(>25-<30) and 25% of normal individuals (Bellentani et al., 2004) reported by 
the European DIONYSOS study. Additionally, the overall prevalence of 
NAFLD is much greater in patients with T2DM with an incidence of 40-70% 
(Argo and Caldwell, 2009).  
 
1.3 Diagnosis, staging and grading of NAFLD  
1.3.1 Diagnosis  
The most common symptoms reported by NAFLD patients are fatigue, 
malaise and an uncomfortable feeling or fullness in the right upper abdomen. 
Patients should have a history of excess alcohol intake (<20g/day for women; 
<30g/day for men) excluded together with alternative diagnoses including 
chronic viral hepatitis (hepatitis B and hepatitis C), autoimmune liver diseases, 
hereditary hemochromatosis, α1-antitrypsin deficiency, Wilson’s disease and 
drug induced liver injury (Anstee et al., 2011a). Obesity and insulin resistance 
or other features of the metabolic syndrome are the most common 
comorbidities found in NAFLD patients. Liver function tests in NAFLD patients 
are commonly within the normal range or exhibit only moderate elevations of 
aspartate transaminase (AST) and alanine transaminase (ALT). Generally, 
the AST/ALT ratio is less than one, but increases in the presence of fibrosis. 
Although hepatic steatosis can be demonstrated by ultrasound and other non-
invasive radiological diagnostic approaches (computerised tomography (CT), 
proton magnetic resonance spectroscopy (1H-MRS) and magnetic resonance 
imaging), a solid histopathological diagnosis of NAFLD (and the presence of 
NASH) can only be confirmed by the golden diagnostic method - liver biopsy 
which effectively documents disease stage and grade (Angulo, 2007; 
Wieckowska and Feldstein, 2008; Burt et al., 2015).     
 
1.3.1.1 Steatosis 
The hallmark and initiation stage of NAFLD is hepatic steatosis, characterised 
by the accumulation of triglycerides (TG) affecting > 5% hepatocytes. 
Steatosis in NAFLD usually is presented as a mixture of macrovesicular 
(large) and microvesicular (small) droplet vacuoles within hepatocytes; true 
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microvesicular steatosis is rarely detected (Yeh and Brunt, 2014). Although 
hepatic steatosis is generally considered to be benign or self-limited, it may 
progress towards NASH in some patients. A widely accepted semiquantitative 
method for steatosis assessment is based on the percentage of hepatocytes 
involvement: four different degrees of steatosis are reported, comprising <5% 
steatosis, 5-33%, 34-66%, and over 66% (Kleiner et al., 2005). 
 
1.3.1.2 NASH 
NASH, the more progressive form of NAFLD, is characterised by specific 
histological features in addition to steatosis. These include hepatocellular 
injury (hepatocellular ballooning degeneration) and lobular inflammation, with 
or without fibrosis. These key lesions usually occur in acinar zone 3, however 
there may be loss of acinar localization in the presence of progressive fibrosis 
and parenchymal remodelling (Yeh and Brunt, 2014). Hepatocellular 
ballooning is characterized by a swollen shape of hepatocytes, usually 
enlarged and lightly stained cytoplasm, in which Mallory-Denk Bodies are 
frequently found on routine histology with cellular diameter > 30 µm. The loss 
of cytoplasmic staining of keratins 8 and 18 by immunohistochemistry has 
been proposed to be the key feature in identification of ballooned hepatocytes 
(Guy et al., 2012). Other helpful, but not necessary, morphological features for 
diagnosis of NASH include micrograulomas and acinar lipograulomas, 
megamitochondria, apoptotic bodies, and pericellular and perivenular fibrosis 
(Neuschwander-Tetri and Caldwell, 2003; Sanyal et al., 2011). Lobular 
inflammatory infiltrates are usually composed of lymphocytes (mainly T cells), 
eosinophils, macrophages, and less frequently neutrophils. Mild, chronic and 
mixed portal inflammation may also be present at this stage, and is suggested 
to be correlated with advanced severity of NASH and serological indicator of 
insulin resistance (IR), homeostatic model assessment (HOMA-IR) in both 
adult and paediatric cases (Brunt et al., 2009; Harmon et al., 2011; Smith, 
2013). Notably, there is a blurred gap between steatosis and NASH 
depending on whether NASH is destined to occur after steatosis or both forms 
are discrete entities (Cohen et al., 2011; Yilmaz, 2012). Around 10-29% of 
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NASH patients could progress to a more advanced stage of cirrhosis in a 10-
year period (Argo and Caldwell, 2009).  
 
1.3.1.3 Fibrosis and cirrhosis 
Hepatic fibrosis is a result of repeated wound-healing in response to chronic 
liver injury, occurring in most types of chronic liver diseases (Albanis and 
Friedman, 2001; Bataller and Brenner, 2005). The predominant concept of 
liver fibrosis is the imbalance between increased generation and reduced 
degradation of extracellular matrix (ECM) proteins under a persistent liver 
injury. The excessive accumulation of ECM proteins results in the 
transformation of hepatic architecture by substituting hepatocytes for ECM, 
including fibrillar collagens. Collagens (I, III and IV), fibronectin, undulin, 
elastin, laminin, hyaluronan, and proteoglycans were found to increase 6 
times more than the normal level in advanced fibrotic-stage (Bataller and 
Brenner, 2005). Hepatic stellate cells (HSCs) are the major ECM producing 
source in prolonged liver injury (Gabele et al., 2003). HSCs are located in the 
space of Disse (between hepatocytes and sinusoidal endothelial cells) and 
are responsible for vitamin A storage. HSCs are activated by inflammatory 
insults to the liver, undergoing a phenotype transformation into myofibroblast-
like cells which lay down ECM. HSC maintaining methods (activated HSC 
model on plastic culture dishes) from rodent and human livers were studied 
and established in the 1980s to provide a useful tool for researchers to 
investigate the essential role of HSCs in liver fibrosis (Otto and Veech, 1980; 
Friedman et al., 1992).  
Mild fibrosis (either in zone 3 perisinusoidal or portal) can be seen in NASH 
patients and it can further progress to bridging fibrosis and consequent 
cirrhosis if inflammatory insults are sustained (Brunt et al., 1999). Patients 
with progressive fibrosis over a period of 15-20 years could develop cirrhosis 
(Bataller and Brenner, 2005). Cirrhosis, the key risk factor for development of 
hepatocellular carcinoma, is encountered when normal hepatic lobules are 
replaced by fibrotic nodules thus causing disruption of the hepatic architecture 
and loss of liver function (Bircher, 1999). 
7 
 
1.3.1.4 Hepatocellular carcinoma (HCC) 
HCC is the fifth most frequently diagnosed cancer worldwide and the third 
most common cause of cancer mortality (Baffy et al., 2012). The progression 
to HCC is most frequently associated with cirrhosis secondary to chronic liver 
infections such as hepatitis B or hepatitis C viruses or by alcoholic injury, 
while genetically defined diseases such as hemochromatosis are associated 
with a lesser proportion (Bosch et al., 2005; El-Serag and Rudolph, 2007). 
The tumour marker blood test alpha-fetoprotein (AFP) is often used to detect 
liver cancer (60-70% of HCC patients are found AFP positive). However, 
patients with elevated AFP should be screened by radiological examinations 
(abdominal ultrasound, X-ray computed tomography (CT), or magnetic 
resonance imaging (MRI)). If serological AFP together with radiological 
evidence is highly significant toward to a diagnosis of liver cancer, the liver 
biopsy is then not warranted. The histopathological hallmark of HCC is the 
resemblance both in its cytology and plate-like morphology, however, this 
aspect is beyond the scope of this chapter and has been summarized 
elsewhere (Paradis, 2013). HCC has been linked to NAFLD in a large number 
of epidemiological studies, illustrating several common NAFLD risk factors 
(overweight, obesity, insulin resistance, and diabetes mellitus) also associated 
with HCC morbidity (Baffy et al., 2012). Though the accurate prevalence of 
NAFLD-related HCC is unclear, it is suggested that 4 to 27% of cirrhotic 
NAFLD patients could develop HCC (Cohen et al., 2011) while HCC is rarer in 
non-cirrhotic NAFLD patients (Baffy et al., 2012).  
 
1.3.2 Staging and grading of NAFLD 
A semi-quantitative scoring system – the NAFLD Activity Score (NAS) 
developed by NASH Clinical Research Network (NASH CRN) Pathology 
Committee, sponsored by National Institute of Diabetes and Digestive and 
Kidney Diseases, is currently the most widely used approach for grading 
disease severity of NAFLD and stage of fibrosis in clinical trials (Kleiner et al., 
2005). It is a revision of the original NAFLD grading system proposed by Brunt 
et al., illustrating the NASH grades according to the combinations mixed by  
steatosis, ballooning and inflammation (Brunt et al., 1999). The NAS is differ 
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from the original one as it is derived from the sum of the discrete scores of 
steatosis (0-3), hepatocellular ballooning (0-2) and lobular (acinar) 
inflammation (0-3), therefore provides a NAS range from 0 to 8. CRN also 
issued a 5-tier method for staging of fibrosis (0-4) (Table 1.1) (Kleiner et al., 
2005).   
Although NAS has been well validated in current clinical and medical practice, 
its sensitivity and specificity for a threshold NAS ≥ 5 as a histological 
diagnosis of NASH was only 57% and 95%, respectively (Hjelkrem et al., 
2011). A further report on a study performed in a cohort of 976 individuals 
demonstrated that only 75% of the biopsies with ‘definite NASH’ reached this 
threshold whilst 28% with borderline NASH, and 7% of them without NASH 
had NAS ≥ 5 (Brunt et al., 2011). Caution therefore should be taken when 
applying NAS for diagnostic purposes as the threshold value does not always 
reflect the actual disease severity. This discrepancy may be best explained by 
inter-observer-related variation among pathologists and the different 
histopathological criteria adopted (Machado et al., 2006; Younossi et al., 
2011). 
To address this, a simplified steatosis (S), activity (A) and fibrosis (F) (SAF) 
score has recently been designed by the European Fatty Liver Inhibition of 
Progression (FLIP) consortium, in an attempt to improve inter-observer 
variability (Bedossa and Consortium, 2014). The key difference in SAF 
scoring evaluation from NASH CRN score is that the degree of steatosis is 
separated from those of inflammation/ballooning to prove three separate 
measures of NAFLD severity. Basically, the FLIP algorithm encompasses 
semi-quantitative scoring of the key features: steatosis (0-3), activity (0-4) as 
the sum for hepatocellular ballooning and lobular inflammation, and fibrosis 
(0-4). Hence, NAFLD activity can be histologically divided into 2 categories; 
mild (A <2 and/or F <2) and significant (A >2 and/or F >2). In a study with 679 
obese patients, the threshold of A >2 correctly identified all patients with 
NASH, and none of the patients below this threshold had NASH (Bedossa 
and Consortium, 2014). Comparison of the SAF Score and the NAFLD Kleiner 
Score for the histological grading and staging of NAFLD/NASH is shown in 
Table 1.1. 
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Table 1.1: Comparison of the FLIP SAF Score and the NAFLD CRN Score for the 
histological grading and staging of NAFLD/NASH. 
SAF Score (Bedossa and Consortium, 2014) Kleiner Score (Kleiner et al., 2005) 
Histological 
Feature 
Category Definition Histological 
Feature 
Category Definition 
Steatosis 0 
1 
2 
3 
<5% 
5-33% 
34-66% 
>66% 
Steatosis 0 
1 
2 
3 
<5% 
5-33% 
34-66% 
>66% 
(S) Steatosis Score 0-3 PLUS 
Hepatocyte 
Ballooning 
0 
1 
2 
None 
Clusters of hepatocytes with rounded 
shape and pale cytoplasm 
Same as grade 1 with enlarged 
hepatocytes (>2x normal size) 
Hepatocyte 
Ballooning 
0 
1 
2 
None 
Few 
Many 
PLUS PLUS 
Inflammation 0 
1 
2 
None 
< 2 foci per 20x field 
> 2 foci per 20x field 
Inflammation 0 
1 
2 
3 
None 
1–2 foci per x20 field 
2–4 foci per x20 field 
>4 foci per x20 field 
(A) Total = Activity Score 0-4 (NAS) Total = NAFLD Activity Score 0-8 
Fibrosis 0 
1a 
1b 
1c 
2 
3 
4 
No fibrosis 
Zone 3 mild perisinusoidal fibrosis 
Zone 3 moderate perisinusoidal 
fibrosis 
Periportal/portal fibrosis only 
Zone 3 plus portal/periportal fibrosis 
Bridging fibrosis 
Cirrhosis 
Fibrosis 0 
1a 
1b 
1c 
2 
3 
4 
No fibrosis 
Zone 3 mild perisinusoidal 
fibrosis 
Zone 3 moderate 
perisinusoidal fibrosis 
Periportal/portal fibrosis 
only 
Zone 3 plus 
portal/periportal fibrosis 
Bridging fibrosis 
Cirrhosis 
(F) Fibrosis Stage 0-4 Fibrosis Stage 0-4 
Table modified from (Dyson et al., 2014) with permission. 
10 
 
1.4 Natural history of NAFLD  
A US-based long-term study with 23-year length revealed that patients with NAFLD 
had higher mortality compared to those in the general population, and the outcome 
of a lower survival rate was associated with age (hazard ratio per decade 2.2, 95%CI 
[1.7-2.7], P<0.0001), impaired fasting glucose (hazard ratio 2.6, 95%CI [1.3-5.2], 
P=0.005), and cirrhosis diagnosed at baseline (hazard ratio 3.1, 95%CI [1.2-7.8], 
P=0.02) (Adams et al., 2005). Other studies on long-term mortality in NAFLD 
patients during 15 year follow-up showed 26% death rate, and this increased 
profoundly to 34-69% compared to the general population sharing the same age and 
gender (Angulo, 2013). In general, the majority of NAFLD patients exhibit only simple 
steatosis which is considered to be benign and self-limited, whilst a small fraction of 
individuals progress to NASH, fibrosis, cirrhosis and HCC. However, recent study 
using serial biopsy data (a median interval of 6.6 years) has challenged this dogma, 
showing that 44% of the NAFLD patients with ‘pure fatty liver’ graduated to NASH, 
and 37% had fibrosis progression (22% of them were at advanced stage) 
(McPherson et al., 2015). Another systematic study of follow-up biopsies over a 
mean of 3.7 years documented that 64% of NAFLD patients progressed to NASH 
from steatosis, while 24% developed advanced fibrosis (Pais et al., 2013). The 
summary of disease progression and natural history of NAFLD is displayed in Figure 
1.1. 
Poor disease prognosis and reduced survival is predicted once patients develop 
NASH. A Swedish study investigated the survival and cause of death within a cohort 
of 129 NAFLD patients with a mean follow-up period of 13.7 years; mortality was not 
increased in patients with steatosis, patients with NASH however exhibited a greater 
than 10-fold increased risk of liver-induced causes (2.8% versus 0.2%) and twofold 
higher risk from CVD-related death (15.5% versus 7.5%) compared with a matched 
reference population (Ekstedt et al., 2006). Estimates of disease progression from 
patients with NASH to fibrosis vary between 27-53% by several studies using paired 
serial histological data within 3-6 years (Fassio et al., 2004; Hui et al., 2005; Wong et 
al., 2010). Correspondingly, a recent meta-analysis pooled 11 studies with a total of 
411 histologically confirmed NAFLD patients and with over 2145.5 person-years of 
follow-up evaluation; this study discovered that the annual fibrosis progression rate 
in patients with steatosis only at index biopsy was 0.07 stages (95%CI [0.02-0.11 
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stages]) and it was 0.14 stages in those with NASH (95%CI [0.07-0.21 stages]). 
Namely, patients with steatosis only progressed to fibrosis stage one on average in 
14.3 years while the average was 7.1 years for those diagnosed with NASH at 
baseline (Singh et al., 2015). Another study suggested that an overall annual rate of 
fibrosis progression from steatosis and NASH patients at baseline were 0.067 and 
0.08 stages, respectively (McPherson et al., 2015). Notably, although fibrosis 
progression is generally slow, rapid progression from simple steatosis or NASH (both 
at F0) to F3-4 does occur in a small set of patients over a mean follow-up period of 
5.9 years (Singh et al., 2015).  
The increased risk of mortality in patients with NASH compared with those with 
steatosis could be explained by the greater incidence and the higher severity of 
fibrosis found in NASH patients as the presence of fibrosis is the key histological 
determinant of long-term prognosis (Younossi et al., 2011; Chan et al., 2014; Singh 
et al., 2015). Supporting evidence from a study with 209 NAFLD patients over a 
median of 12.1 years demonstrated that NASH only correlated with liver-related 
mortality in the presence of advanced fibrosis; only F3 portal fibrosis was 
independently associated with liver mortality (hazard ratio 5.68, 95%CI [1.5-21.5]) 
when those with histological features of NASH were selected (Younossi et al., 2011). 
Additional study also supports this assertion; a longitudinal study with a median 
follow-up period of 12.6 years recruited 619 NAFLD patients at medical centres in 
USA, Europe and Thailand, investigating the long-term prognostic relevance of 
histological features and analysing the overall mortality, liver transplantation and 
liver-related events as outcomes (Angulo et al., 2015). The key finding was that 
histologic feature of fibrosis, but no other features of steatohepatitis, was 
independently associated with death, liver transplantation and liver-induced events 
included fibrosis stage 1 (hazard ratio 1.88, 95%CI [1.28-2.77]), stage 2 (hazard ratio 
2.89, 95%CI [1.93-4.33]), stage 3 (hazard ratio 3.76, 95%CI [2.40-5.89]) and stage 4 
(hazard ratio 10.9, 95%CI [6.06-19.62]).  
Approximately 10-25% of NASH patients progress to extensive fibrosis and cirrhosis 
(McCullough, 2004; Onnerhag et al., 2014; Goh and McCullough, 2016). The natural 
history of cirrhosis is characterised by two phases termed ‘compensated’ and 
‘decompensated’ with the status of portal pressure as the watershed. The 
decompensated phase is subject to a series of liver complications once portal 
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hypertension develops, including varices, portal hypertensive gastrointestinal 
bleeding, ascites, jaundice, hepatic encephalopathy, and ultimately to HCC (D'Amico 
et al., 2006). Accumulating data has provided some information on the mortality of 
cirrhosis due to NASH (Hui et al., 2003; Sanyal et al., 2006; Yatsuji et al., 2009; 
Bhala et al., 2011). An Australian study compared the rates of liver complications 
and survival between 23 patients with NASH-associated cirrhosis and those with 
hepatitis C virus (HCV)-related disease over 7 years follow-up; liver failure was the 
main cause of morbidity and mortality in NASH-related cirrhosis, but with a lower risk 
of HCC development despite a similar survival was seen in both groups (Hui et al., 
2003). Conversely, a separate study over 10-year period (152 NASH-cirrhosis 
patients vs. 150 HCV-cirrhosis) reached different conclusions; compensated 
cirrhosis due to NASH had a lower mortality rate and lower incidence for 
development of ascites, hyperbilirubinemia, and HCC against HCV-cirrhosis. 
However, patients with NASH-cirrhosis had a higher risk of CVD-related mortality 
(Sanyal et al., 2006). Nonetheless, one Japanese study with 5-year follow-up using a 
relatively small cohort of 68 NASH cases demonstrated that similar rates of 
complications of cirrhosis (ascites, varices, hepatic encephalopathy and HCC) were 
found in both cohorts of NASH and HCV related cirrhosis (Yatsuji et al., 2009). The 
discrepancy between the above studies may be explained by ethnic differences and 
variation in study design. Further information on the natural history of NAFLD/NASH-
associated cirrhosis could be obtained from data on cryptogenic cirrhosis as there is 
growing recognition that NAFLD/NASH may be responsible for a great proportion of 
cryptogenic cirrhosis since metabolic syndrome is also the most common feature in 
those patients (Powell et al., 1990; Bugianesi et al., 2002). Moreover, as a frequent 
cause of cirrhosis, NASH is projected to be the leading indication for liver 
transplantation in the US by 2020 (Ratziu et al., 2010; Sanyal et al., 2011). 
As progression to advanced fibrosis and cirrhosis in NASH patients has become a 
global concern, this also naturally extends to the risk for development of HCC 
(Adams et al., 2005; Rafiq et al., 2009; Satapathy and Sanyal, 2015). Available data 
suggests that the prevalence of HCC in NAFLD and NASH patients is estimated to 
be 0.5% and 2.8%, respectively (Starley et al., 2010). A recent Surveillance, 
Epidemiology, and End Results (SEER) database study in United States 
demonstrated that individuals affected by NAFLD had 2.6-fold higher risk for HCC, 
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with a 9% annual increase over 6-year period (Younossi et al., 2015). These 
estimates are forecast to be greatly increased in parallel to the NAFLD epidemic 
(Baffy et al., 2012). In general, HCV and alcohol currently account for the majority of 
HCC underlying causes. However, a US-based study with 4,406 HCC patients 
recruited between 2002-2008 challenged this assertion, providing evidence that 
NAFLD/NASH was the most common aetiological factor among those cases (59%), 
followed by T2DM (36%) and HCV (22%) (Sanyal et al., 2010). The presence of 
cirrhosis is the key risk factor for HCC and a surveillance study from Japan indicates 
that 80% of HCC patients are cirrhotic irrespective of aetiology (Hashimoto et al., 
2009). The cumulative incidence of HCC in patients with NASH-related cirrhosis has 
been suggested in one systemic review to range from 2.4% (over 7 years) to 12.8% 
(over 3 years) (White et al., 2012), whilst another study reported the annually 
cumulative incidence of HCC was 2.6% in NASH-associated cirrhosis compared to 
4% for those with HCV-related cirrhosis (Ascha et al., 2010).  
Yet, a growing number of case reports suggest that cirrhosis is not a necessary 
determinant for HCC, especially in NAFLD patients. In a US prospective study, the 
absence of cirrhosis was found to be 54% in all NAFLD-HCC cases while there was 
only 22% with absence in the HCV-cirrhosis group (Sanyal et al., 2010). Another 
German study examined the prevalence of HCC with different aetiologies and 
revealed that 41.7% of NAFLD/NASH-related HCC patients were non-cirrhotic (Ertle 
et al., 2011). In a study involving 1,500 U.S veterans over 6-year period, non-
cirrhotic HCC was mainly due to NAFLD and patients with either NAFLD (unadjusted 
odds ratio 5.4; 95% CI [3.4-8.5]) or metabolic syndrome (unadjusted odds ratio, 5.0; 
95% CI [3.1-7.8]) had a greater than 5-fold risk to present with HCC in the absence 
of cirrhosis, compared with the cohort of HCV-related HCC (Mittal et al., 2016).  
This specific characteristic (the absence of cirrhosis in progression of NAFLD-HCC) 
could be explained by the well-known NAFLD-associated risk factors, obesity and 
metabolic syndrome (Hardy et al., 2016). A large American prospective study with 
more than 900,000 adults demonstrated that men with a BMI of 35 kg/m2 or above 
had 4.5 times higher risk of dying from liver cancer while the risk was 1.68 higher in 
women when compared to individuals with normal BMI (Calle et al., 2003). One 
meta-analysis also concluded that the summary relative risks for HCC were 1.17 for 
overweight and 1.89 for obese subjects (Larsson and Wolk, 2007). Substantial data 
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suggests that T2DM promotes the development and progression of HCC (El-Serag 
et al., 2004; Davila et al., 2005; El-Serag et al., 2006; Welzel et al., 2011). 
Supporting evidence from a systematic review of 26 studies published during the last 
decade, 13 case-control studies and another 13 cohort studies, shows that the 
presence of diabetes was associated with a relatively consistent 2.5-fold increase in 
HCC risk in different populations and geographic areas (El-Serag et al., 2006). Since 
NAFLD is the major hepatic manifestation of obesity, impaired glucose tolerance and 
insulin resistance, T2DM and other associated metabolic conditions, this once again 
supports the notion that NAFLD/NASH would be the leading future cause of HCC 
and liver transplantation (Marrero et al., 2002; Starley et al., 2010). 
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Figure 1.1: Summary of the progression and natural history of NAFLD. Adapted and modified from (Cohen et al., 2011; Goh and McCullough, 2016).
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1.5 Risk factors  
NAFLD is best considered as a paradigm of complex genetic disease trait, since 
susceptibility appears to involve a combination of inter-patient genetic variation and 
environmental factors. With respect to environmental risk factors contributing to 
NAFLD, high calorific diet and sedentary life-style are well-known risk factors (Day, 
2006). Older age has also been linked to NAFLD (Chen et al., 2007a; Frith et al., 
2009). One Chinese case-control study investigated 4,226 adults aged above 60 
years compared with 3,145 randomly selected younger controls and found that the 
prevalence of NAFLD was slightly higher in the elderly (26.7%) than in non-elderly 
(22.8%) (Wang et al., 2013). It is noteworthy that whether age has its true effect on 
NAFLD/NASH or this is owing to a cumulative end results of other risk components 
(metabolic syndrome and fibrosis for example) and longer duration of disease 
progression in these patients (Vacca et al., 2015). Available data investigating 
gender difference in NAFLD remains conflicting. Women accounted for 60%-83% of 
NAFLD/NASH diagnosis in several early clinical studies (Ludwig et al., 1980; Powell 
et al., 1990; Angulo et al., 1999; Caldwell et al., 1999; Matteoni et al., 1999). In 
further studies on women, NAFLD has recently been reported to associate with late 
menopausal transition and postmenopausal stages (Ryu et al., 2015b), miscarriage 
and induced abortion (Liu et al., 2013), but an inverse association was found 
between age at menarche and NAFLD in a Korean study involved 76,415 middle-
aged women (Ryu et al., 2015a). Although some of these findings suggest a 
particular female predisposition, several other reports suggest a male predominance 
in NAFLD (Bacon et al., 1994; Sanyal and American Gastroenterological, 2002; 
Browning et al., 2004b; Williams et al., 2011).  
It is globally acknowledged that NAFLD is strongly correlated with the metabolic 
syndrome, especially obesity and T2DM (Bian and Ma, 2012; Ortiz-Lopez et al., 
2012) and this section mainly focuses on this aspect. The metabolic syndrome, also 
known as the X syndrome, the insulin resistance syndrome, and the deadly quartet, 
was recognized at least eight decades ago (Cameron et al., 2004; Eckel et al., 
2005). Although the definitions of metabolic syndrome slightly differ between the 
criteria established either by World Health Organization (WHO) (Alberti and Zimmet, 
1998), European Group for the Study of Insulin Resistance (Balkau and Charles, 
1999), and the National Cholesterol Education Program’s Adult Treatment Panel III 
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(NECP: ATPIII) (Expert Panel on Detection and Treatment of High Blood Cholesterol 
in, 2001), the agreed essential elements are glucose intolerance, central obesity, 
dyslipidaemia and hypertension. The criterion of ‘glucose intolerance’ also involves 
impaired glucose tolerance, impaired fasting glycaemia, IR and T2DM (Eckel et al., 
2005). These key components of metabolic syndrome have been proposed as 
potential risk factors in developing diabetes, CVD, stroke, chronic kidney disease 
(CKD), and NAFLD (Eckel et al., 2005; Anstee et al., 2013b). A proportion greater 
than 90% of the NAFLD patients have at least one component of the metabolic 
syndrome (Marchesini et al., 2003). While environmental factors in NAFLD are well-
established, the underlying mechanisms of genetic factors remain unclear. Current 
understanding on the genetic basis of NAFLD is described in detail in the next 
section 1.7. 
 
1.5.1 NAFLD and obesity  
Obesity is defined by BMI ≥ 30 kg/m2 and BMI ≥ 40 kg/m2  is defined as morbid 
obesity (Kubik et al., 2013). NAFLD was first recognized as a clinical entity based on 
the studies discovering the presence of fatty liver, variable degrees of inflammation 
and fibrosis in morbidly obese individuals (Payne et al., 1963; Kern et al., 1973; 
Catlin, 1976). Since then, accumulating data confirmed that obesity is a major risk 
factor in the development of NAFLD (Nasrallah et al., 1981; Braillon et al., 1985; 
Angulo et al., 1999; Matteoni et al., 1999). As described in section 1.2, the 
prevalence of NAFLD increased greatly in obese patients (Bellentani et al., 2004). 
One Italian study reported that 75.8% of obese patients had NAFLD compared to 
only 16% of those with normal BMI and without metabolic syndrome (Bellentani et 
al., 2000). Overall, the prevalence of NAFLD is estimated at between 74-91% in 
obese subjects (Angulo, 2002; Abrams et al., 2004; Bellentani et al., 2004) while 
NASH is thought to be present in 25-30% of an obese population and >35% when 
coexisting with T2DM (Silverman et al., 1989; Musso et al., 2011; Smith and Adams, 
2011). Visceral adiposity (central obesity), not overall obesity, is significantly 
associated with NASH (Kral et al., 1993; Omagari et al., 2002; Thomas et al., 2005; 
Farrell and Larter, 2006), especially for ‘non-obese’ NAFLD (Ha et al., 2015). On the 
other hand, bariatric surgery does ameliorate disease severity in NAFLD (Angulo, 
2006; Mummadi et al., 2008). One meta-analysis pooled 15 studies which 
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investigated the effect of bariatric surgery on NAFLD and revealed that 91.6% of 
patients had improvement or resolution in steatosis (95%CI [82.4%-97.6%]), 81.3% 
in NASH (95%CI [61.9%-94.9%]), and 65.5% in fibrosis (95%CI [38.2%-88.1%]); the 
completely disappearance of NASH was found in 69.5% (95%CI [42.2%-90.8%]) 
(Mummadi et al., 2008). A recent study with 1-year of follow-up also showed that 
nearly 85% of patients had reversal of NASH and reduced pathologic features of the 
disease after bariatric surgery (Lassailly et al., 2015).  
 
1.5.2 NAFLD and type 2 diabetes mellitus 
NAFLD is closely associated with IR and T2DM, it however remains unclear whether 
it is NAFLD that induces T2DM or vice versa. NAFLD patients have an average of 2 
fold increased risk of incident T2DM as reported in numerous studies (Fan et al., 
2007; Shibata et al., 2007; Fraser et al., 2009; Yamada et al., 2010; Sung et al., 
2012). These studies however performed a NAFLD diagnosis by ultrasonography or 
serum levels of liver enzymes which has limitations due to intraobserver variability 
and the fact that 80-85% of patients with T2DM and NAFLD are negative for 
increased serum levels of liver enzymes (Targher et al., 2007a; Williams et al., 2011; 
Williamson et al., 2011). Only one available data has so far demonstrated the 
association between histologically diagnosed NAFLD and the risk of incident T2DM. 
In a cohort of 129 histologically-proven NAFLD patients who were followed up for a 
mean period of 13.7 years, Ekstedt et al. showed that the prevalence of previously 
known T2DM was 8.5% at baseline, but a striking proportion of 78% of these 
individuals developed either T2DM (58%) or impaired glucose tolerance at the end of 
the study (Ekstedt et al., 2006).  
When considering NAFLD in patients with established T2DM, the prevalence of 
NAFLD is thought to be over 70% (Targher et al., 2007a; Leite et al., 2009). Both a 
personal and family history of IR and diabetes mellitus (DM) increases predisposition 
to NASH and fibrosis (Loomba et al., 2012). One study reinforced the notion that 
NAFLD is an independent risk factor for T2DM after adjustment for other elements of 
metabolic syndrome (Musso et al., 2011). In addition, patients with both T2DM and 
NAFLD often have poorer glycaemic control compared to those with T2DM only 
(Jimba et al., 2005; Williamson et al., 2011). The presence of T2DM itself is a strong 
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risk factor for liver disease as its long-term prognostic significance includes NASH, 
cirrhosis and HCC (de Marco et al., 1999; Bugianesi et al., 2002; El-Serag et al., 
2004; Bugianesi, 2007; Anstee et al., 2013b). 
 
1.5.3 NAFLD, cardiovascular disease and chronic kidney disease 
The recognition that NAFLD may stimulate the progression and development of CVD 
has already been a heated topic as common features of NAFLD (i.e. hypertension, 
atherogenic dyslipidaemia, dysglycaemia, IR and obesity) are risk factors for CVD 
(Marchesini et al., 2003). Numerous reports showed that NAFLD has been linked to 
markers of subclinical atherosclerosis (i.e. impaired flow-mediated vasodilation) that 
are dependent on endothelium, increased arterial stiffness, and increased carotid 
artery intima-media thickness (IMT) (Anstee et al., 2013b; Oni et al., 2013). One 
meta-analysis with seven cross-sectional studies (involving a total of 3,497 subjects) 
confirmed that NAFLD patients diagnosed with ultrasonography had a significantly 
increased prevalence of carotid artery IMT and carotid plaques (Sookoian and Pirola, 
2011). In a recent prospective study of 465 consecutive patients with ischaemic 
heart disease diagnosed by coronary angiography, the prevalence of fatty liver was 
64.7% and fatty liver was associated with more severe coronary artery disease 
(Wong et al., 2011). The intimate correlation between CVD and NAFLD could be 
further demonstrated by several retrospective studies (NAFLD diagnostic approach 
as imaging or biopsy) examining the natural history of NAFLD patients within a 
reasonably long duration; CVD is a very common cause of death among these 
patients (Adams et al., 2005; Ekstedt et al., 2006; Targher et al., 2007b; Rafiq et al., 
2009; Soderberg et al., 2010; Treeprasertsuk et al., 2012; Zhou et al., 2012). Two of 
the studies with biopsy-proven NAFLD also reported that patients with NASH, not 
those with simple steatosis, possess an increased risk of death from CVD compared 
with the reference population (Ekstedt et al., 2006; Soderberg et al., 2010).  
There is growing awareness regarding the interaction between NAFLD and CKD as 
it is a microvascular diabetic complication in people with T2DM which is also a 
common feature in NAFLD (Targher et al., 2011). The presence of CKD is usually 
defined as estimated glomerular filtration rate of <60 mL/min/1.73 m2 and/or 
microalbuminuria and/or overt proteinuria. In a study with 2,103 Type 2 diabetic 
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patients, those who coexisted with NAFLD (ultrasonography) had almost 2-fold 
increased prevalence of CKD (OR 1.87, 95CI% [1.3-4.1]) and proliferative/laser-
treated retinopathy (OR 1.75, 95CI% [1.1-3.7]) than in those without NAFLD (after 
adjustment for age, gender, BMI, waist circumference, blood pressure level, 
hypertension, duration of T2DM, haemoglobin A1c (HbA1c), lipids, smoking status and 
medications use) (Targher et al., 2008). An increased incidence of CKD in NAFLD 
patients also has been reported in several other cross-sectional studies (Hwang et 
al., 2010; Arase et al., 2011; Yasui et al., 2011).  
Although there is accumulating data concerning the close correlation between 
NAFLD and CVD/CKD, study bias should be noted; factors such as ethnicity, 
population studied (hospital-based or community-based), an adequate adjustment 
with potential confounders (i.e. IR, obesity, T2DM, hypertension and other traditional 
and non-traditional risk factors for CVD) and the diagnostic method used is needed. 
Whether NAFLD is simply a risk marker which coexists in patients of these two 
disease entities or is an independent risk factors remains to be fully elucidated. 
However, data to date is sufficient to consider that NAFLD patients are at high-risk 
for CVD/CKD events. More comprehensive information regarding current knowledge 
on the relationship between NAFLD and CVD/CKD can be found in two other review 
articles (Anstee et al., 2013b; Vanni et al., 2015).  
 
1.6 Pathogenesis 
The preeminent hypothesis for NAFLD pathogenesis was proposed by Day and 
James in 1998, suggesting that NAFLD might be driven in a “two-hit” fashion. The 
initial stage of NAFLD, steatosis, begins with an imbalance between lipid acquisition 
and removal in the liver, followed by steatohepatitis resulted from a complex system 
of inflammatory cascade which promotes lipotoxicity, oxidative stress and further 
induction of subsequent stages of NAFLD (Day and James, 1998). However, 
accumulating evidence during the past decade suggests that NAFLD may be 
contributed from “multiple hits”, a combination of several biochemical and 
immunological effects, rather than a simple “two-hit” manner. It is generally accepted 
that initiation of NAFLD is dependent on development of obesity and IR/T2DM, 
therefore this section mainly focuses on involvement of lipotoxicity, damage caused 
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by overwhelming oxidative stress, impaired metabolic homeostasis, cellular 
dysfunction (Hardy et al., 2016) and how these effects are governed by insulin and 
nutrient-sensing transcription factors.  
 
1.6.1 Lipid metabolism in NAFLD 
The liver plays a crucial role in the metabolism of carbohydrate, lipid and protein. 
Hepatic dysfunction usually is associated with systemic metabolic imbalances, and it 
is universally agreed that an imbalance in the acquisition, delivery and removal of 
long chain fatty acids (LCFAs) and triglycerides (TGs) is fundamental to NAFLD. 
 
1.6.1.1 Free fatty acids supply 
Free fatty acids (FFAs) are the key elements forming TGs, which can be further 
stored in adipocytes or be hydrolysed into three FFAs when the body requires higher 
energy demand. Liver FFAs are sourced from dietary TGs intake, enhanced de novo 
lipogenesis (DNL), and excess fatty acids influx via adipose tissue lipolysis (Vacca et 
al., 2015). In NAFLD cases, it has been reported that 59% of TG in the liver is 
derived from circulating FFAs, also known as nonesterifed fatty acids (NEFAs), 26% 
from DNL, and the remaining 15% from the diet (Donnelly et al., 2005). Acetyl-
coenzyme A carboxylase (ACC) and fatty acid synthase (FAS) are the predominant 
enzymes that catalyse FFA synthesis in the liver, while acetyl-coenzyme A (acetyl-
CoA) and malonyl-coenzyme A (malonyl-CoA) are the essential metabolic 
intermediates in DNL (Mendez-Sanchez et al., 2007) since increased DNL is found 
in NAFLD patients (Adams et al., 2005). DNL is strongly regulated by nutritional level 
of insulin and glucose, via two transcription factors - carbohydrate response element-
binding protein (ChREBP) and sterol regulatory element-binding protein-1c (SREBP-
1c), respectively. SREBP-1c, a membrane bound transcription factor to the 
endoplasmic reticulum (ER) (Horton et al., 2002), is regulated by insulin, saturated 
fatty acids (SFAs) and a nuclear receptor, liver X receptor (LXR), to promote fatty 
acid synthesis under hyperglycaemia. Conversely, glucagon, polyunsaturated fatty 
acids (PUFAs) inhibit its expression (Vacca et al., 2015). Mice with a SREBP-1c 
deletion showed remarkable reduction of insulin-mediated lipogenic gene expression 
(Shimano et al., 1999). Similar results were reported in LXRα-null mice with 
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decreased SREBP-1c and reduced lipogenesis (Repa et al., 2000). In 
hyperglycaemia, excess carbohydrates are converted to FFAs/TGs in the liver via 
glycolytic enzymes such as glucokinase, liver-type pyruvate kinase (L-PK), and the 
previously mentioned enzymes of DNL - ACC and FAS (Towle et al., 1997). 
ChREBP is expressed abundantly in lipogenic organs: liver, brown and white 
adipose tissue, small intestine, kidney, and muscle (Yamashita et al., 2001). Genes 
that are regulated by ChREBP are involved in glycolysis (L-PK), the NADPH supply 
system (e.g. glucose-6-phosphate dehydrogenase, transketolase, and malic 
enzyme), gluconeogenesis, and lipogenesis (ACC, FAS) (Iizuka et al., 2004; Ma et 
al., 2006). Inhibition of ChREBP in vivo resulted in suppression of lipogenic 
genes/enzymes expression in the liver, and amelioration of hepatic steatosis, insulin 
signalling and glucose intolerance (Iizuka et al., 2004; Dentin et al., 2006). Taken 
together, SREBP-1c and ChREBP are activated by insulin and glucose during 
hyperglycaemia, inducing glycolysis (to release more acetyl-Co A as substrate for 
FFA synthesis) and lipogenesis, thus further worsening steatosis. 
 
1.6.1.2 Free fatty acids removal  
Clearance of hepatic TG is accomplished by the only disposal pathway – through the 
formation of very low-density lipoproteins (VLDLs) which can be further secreted 
from the liver. Apolipoprotein B-100 (apoB-100) is required for VLDL assembly, and 
microsomal triglyceride transfer protein (MTTP) is required for incorporating TG. In 
general, TG, cholesterol ester (CE) and phospholipid are first transferred to rough 
ER to be incorporated with newly formed apo B, known as the formation of the 
primordial particle. Further in the lumen of the rough ER, TG-enriched globules 
produced by the smooth ER are incorporated into the primordial particle to form the 
mature VLDL. Once VLDL is assembled, it is then transported to the Golgi and 
released from the cell as secretory vesicles. This secretory pathway is entirely 
assisted by apo B-100 (Mason, 1998). The secretion of VLDL is inhibited by SREBP-
1c through decreasing expression of MTTP (Sato et al., 1999).   
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1.6.1.3 Free fatty acids oxidation  
FFAs can be utilised for energy production, the most efficient mechanism during 
energy deficiency. FFAs oxidation may be performed in three unique locations: 1) β-
oxidation in the mitochondria, 2) in the peroxisomes, and 3) ω-oxidation in the ER of 
hepatocytes (Koek et al., 2011). Under normal physiological conditions, β-oxidation 
of FFA in the mitochondria is the main source of short, medium, and long chain fatty 
acids (LCFAs) (Anstee and Goldin, 2006). Oxidation of FFA yields acetyl-CoA which 
is an important substrate for entering the citric acid cycle to generate electrons. 
These electrons further pass to oxygen via mitochondrial ‘respiratory chain’ (electron 
transport chain, ETC) and providing the energy for adenosine triphosphate (ATP) 
synthesis by oxidative phosphorylation (OXPHOS) (Lehninger et al., 2000). Short- 
and medium-chain FFAs (below 12 carbons length) can simply diffuse across the 
mitochondrial membrane for β-oxidation. However, LCFAs (chain length with 14 or 
more carbons) are activated by acyl-CoA-synthetase in the cytosol as acyl-CoA, 
which then be catalyzed and be transported into the mitochondrial matrix in 3 steps 
(Serviddio et al., 2011): 
1. Acyl-CoA is catalyzed by carnitine palmitoyl transferase I (CPT-I) as fatty acyl-
carnitine at the outer mitochondrial membrane, then passing through the 
intermembrane space. 
2. The inner membrane delivery is accomplished by acyl-carnitine translocase. 
3. At the inner face of the inner mitochondrial membrane, the reconversion of 
acyl-CoA is catalyzed and released by carnitine palmitoyl transferase II (CPT-
II) into the matrix along with free carnitine.  
Notably, CPT-I can be inhibited by malonyl-CoA, the key intermediate of DNL, and 
insulin. In general, hepatic lipogenesis is activated with carbohydrate feeding, 
resulting in elevated levels of insulin and malonyl-CoA; the expression of CPT-I is 
therefore suppressed and LCFAs are not oxidised but instead esterified, principally 
into TG (McGarry and Brown, 1997). 
 
1.6.2 Oxidative stress 
Oxidative stress, the essential underlying mechanisms of NAFLD, occurs when 
reactive oxygen species (ROS) exceed the production of protective antioxidants. 
Oxidation of FFAs is the primary source of ROS. ROS are constituted by oxygen-
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centered radicals and oxygen-centered nonradicals. Superoxide anion (O2-), 
hydroxyl radical (·OH), alkoxyl radical (RO·), and peroxyl radical (ROO·) comprised 
the former group, while the latter one includes hydrogen peroxide (H2O2) and singlet 
oxygen (1O2). Other reactive species are nitrogen species such as nitric oxide (NO·), 
nitric dioxide (NO2·), and peroxynitrite (OONO-) (Halliwell et al., 1995; Simon et al., 
2000). The nature of oxygen is readily to accept electrons, forming oxygen radicals 
which react with proteins, FFAs and DNA causing biological and physiological 
damage. The hydroxyl radical, nitric oxide radical and superoxide anion are the most 
dangerous ones among ROS group. Although the dominant source of cellular ROS 
is β-oxidation in the mitochondria, alternative pathways of β-oxidation in the 
peroxisomes and ω-oxidation in the ER are also ROS donors while oxidative 
capacity in mitochondria becomes overwhelmed in the event of FFAs overloading 
(Reddy, 2001). Upregulation in β-oxidation of LCFAs within peroxisomes and ω-
oxidation in the ER has been reported in NASH (Robertson et al., 2001). This could 
also be explained by an accumulation of malonyl-CoA in hyperglycaemia causing 
reduced mitochondrial β-oxidation due to inhibition of CPT-I (Donnelly et al., 2005; 
Dentin et al., 2006).   
Once ROS are elevated, peroxisome-proliferator-activated receptor α (PPAR-α) is 
then activated for compensation. PPAR-α is expressed predominantly in the liver, 
and it belongs to the nuclear receptor subfamily of ligand-activated transcription 
factors, the key regulator of long chain and PUFAs catabolism (Reddy, 2001). 
Although the major function of PPAR-α is to increase FFA utilization during fasting 
for gluconeogenesis (Le May et al., 2000; Atherton et al., 2009), it is one of the key 
regulators that drives an adaptive response to FFA overloading. PPAR-α is involved 
in several aspects: modulation of FFA uptake, lipid trafficking, promotion of β-
oxidation, and inhibition of DNL (Vacca et al., 2015). PPAR-α regulates proteins 
involved in mitochondrial, peroxisomal and microsomal oxidation with the latter two 
preferentially induced by PPAR-α (Anstee and Goldin, 2006).  
 
1.6.2.1 FFA oxidation in mitochondria, peroxisomes and microsomes 
Two major physiological and chemical events occur in the mitochondria: fat 
metabolism and energy production. Each β-oxidation generates reducing equivalents 
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of nicotinamide adenine dinucleotide (NADH, reduced form) and flavin adenine 
dinucleotide (FADH2), which serve as substrate and donate their electrons to the 
ETC. The ETC, a collection of mitochondrial membrane protein complexes 
embedded in the inner membrane (Pessayre et al., 2001), is the main source of ROS 
and the dominant site of ATP synthesis in eukaryotic organelles. Under physiological 
conditions, electron transport throughout the respiratory chain matches with the 
pumping of protons (from matrix to intermembrane space) via Complexes I, III and 
IV. A proton gradient is then generated during this process, creating an 
electrochemical potential difference across the inner membrane. By this potential 
force, ATP is ultimately synthesized at Complex V (ATP synthase) (Pessayre et al., 
2001; Serviddio et al., 2011).  
Normally, a large fraction of electrons participating in ETC is safely dissipated via 
cytochrome c oxidase with oxygen and water (Pessayre, 2007). Two regions of ETC, 
Complex I and III, however are the major sources of ROS by production of the 
superoxide anion. Estimates of the fraction of oxygen that is diverted into ROS 
production are between 0.15 to 4% (Brand, 2010; Koek et al., 2011; Serviddio et al., 
2011).  
A rodent study revealed that 50% of FFA β –oxidation takes place in the 
peroxisomes (Latruffe et al., 2000). However, peroxisomal β-oxidation only accounts 
for a minority of total FFA oxidation in human body under normal status. Peroxisomal 
proliferation is only augmented when the capacity of oxidation in the mitochondria is 
overwhelmed. Hydrogen peroxide, generated during peroxisomal β-oxidation, can be 
easily transformed into reactive hydroxyl radicals, thus contributing more ROS 
production. As previously mentioned, peroxisomal β-oxidation is also regulated by 
PPAR-α as it encodes acetyl-CoA oxidase, the rate-limiting enzyme for the oxidation 
(Benzie, 1996). The microsomal ω-oxidation is mediated by cytochrome P450 4A 
(CYP4A) and cytochrome P450 2A1 (CYP2E1). Both P450s produce ROS during ω-
oxidation, further exacerbating oxidative stress within hepatocytes (Anstee and 
Goldin, 2006; Koek et al., 2011).  
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1.6.2.2 Antioxidants  
Human body develops a defence system of anti-oxidants to compensate oxidative 
stress. This protective system is performed by scavenging free radicals and reactive 
metabolites. The major enzymatic anti-oxidants include superoxide dismutase 
(SOD), catalase, and glutathione peroxidase (GPx). There are three different forms 
and localizations of SOD: 1) SOD1: copper/zinc-containing SOD, localized to 
cytoplasm (Cu/Zn-SOD); 2) SOD2: manganese-containing SOD, located in 
mitochondrial matrix (MnSOD), 3) SOD3: presented in extracellular space (EC-
SOD). SOD mediates the conversion of superoxide anion radicals into hydrogen 
peroxide. This is followed by the detoxification of hydrogen peroxide into H2O which 
is accomplished by catalase and GPx (Pessayre et al., 2001). SOD2 has been 
suggested to be associated with NAFLD due to its mitochondrial localization; NASH-
related fibrotic patients show an increased frequency of a common non-synonymous 
polymorphism in SOD2 (C47T; rs4880) which is associated with a reduction in SOD2 
mitochondrial targeting and activity (Al-Serri et al., 2012).  
Glutathione (GSH), S-adenosylmethionine (SAMe), and vitamins are major sources 
of non-enzymatic anti-oxidants. GSH is the dominant anti-oxidant in the liver with two 
forms: thiol-induced glutathione (GSH) and oxidized state of glutathione (glutathione 
disulphide, GSSG) (Chen et al., 2007b; Koek et al., 2011). The rate of GSH 
synthesis is mediated by cysteine, with assistance of two subunits of glutamate 
cysteine ligase (GCL): a catalytic form (GCLC) and a modifier (GCLM) (Meister and 
Anderson, 1983). GCLC knock-out mice resulted in depletion of GSH, leading to 
promotion of steatosis, mitochondrial and hepatic injuries has been reported (Chen 
et al., 2007b).  
Deficiency of GSH could be due to SAMe shortage as it is a precursor for GSH 
synthesis. SAMe is synthesized from methionine and catalysed by methionine 
adenosyl transferase (MAT) (Mato et al., 2002). MAT is encoded by MAT1A and 
MAT2A. Deletion of MAT1A leads to liver injury due to a profound reduction of SAMe 
expression (Lu et al., 2001). Additionally, SAMe knock-out mice had a tendency of 
developing hepatic steatosis and NASH (Wortham et al., 2008). Other anti-oxidants 
such as vitamin C and E are also major free radical scavengers (Valko et al., 2004). 
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1.6.2.3 Multiple insults driven by ROS  
As previously described, excess accumulation of fat eventually lead to ROS 
overproduction. Although ROS have a short half-life, they are able to oxidise nuclear 
and mitochondrial DNA (mtDNA), causing mtDNA lesions and somatic point 
mutations (Pessayre, 2007). A comprehensive pathway of cellular injury can 
therefore be activated by the liberation of pro-inflammatory, necro-inflammatory or 
pro-fibrotic cytokines due to nuclear and mtDNA damage, phospholipid membrane 
disruption by lipid peroxidation, and mitochondrial dysfunction (Browning and Horton, 
2004). Impaired mtDNA-encoded polypeptides (e.g. cytochrome c oxidase) involved 
in ETC can be affected by mtDNA lesions further aggravating ROS effects by 
blocking electron flow along through the ETC and disrupting hepatic ATP 
homeostasis (Pessayre, 2007). Reduced ATP synthesis due to impaired ETC has 
been demonstrated in both rodent models and NASH patients (Cortez-Pinto et al., 
1999; Serviddio et al., 2008). Lipid peroxidation of PUFAs generates toxic 
intermediates of aldehyde such as 4-hydroxy-2-nonenal (HNE) and malondialdehyde 
(MDA). These by-products possess longer half-lives than ROS and so can damage 
more distant intracellular targets, causing cell death (Levene and Goldin, 2012).  
ROS is a well-known inducer of nuclear factor kappa-light-chain-enhancer of 
activated B-cells (NF-ĸB), a pro-inflammatory signalling pathway which can also be 
activated by tumour necrosis factor-alpha (TNFα) (Serviddio et al., 2011). NF-ĸB 
promotes survival of hepatic myofibroblasts and hepatic fibrogenesis (Oakley et al., 
2009). TNFα is secreted by enlarged adipocytes (Kern et al., 1995) and fat-laden 
hepatocytes (Crespo et al., 2001; Feldstein et al., 2004), triggering permeability of 
the mitochondrial membranes by the reaction with its receptor on hepatocytes. 
Upregulation of cascade-8, Bid and Bax are mediated by TNFα, triggering 
hepatocyte apoptosis by releasing cytochrome C (Pessayre and Fromenty, 2005). 
Other key inflammatory mediators such as transforming growth factor beta (TGFβ) 
and interleukin-8 (IL-8) are also activated by oxidative stress, worsening hepatic 
inflammation and promoting fibrogenesis by activation of HSCs (Bataller and 
Brenner, 2005; Levene and Goldin, 2012).  
When ER stress is overwhelmed due to the presence of excess FFAs, misfolded or 
unfolded proteins (also known as uncoupling proteins, UPCs) may ensue as ER is 
an intracellular membranous network where the majority of secreted and membrane 
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proteins are folded. An activation called the unfolded protein response (UPR) is then 
triggered by the aggregation of UPCs. This response helps re-establish normal 
homeostasis within the cell by triggering cell cycle arrest, folding catalysts, induction 
of ER-localized chaperone proteins, and ER-associated protein degradation. The 
UPR can lead to the induction of autophagy if required (Yang et al., 2010). Apoptosis 
can also be triggered if this response fails by activation of stress-sensor proteins 
which include activating transcription factor 6 (ATF6), inositol-requiring enzyme-1 
(IRE-1), and protein kinase R-like ER kinase (PERK) (Puri et al., 2008; Tilg and 
Moschen, 2010). 
 
1.6.3 Lipotoxicity and insulin resistance in NAFLD 
Lipotoxicity is induced by fat overloading. The phenomenon - ‘adipose tissue 
remodeling’ refers to a phenotypic alteration of adipocytes to compensate for excess 
nutrition and fat within the cell; adipocyte enlargement results in the release of 
several cytokines. These cytokines are principally adiponectin, leptin, TNFα, and 
Interleukin-6 (IL-6). Although adiponectin has anti-inflammation, anti-fibrosis, anti-
angiogenesis, sensitization of insulin, and tumor-growth limiting properties 
(Dalamaga et al., 2012; Karagozian et al., 2014), its availability is diminished in 
obesity, IR, and NAFLD (Pajvani et al., 2003; Targher et al., 2004; Pagano et al., 
2005; Levene and Goldin, 2012). Adiponectin mediates FFA and glucose 
metabolism by activating adenosine monophosphate-activated protein kinase 
(AMPK), a metabolic regulator. AMPK was first identified as a kinase which 
phosphorylates and inhibits ACC (rate-limiting enzyme for DNL) and 
hydroxymethylglutaryl-CoA synthase (HMG-CoA) reductase (rate-limiting enzyme for 
DNL cholesterol synthesis). Overall, activation of AMPK stimulates FFA oxidation, 
inhibits FFA synthesis and esterification, enhances insulin sensitivity, stimulates 
glucose uptake in muscle, negatively regulates hepatic glucose production, and 
diminishes pro-inflammatory activity (Luo et al., 2010). AMPK has been suggested to 
inhibit lipogenesis by negatively regulating SREBP-1c (Zhou et al., 2001). 
Adiponectin promotes lipogenesis not only through activation of AMPK, but also via 
PPAR-γ (Anstee and Goldin, 2006; Levene and Goldin, 2012). Hepatic stellate cells 
(HSCs) are also regulated by adiponectin which has anti-fibrotic effects including 
inhibition of a pro-inflammatory pathway involving NF-ĸB, decreased transforming 
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growth factor beta (TGFβ) -induced profibrogenic gene expression, and increased 
caspase-mediated apoptosis. The apoptosis effect is via activation of AMPK which 
downregulates the mammalian target of rapamycin, mTOR (Ding et al., 2005).  
Conversely, leptin possesses totally opposite functions to adiponectin, pro-
inflammatory and pro-fibrotic. Leptin deficient (ob/ob) mice have reduced 
fibrogenesis (Leclercq et al., 2002). Leptin is predominantly secreted from 
adipocytes, but can also be produced by HSCs (Bian and Ma, 2012). Leptin also 
targets sinusoidal endothelial and Kupffer cells, inducing the expression of TGFβ 
(Wang et al., 2009). Activation of HSCs is modulated by leptin as its functional 
receptors are located on stellate cells. Levels of leptin appear low in quiescent HSCs 
and increase after activation (Ding et al., 2005). Leptin can induce inflammation and 
fibrosis via HSC activation, including stimulation of proliferation, activation of NADPH 
and ROS, and increase in collagen 1 and tissue inhibitor of metalloproteinase 1 
expression (Marra, 2007). Leptin can ultimately promote carcinogenesis via Janus 
kinase/signal transducers and activators of transcription (JAK/STAT) and 
phosphoinositide-3 kinase/protein kinase B/mTOR (PI3K/Akt/mTOR) signalling 
pathways (Saxena et al., 2007).  
TNFα, a potent activator of pro-inflammation and oncogenesis, was found to be 
upregulated in both obese human and mice studies (Anstee and Goldin, 2006; Park 
et al., 2010). Overexpression of TNFα disrupts insulin-mediated suppression of 
hormone-sensitive lipase (HSL, the enzyme involved in TG hydrolysis) by inhibited 
phosphorylation of insulin receptor substrates (IRS-1 & IRS-2), hence more FFA is 
released (Anstee and Goldin, 2006; Sugimoto and Takei, 2011). Available data also 
indicates that dietary or genetic obesity promoted the growth of diethyl nitrosamine 
(DEN)-induced liver tumours in mice and this effect was dependent on TNFα and IL-
6 mediated oncogenic signalling pathways via activation of STAT3 (Park et al., 
2010). 
Insulin plays an essential role in glucose and lipid metabolism (Schreuder et al., 
2008). Insulin is released from β-cells in the islets of Langerhans, and further binds 
to its receptor, insulin receptor substrate proteins (IRS-1 and IRS-2) to transmit the 
signal. IRS-1 act as the initiator in glucose metabolism via stimulating PI3K/Akt 
pathway, resulting in recruitment of glucose transporter (GULT) and the suppression 
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of hepatic glucose production. Whereas IRS-2 is responsible for lipid metabolism as 
a regulator of DNL via SREBP-1c (Schreuder et al., 2008). Insulin resistance (IR) is 
a condition when the signalling pathway has been disrupted by several insults, 
leading to an impaired cellular responses to insulin. NAFLD patients commonly have 
both hepatic and adipose tissue IR, together with diminished whole-body insulin 
sensitivity (Marchesini et al., 2001; Seppala-Lindroos et al., 2002; Bugianesi et al., 
2005). Whether IR is a result of lipotoxicity due to excess FFA flux to the liver or vice 
versa however remains unclear. The potential molecular mechanism of lipid-induced 
IR has been discussed thoroughly in a recent review article (Perry et al., 2014). In 
summary, increased liver fat content (especially diacylglycerol, DAG) cause a key 
alteration – the translocation of the primary novel protein kinase C (PKC) isoform in 
the liver, PKCε. Following PKCε translocation (from cytosol to the plasma 
membrane), the enzyme binds to and inhibits the activity of the intracellular kinase 
domain of insulin receptors (Perry et al., 2014), disrupting insulin signalling. This 
results in decreased IRS-2 phosphorylation, decreased IRS-2-induced PI3K activity, 
impaired phosphorylation of Akt, and suppression of glycogen synthase kinase-3 
(GSK3) phosphorylation. The overall effect is a reduction of insulin-mediated 
glycogen synthesis via diminished activity of glycogen synthase (GS). The other way 
for insulin suppression of glucose production is the inhibition of gluconeogenesis in 
the liver; insulin decreases the expression of gluconeogenic enzymes by 
phosphorylation and nuclear exclusion of the folkhead box protein O1 (FOXO1) and 
its downstream targets. Impaired Akt activity promotes FOXO1 translocation to the 
nucleus (due to reduced phosphorylation of this transcriptional regulator) thus 
inducing the expression of key gluconeogenic proteins, principally pyruvate 
carboxylase (PC), phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6-
phosphatase (G6Pase) (Perry et al., 2014).  
Insulin resistance in NAFLD could be driven by multiple insults including direct toxic 
effects of FFAs, inflammation, oxidative injury and ER stress associated with obesity. 
These factors may impair the insulin signalling pathway, consequently leading to 
hyperinsulinemia resulting in increased glucose synthesis and lipogenesis (Saltiel 
and Kahn, 2001). Expression of SREBP-1c and ChREBP thus be activated once 
increased circulating levels of glucose and insulin occur, initiating a vicious cycle 
from promotion of glucose synthesis and lipogenesis to lipotoxicity. In addition, 
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adipose expansion, adipocytokine imbalance, immune dysregulation, ectopic fat 
deposition, lipotoxicity, IR, and hyperinsulinemia have all been suggested to be the 
fundamental risk factors that promote HCC development in NAFLD (Baffy et al., 
2012; Karagozian et al., 2014). 
 
1.7 Genetics of NAFLD 
NAFLD is now considered as the product of multi-directional interactions between 
intrinsic factors (genetic, epigenetic and age related) and a range of extrinsic 
(environmental) influences (including dietary/nutritional factors, intestinal 
flora/microbiome, xenobiotics as well as activity/behavioural factors). Intestinal 
flora/microbiome and xenobiotics in NAFLD is beyond the scope of this thesis, but 
have been reviewed in depth by (Leung et al., 2016) and (Naik et al., 2013), 
respectively. Identification of genetic factors involved in susceptibility to NAFLD not 
only sheds light onto the background of disease pathogenesis, but also allows a non-
invasive strategy that could help prevent/control disease initiation/progression and 
more importantly may develop new pharmacological treatments that exploit this 
knowledge. 
 
1.7.1 Evidence for a heritable component to NAFLD 
As has already been discussed, NAFLD is best considered a complex disease trait 
(Anstee and Day, 2013). Unlike Mendelian disorders (i.e. cystic fibrosis and sickle-
cell disease) when rare and highly penetrant single-gene mutations are necessary 
and sufficient to cause disease, complex diseases traits are attributable to multiple 
genetic modifiers (where disease susceptibility in a population is determined by 
multiple variants as each is insufficient in isolation to cause disease) (Hirschhorn and 
Gajdos, 2011). Thus, a complex disease arises from a contribution of individual 
genetic variants in the presence of a permissive environment. In the case of NAFLD, 
the degree of heritability (fraction of the variation in the disease attributable to 
genetic causes) is estimated to be 26%-27% for radiologically measured hepatic 
triglyceride content (HTGC) (Speliotes et al., 2011). Established evidence comes 
from familial disease clustering and inter-ethnic variation studies further supporting 
that there is a heritable component to NAFLD. 
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 Familial aggregation: a study comparing HTGC in parents and siblings of 
obese children with NAFLD to those without discovered that steatosis was 
significantly more common in the siblings and parents of children than those 
without NAFLD (59% and 78% vs. 17% and 37% respectively) (Schwimmer et 
al., 2009). Additionally, MRI-measured hepatic fat fraction was correlated 
more closely with BMI in the families of children with NAFLD than those 
without (Schwimmer et al., 2009). Further evidence from a Finnish study with 
a large cohort of twins discovered that intra-pair correlations of ALT and 
fasting serum levels were much higher in monozygotic than dizygotic twins 
(Makkonen et al., 2009). Another study performed a cross-sectional analysis 
of a cohort of well-characterized twins in Southern California, reporting that 
hepatic steatosis and fibrosis were correlated with monozygotic but not 
dizygotic twins (Loomba et al., 2015). Studies in adults with NAFLD showed 
co-existence of NASH and/or cryptogenic cirrhosis in 7 out of 8 kindreds 
(Struben et al., 2000). Another familial study found that 18% of NASH patients 
had an affected first-degree relative (Willner et al., 2001).  
 Inter-ethnic variations in susceptibility to NAFLD: the prevalence of 
NAFLD and NAFLD-associated ‘cryptogenic cirrhosis’ varied substantially 
between ethnicities in the presence of similar incidences of T2DM (Browning 
et al., 2004a; Bambha et al., 2012). Further evidence from the Dallas Heart 
Study in a multi-ethnic population (n=2349) reported that NAFLD was present 
in 45% of Hispanics, 33% of whites and 24% of blacks, independent of BMI, 
IR, ethanol ingestion, or use of medication (Browning et al., 2004b). It is 
difficult to make a precise interpretation of these data because of the 
differences in some metabolic risk factors and socioeconomic characteristics 
associated with NAFLD in these ethnic groups. As discussed below, 
differences in population prevalence of one genetic variant, rs738409 in the 
gene called patatin-like phospholipase domain-containing 3 (PNPLA3), which 
contributed to this variability, accounted for up to 72% of ethnic differences in 
the Dallas Heart Study cohort (Romeo et al., 2008).  
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1.7.2 Approaches to identify genetic risk factors for NAFLD 
Genetic approach such as linkage analysis has been very successful in identifying 
causative variants for many rare single-gene disorders (Risch and Merikangas, 
1996). However, linkage analysis has limited value for detection of common genetic 
risk factors associated with complex diseases due to: 1) the principle of linkage 
analysis is based on chromosomal crossover during meiosis, therefore it is restricted 
in familial cluster; 2) limitations for discovering weakly penetrant alleles; 3) low 
feasibility to obtain large families with complex diseases (Risch and Merikangas, 
1996; Hirschhorn and Gajdos, 2011). These issues however can be addressed by 
candidate gene case-control association studies, performing direct association within 
large unrelated population (considered as a single family with unknown pedigree) 
between phenotype (disease) and variants in targeted genes with a priori biological 
support (Witte, 2010). Nonetheless, other causal genes that may influence a disease 
could be easily missed as it only focuses on particular genes. Logically, it would be 
inappropriate to adopt candidate gene studies to test genetic basis of any disease in 
the absence of a biological hypothesis (Hirschhorn and Daly, 2005). Up to date, 
candidate-gene studies have only identified a small number of genes that are 
reproducibly associated with common diseases; this may owe to the small sample-
size used in the analyses or insufficient background knowledge of the genes 
targeted (Hirschhorn, 2009). After the establishment of final draft of human genome 
sequence, the International HapMap (haplotype map) Project, revolutionized the 
study of complex diseases (International HapMap, 2003; International HapMap, 
2005). The HapMap Project was to determine the patterns of common sequence 
variation in human genome, providing sequence variants and their frequencies and 
correlations. Millions of common variants (single nucleotide polymorphisms, SNPs) 
were tagged by using the techniques of linkage disequilibrium (LD) and haplotype, 
and were further served as proxies for group of other SNPs that are nearby, thus 
eventually enabled the development of SNP genotyping arrays (International 
HapMap, 2005). These tools allow the majority of common (minor allele frequency 
[MAF]>5%) variability in human genome (approximately 1 million of different SNPs) 
to be captured by genotyping methods of cases and controls in genome-wide 
association studies (GWAS) (International HapMap, 2005). GWAS have the ability to 
discover variants with modest effects across the whole genome without particular 
biological evidence, improving the weakness of linkage analysis and candidate-gene 
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studies. But the loci identified are usually fairly novel, requiring further replications 
and functional experiments to ascertain their significance and to elucidate their 
biological/pathogenic role in disease mechanisms (Witte, 2010). A few years after 
the HapMap was established, GWAS in seven different complex diseases were 
reported (Wellcome Trust Case Control, 2007). Additional GWAS data relating to 
other important diseases, including cancer, soon became available  (Manolio et al., 
2008). 
 
1.7.3 Identified genetic risk factors for NAFLD by GWAS 
Several genes have been identified to influence susceptibility to NAFLD by GWAS 
Table 1.2, and their suggested effects have been independently confirmed in either 
GWAS or candidate-gene association studies. Among all, two loci PNPLA3 and 
TM6SF2 genes on chromosome 22 and chromosome 19 deserve particular attention 
and so will be discussed in detail in section 1.7.3.6 and section 1.7.3.7, respectively. 
 
1.7.3.1 Identified genetic risk factors by radiological-based GWAS 
The first GWAS-like association study in NAFLD was published in 2008 (Romeo et 
al., 2008), this study partly covered the whole genome involving only genotyping for 
nonsynonymous variants. This study examined 9229 non-synonymous 
polymorphisms in a multi-ethnic population (Hispanic, African-American and 
European ancestry) from the Dallas Heart Study (Victor et al., 2004), 2051 patients 
with 1H-MRS-measured HTGC were recruited. Romeo et al. provided preliminary 
evidence that a SNP (rs738409) located in PNPLA3 is significantly associated with 
increased HTGC (P=5.9x 10-10) and elevated level of ALT (P=3.7x 10-4). This index 
SNP is a non-synonymous transversion from cytosine to guanine, resulting in an 
amino acid substitution from isoleucine to methionine at residue 148 (I148M). The 
MAF of this polymorphism was most common in Hispanics (0.49), the group with 
higher prevalence of aggressive NAFLD and increased levels of ALT and AST 
(P=3.7x10-4), and was lower in European ancestry (0.23) and African-Americans 
(0.17). A gene dosage effect of PNPLA3-I148M has been reported with a stepwise 
increase in HTGC with increasing carriage of the minor allele, and the homozygous 
148M had twofold elevated HTGC compared to the wild-type carriers (Romeo et al., 
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2008). Conversely, the other SNP also located in PNPLA3 (rs6006460, p.S453I) had 
opposite ethnic distribution; African-Americans (0.104), European ancestry (0.003), 
and Hispanics (0.008), and was strongly linked to reduced HTGC. Taken together, 
these two SNPs accounted for 72% of the ethnic differences in the population 
studied, indicating that PNPLA3 may be responsible for the ethnic variation in 
susceptibility to NAFLD (Romeo et al., 2008).  
Three years later, a two-stage study with a large US-based population (n=7,176) 
confirmed the association between PNPLA3 genotype and fatty liver (Speliotes et al., 
2011). At stage 1 with computer-based imputation, Speliotes et al. performed a 
meta-analysis from four studies (Age/Gene/Environment Susceptibility –Reykjavik 
Study, Old Order Amish Study, Family Heart Study, and Framingham Heart Study). 
In this analysis, 2.4 million SNPs were examined and 45 loci were identified to be 
greatly associated with CT-measured HTGC (P<10-3 was adopted as a permissive 
significant threshold). These loci were subsequently tested in stage 2 using a 
candidate-gene approach in a separate cohort with histology-proven NAFLD 
(n=592). To summarize, this study validated that carriage of PNPLA3 rs738409 
polymorphism was a major genetic modifier of NAFLD and also identified other 
potential variant risk factors; these included neurocan (NCAN, rs2228603), 
glucokinase regulatory protein (GCKR, rs780094), protein phosphatase 1 regulatory 
subunit 3B (PPP1R3B, rs4240624), and lysophospholipase-like protein 1 (LYPLAL1, 
rs12137855). The above SNPs were significantly associated with both CT and 
histological confirmed steatosis, lobular inflammation and/or fibrosis, with the 
exception of PPP1R3B (rs4240624) as its effect did not remain significant in 
histologic NAFLD. Nonetheless, another SNP near PPP1R3B (rs2126259), in 
complete linkage disequilibrium with rs4240624 (LD=1, r2=0.8), has been suggested 
to be associated with CT-measured steatosis in a later GWAS (Feitosa et al., 2013).  
 
1.7.3.2 Identified genetic risk factors for NAFLD by histological-based GWAS 
In terms of histologically based GWAS for NAFLD, the first one was performed by 
Chalasani et al. on a limited cohort of 236 female NAFLD patients (Chalasani et al., 
2010). Instead of reporting associations with each stage of NAS (namely the 
individual stages of steatosis, ballooning degeneration, portal/lobular inflammation, 
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and fibrosis), they reported that the overall NAS (as primary outcome of interest) was 
significantly associated with a variant in a gene on chromosome 8 - FDFT1 (farnesyl 
diphosphate farnesyl transferase 1, rs2645424) after adjustment for age, BMI, 
waist/hip ratio, diabetic status, and HbA1c level, (P=6.8x10-7). Although FDFT1 has 
been suggested to have a role in biosynthesis of cholesterol, this effect was not 
replicated in a later study using a cohort of 340 NAFLD cases (Ballestri et al., 2011). 
PNPLA3 was not associated with any NAFLD phenotype in the GWAS published by 
Chalasani et al.; the key rs738409 SNP was not captured in their study and the other 
5 SNPs in complete LD with rs738409 also failed to show significance. Additional loci 
were associated with secondary outcomes; a SNP on chromosome 7 was linked to 
the degree of fibrosis (rs343062, P=2.7x10-8) and a variant on chromosome 10 with 
lobular inflammation (rs1227756, P=2.0x10-7). Notably, caution should be taken in 
interpreting these results as type I or type II error may have occurred due to limited 
statistical power within this small cohort. Further independent validations are 
warranted.  
Up to date, there have been two histological-based GWAS reported in East Asian 
populations (Kawaguchi et al., 2012; Kitamoto et al., 2013). Kawaguchi et al. 
recruited 529 biopsy-diagnosed NAFLD patients according to Matteoni classification 
and 932 population controls; 484,751 SNPs were genotyped (Kawaguchi et al., 
2012). The second study by Kitamoto et al. was a two-stage study; 261,540 SNPs 
were initially genotyped in 392 NAFLD patients and 932 population controls, and the 
findings were subsequently validated in a separate cohort of 172 NAFLD versus 
1,012 controls (Kitamoto et al., 2013). Both studies clearly confirmed the association 
between NAFLD and the SNPs flanking PNPLA3 (with rs738409 having strongest 
signal) in this population, but no novel findings were identified.   
 
1.7.3.3 Identified genetic factors for NAFLD by clinical chemistry-based GWAS 
Although liver biochemistry is insufficient for NAFLD diagnosis and results in reports 
of a 3-12% lower disease prevalence than studies based on radiology or histology 
(Musso et al., 2011), there are two established GWAS identifying genes that 
influence plasma levels of liver enzymes, principally ALT (Yuan et al., 2008; 
Chambers et al., 2011). The first one was reported by Yuan et al. and included 3 
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discovery and 3 replication groups with a total number of 12,419 patients. Two loci 
were identified to be associated with rasied serum ALT level, including 22q13.31 
where PNPLA3 is found (rs738409, rs22949158, rs2076211, rs2281135, rs2073081 
were all genome-wide significant) and 10q24.2 spanning three genes CPN1-
ERLIN1-CHUK (carboxypeptidase N subunit 1-ER lipid raft associated 1-conserved 
helix-loop-helix ubiquitous kinase; rs11597390, rs11591741, rs11597086) (Yuan et 
al., 2008). The latter association has since been confirmed with CT-measured 
steatosis and ALT levels in another GWAS-correlated meta-analysis using ~2.5 
million imputed SNPs with 9 variants genome-wide significant (rs2862954, 
rs1408579, rs10883451, rs11597086, rs11591741, rs17729876, rs17668255, 
rs17668357, rs12784396) (Feitosa et al., 2013). A second GWAS on liver enzymes 
with 61,089 individuals enrolled identified 42 novel loci that associated with serum 
liver transaminase; 4 of them were associated with raised ALT, the major PNPLA3 
rs738409, rs2954021 near TRIB1 (tribbles pseudokinase 1), rs10883437 near CPN1 
(carboxypeptidase N subunit 1), and rs6834314 near HSD17B13 (hydroxysteroid 17-
beta dehydrogenase 13) and MAPK10 (mitogen-activated protein kinase 10) 
(Chambers et al., 2011).  
 
1.7.3.4 Novel genetic risk factors for NAFLD reported in recent GWAS  
One recent GWAS published by the same group that originally reported the PNPLA3 
association (Kozlitina et al., 2014) deserves particular attention as they discovered 
another novel SNP involved in the pathogenic mechanisms of NAFLD, also 
suggesting that this SNP is the causative variant within the well-known region 
(19p13.11) which has been associated with lipid levels (Kathiresan et al., 2008; 
Teslovich et al., 2010). In addition to the well-established association between 
PNPLA3 and NAFLD, Kozlitina et al. determined that a non-synonymous SNP in a 
gene of unknown function called TM6SF2 (rs58542926 c.449 C>T, p.Glu167Lys 
(E167K)), transmembrane 6 superfamily member 2 on chromosome 19 (19p13.11), 
was strongly associated with 1H-MRS quantified HTGC based on genotyping with a 
genome-wide exome chip (Kozlitina et al., 2014).  
The region (19p13.11) that the TM6SF2 rs58542926 SNP is located on also contains 
several genes including NCAN, CILP2 (cartilage intermediate layer protein 2), and 
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PBX4 (PBX homeobox 4) which have been reported in a previous study (Speliotes et 
al., 2011). This region had also been associated with variations in plasma 
cholesterol, triglyceride and low-density lipoprotein levels in the previous studies 
(Kathiresan et al., 2008; Teslovich et al., 2010). Initial research focussed on NCAN 
as the lead candidate gene for this association, which was replicated for steatosis, 
inflammation and fibrosis. However, NCAN lacked biologically plausible evidence of 
a functional role in NAFLD (Anstee and Day, 2013). The use of a genome-wide 
exome-chip genotyping approach in 2,736 individuals, combined with detailed 
association analysis conditioning on previously identified variants across the 
19p13.11 region, determined that the causative non-synonymous variant affecting 
HTGC is in strong linkage disequilibrium (D’=0.926, r2=0.798) with the previously 
identified NCAN variant (rs2228603) but actually lies within the neighbouring gene, 
TM6SF2 (rs58542926) (Kozlitina et al., 2014). Most importantly, the effect of the 
NCAN variant was completely abrogated when conditioning on the TM6SF2 variant 
whilst the reverse did not occur, suggesting that the association with HTGC at this 
locus is driven by TM6SF2 rs58542926. Homozygous carriage of the TM6SF2 
rs58542926 minor (T) allele was shown to be associated with a modest but 
statistically significant increase in 1H-MRS measured HTGC from 5.86±0.25% in CC 
homozygotes to 15.04±2.23% in TT homozygotes (Kozlitina et al., 2014). While 
carriage of the TM6SF2 rs58542926 minor (T) allele was associated with increased 
HTGC, another group coincidentally demonstrated that carriage of the common (C) 
allele of the TM6SF2 rs58542926 was significantly associated with increased 
circulating cholesterol levels and greater risk for developing cardiovascular disease 
(CVD) (Holmen et al., 2014). Another newly published GWAS enrolled 2,300 
extremely obese individuals with liver biopsy data, once again validating the 
strongest association of PNPLA3 and suggesting a locus (rs10401969) in the gene 
SURP and G-patch domain containing 1 (SUGP1) near TM6SF2 was significantly 
linked to hepatic steatosis (DiStefano et al., 2015). 
 
1.7.3.5 Additional genetic risk factors for NAFLD identified in candidate gene studies 
Other than PNPLA3 and TM6SF2, only a few loci associated with NAFLD have been 
independently validated and can be considered of proven importance. These 
include: GCKR, a key regulator of glucokinase activity that controls glucose 
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metabolism (Speliotes et al., 2011); SOD2, which affects intracellular resistance to 
oxidative stress (Al-Serri et al., 2012); phosphatidylethanolamine N-
methyltransferase (PEMT), which catalyses the conversion of 
phosphatidylethanolamine to phosphatidylcholine and so is needed for normal 
hepatic VLDL secretion (Dong et al., 2007); and kruppel-like factor 6 (KLF6), a 
transcription factor that is highly expressed by activated stellate cells soon after 
injury (Ratziu et al., 1998; Miele et al., 2008).  
The rs780094 SNP in GCKR is in strong LD with a functional nonsynonymous SNP 
(rs1260326, encoding Pro446Leu), and has been associated with hepatic TAG 
accumulation due to consistent increase in glucokinase activity and glucose uptake 
caused by impaired GCKR ability (Beer et al., 2009). The role of GCKR in NAFLD 
has also been independently validated across several ethnic groups (Palmer et al., 
2013; Tan et al., 2014). The rs4880 SNP in SOD2 has been linked to advanced 
fibrosis in Japanese (Namikawa et al., 2004) and European (Al-Serri et al., 2012) 
cohorts. Carriers of the common (C) allele of rs4880 have more effective MnSOD 
mitochondrial transport and are thus potentially protected from cell damage 
compared to those are homozygous mutant (TT). Two studies reported that carriers 
of the PEMT variant (rs7946, p.Val175Met) had an increased susceptibility to NAFLD 
(Song et al., 2005; Dong et al., 2007). The KLF6–IVS1 –27G>A (rs3750861) SNP 
has been associated with milder NAFLD-related hepatic fibrosis in three separate 
European cohorts (Miele et al., 2008). Carriage of the KLF6-IVS1 –27A polymor-
phism generates more of the KLF6-SV1 alternative spice isoform, lowering hepatic 
insulin resistance and blood glucose levels. This may in part be mediated through 
GCKR and glucokinase activity (Bechmann et al., 2012).   
Other genetic modifiers that have been identified by GWAS or candidate-gene 
association studies, involving in different aspects of NAFLD pathogenic mechanisms 
are summarised in Table 1.3. 
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Table 1.2: Genetic risk factors identified by GWAS, adapted and slightly modified from (Liu et al., 2016b). 
Genetic risk factor  Population (sample size, n) Methodology (Numbers of SNPs) Reference 
Chr 22: PNPLA3 (rs738409) United States, mixed ethnicity (n=2,051) 
(B: 1,032; W: 636; H: 383) 
1H-MRS Steatosis (9,229) (Romeo et al., 2008) 
Chr 22: PNPLA3 (rs738409, rs22949158, 
rs2076211, rs2281135, rs2073081) 
CPN1-ERLIN1-CHUK  
(rs11597390, rs11591741, rs11597086) 
European, mixed ethnicity (n=12,419) 
(3 discovery and 3 replication groups) 
Clinical Biochemistry, ALT (not applicable) (Yuan et al., 2008) 
FDFT1 (rs2645424), COL13A1 (rs1227756) 
EFCAB4B (rs887304), PZP (rs6487679) 
Chromosome 7 (rs343062) 
United States, European Caucasian with 
female only (n=236) 
Histology (324,623)  (Chalasani et al., 2010) 
Chr 22: PNPLA3 (rs738409) 
Chr 19: NCAN (rs2228603) 
GCKR (rs780094), LYPLAL1 (rs12137855), 
PPP1R3B (rs4240624) 
Meta-analysis of previous studies from 
United States & Europe (n=7,176) 
CT-measured steatosis with histological 
‘candidate gene’ validation set (Range 329k-618k 
before imputation) 
(Speliotes et al., 2011) 
Chr 22: PNPLA3 (rs738409) 
TRIB1 (rs2954021) 
Loci near HSD17B13 and MAPK10 
(rs6834314) 
CPN1 (rs10883437) 
European, mixed ethnicity (n=61,089) Clinical Biochemistry, ALT (~2.6 million) (Chambers et al., 2011) 
Chr 22: PNPLA3 (rs738409) Japanese (n=529) Histology (484,751) (Kawaguchi et al., 2012) 
Chr 22: PNPLA3 (rs738409) Japanese (n=392) Histology (261,540) 
 
(Kitamoto et al., 2013) 
Chr 22: PNPLA3 (rs738409), 
PPP1R3B (rs2126259), 
ERLIN1–CHUK–CWF19L1 gene cluster 
(9 SNPs in two haplotype blocks) 
United States (n=2,705) CT-measured steatosis (~2.5 million) (Feitosa et al., 2013) 
Chr 22: PNPLA3 (rs738409) 
Chr 19: TM6SF2 (rs58542926) 
United States, mixed ethnicity (n=2,736) 
(B: 1,324; W: 882; H: 467; O:63) 
1H-MRS Steatosis (138,374, exome) (Kozlitina et al., 2014) 
PNPLA3 and SUGP1  
(neighbouring gene to TM6SF2) 
United States, mixed ethnicity (n=2,300) Histology (DiStefano et al., 2015) 
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Table 1.3: Additional genetic risk factors for NAFLD identified in candidate gene studies.  
Gene Protein Comments 
Glucose metabolism and insulin resistance 
ENPP1; 
IRS1 
Ectonucleotide pyrophosphatase/phosphodiesterase 
family member 1; Insulin receptor substrate 1 
Functional variants in ENPP1/PC-1 and IRS1 impair insulin receptor signalling and promote insulin resistance (McGettrick 
et al., 2005; Grarup et al., 2006). 
In 702 biopsy-proven NAFLD cases, carriage of nonsynonymous SNPs in ENPP1 (rs1044498, encoding Lys121Gln) and IRS1 
(rs1801278, encoding Gln972Arg) reduced AKT activation, promoted insulin resistance and were independently 
associated with greater fibrosis (Dongiovanni et al., 2010b). 
A second smaller (underpowered) study on ENPP1 did not find a significant effect (Carulli et al., 2009). 
 
GCKR Glucokinase regulatory protein GCKR SNP rs780094 is in strong LD with a functional nonsynonymous SNP (rs1260326, encoding Pro446Leu) and has 
been associated with hepatic TAG accumulation in several studies (Chambers et al., 2011; Speliotes et al., 2011). 
 
SLC2A1 Solute carrier family 2, facilitated glucose transporter 
member 1 
A study examining 3,072 SNPs across 92 candidate genes identified variants in SLC2A1 associated with NAFLD, 
independent of insulin resistance or T2DM (Petta et al., 2014). 
Downregulation of SLC2A1 in vitro promoted lipid accumulation and increased oxidative stress, potentially linking the key 
pathogenic features of NAFLD: oxidative injury and increased lipid storage (Vazquez-Chantada et al., 2013). 
 
TCF7L2 Transcription factor 7-like 2 A role for TCF7L2, which has a key role in Wnt signalling and has been implicated in T2DM, has been reported in NAFLD 
(Musso et al., 2009). 
 
PPARG Peroxisome proliferator-activated receptor γ A loss-of-function SNP (rs1805192, encoding Pro12Ala) impairs transcriptional activation and affects insulin sensitivity 
(Tonjes et al., 2006). Carriage of haplotypes including the Pro12Ala allele were associated with progressive NAFLD 
(Gawrieh et al., 2012), but two studies found no association (Dongiovanni et al., 2010a; Rey et al., 2010). 
 
Steatosis 
Hepatic lipid import or synthesis 
SLC27A5  Very long-chain acyl-CoA synthetase Two principal isoforms of FATPs are expressed in the liver, SLC27A2 (also known as FATP2) and SLC27A5 (also known as 
FATP5) (Hirsch et al., 1998). 
Silencing Slc27a5 reverses diet-induced NAFLD and improves hyperglycaemia in mice (Doege et al., 2008). 
Carriage of the SLC27A5 rs56225452 promoter region polymorphism has been associated with higher ALT levels, and 
greater postprandial insulin and triglyceride levels (Doege et al., 2008). 
In patients with histologically proven NAFLD, the effect of BMI on degree of steatosis differed with SLC27A5 genotype 
(Auinger et al., 2010). 
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LPIN1 Phophatidate phosphatase LPIN1 LPIN1 is required for adipogenesis and the normal metabolic flux between adipose tissue and liver, where it also acts as 
an inducible transcriptional co-activator to regulate fatty-acid metabolism (Reue and Zhang, 2008; Reue, 2009). 
Variants have been associated with multiple components of the metabolic syndrome (Reue and Zhang, 2008; Wiedmann 
et al., 2008). 
Although a large case–control study found no association with T2DM, obesity or related traits in 17,538 individuals 
(Burgdorf et al., 2010), a meta-analysis in 8,504 individuals found that the LPIN1 rs13412852 [T] allele was associated 
with lower BMI and insulin levels (Fawcett et al., 2008). 
This same polymorphism was under-represented in paediatric (but not adult) NAFLD with a suggestion of less severe liver 
damage (Valenti et al., 2012). 
Hepatic lipid export or oxidation in steatosis 
PNPLA3 Patatin-like phospholipase domain-containing 3 The nonsynonymous 617C>G nucleotide transversion mutation SNP (rs738409, encoding Ile148Met) has been 
consistently associated with steatosis, steatohepatitis and hepatic fibrosis; however, function remains incompletely 
understood (Romeo et al., 2008; Valenti et al., 2010a). 
 
NR1I2 Nuclear receptor subfamily 1 group I member 2 (also 
known as pregnane X receptor) 
NR1I2 encodes a transcription factor that regulates hepatic detoxification (Zhang et al., 2008) and acts through CD36 
(fatty-acidtranslocase) and various lipogenic enzymes to control lipid metabolism (Zhou et al., 2006). 
Nr1i2-deficient mice develop steatosis (Zhou et al., 2006). 
Two SNPs (rs7643645 and rs2461823) were associated with NAFLD and were also a predictor of disease severity 
(Sookoian et al., 2010). 
 
PPARA Peroxisome proliferator-activated receptor α PPAR-α is a molecular sensor for long-chain fatty acids, eicosanoids and fibrates; activated by increased hepatocyte fatty-
acid load, it limits TAG accumulation by increasing fatty-acid oxidation (Kim et al., 2003). 
Carriage of a nonsynonymous SNP (rs1800234, encoding Val227Ala) increases activity, and was associated with NAFLD 
despite reduced BMI (Yamakawa-Kobayashi et al., 2002; Chen et al., 2008). 
A loss-of-function polymorphism (rs1800206, encoding Leu162Val) was not associated with NAFLD (Dongiovanni et al., 
2010a). 
 
PEMT Phosphatidylethanolamine N-methyltransferase Two studies have reported an association between NAFLD and a nonsynonymous PEMT exon 8 590G>A transversion 
(rs7946, encoding Val175Met) (Song et al., 2005; Dong et al., 2007). 
 
MTTP Microsomal triglyceride transfer protein  MTTP mediates hepatic synthesis and secretion of VLDL. 
Abetalipoproteinaemia (OMIM#200100) results from a loss-of-function frameshift mutation in MTTP; however, whereas 
this mutation causes severe hepatic TAG accumulation, steatohepatitis and fibrosis are infrequent (Lonardo et al., 2006). 
A promoter region transversion (–493G>T; rs1800591), predisposed to steatosis and NASH (Bernard et al., 2000; 
Namikawa et al., 2004) in a small cohort, but a larger study in 131 patients found no association (Oliveira et al., 2010). 
 
APOC3 Apolipoprotein C-III Two promoter region SNPs –455T>C; rs2854116 and –482C>T; rs2854117) that increased steatosis were reported in 
small (n = 95 and 163) cohorts of Asian-Indian and non-Asian ethnicity (Petersen et al., 2010). 
To date, studies together examining >4,000 individuals have been unable to replicate these findings (Kozlitina et al., 
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2011; Sentinelli et al., 2011; Valenti et al., 2011a; Verrijken et al., 2013). 
 
APOE Apolipoprotein E ApoE is a plasma protein involved in lipid transport and metabolism (Utermann et al., 1977). 
Three alleles (ε2, ε3 and ε4) determine three isoforms (ApoE2, ApoE3 and ApoE4) resulting in six ApoE genotypes (E2/2, 
E3/3, E4/4, E2/3, E2/4, E3/4). Overall homozygosity for the ε2 allele in one study was associated with dyslipidaemia, but 
not NAFLD (Demirag et al., 2007). 
In a subgroup of nonobese individuals, the ε2 allele and the E2/3 genotype were more prevalent in controls, suggesting 
this allele might be protective. (Demirag et al., 2007).  
Consistent with this result, the ApoE3/3 genotype was associated with NASH in a Turkish cohort, whereas ApoE3/4 was 
protective (Sazci et al., 2008). 
Steatohepatitis 
Oxidative stress 
HFE Hereditary hemochromatosis protein Hepatic iron accumulation promotes oxidative stress. Two studies, examining 177 patients, reported carriage of an HFE 
polymorphism (rs1800562, encoding Cys282Tyr) that was associated with more severe steatohepatitis and advanced 
fibrosis (George et al., 1998; Nelson et al., 2007). 
However, three other studies (Bugianesi et al., 2004; Raszeja-Wyszomirska et al., 2010; Valenti et al., 2010c)have not 
shown increased carriage of either the Cys282Tyr or His63Asp (rs1799945) mutations. 
Meta-analyses have also provided conflicting results, with the latest finding no evidence of an effect (Ellervik et al., 2007; 
Hernaez et al., 2011). 
 
GCLC; 
GCLM 
Glutamate-cystein ligase catalytic unit; glutamate-
cystein ligase regulatory unit 
Glutamate-cysteine ligase (γ-glutamyl cysteine synthetase) is the rate-limiting step in glutathione synthesis; absence of 
Gclc causes steatosis and liver failure in mice (Buch et al., 2007). 
A study of 131 patients with NAFLD found the GCLC promoter region polymorphism (–129C>T, rs17883901) was 
associated with steatohepatitis compared with simple steatosis (Oliveira et al., 2010). 
 
ABCC2 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 2 
Association studies support a role for ABCC2 (also known as MRP2), which facilitates terminal excretion and 
detoxification of endogenous and xenobiotic organic anions, including lipid peroxidation products (Sookoian et al., 
2009a). 
 
SOD2 Superoxide dismutase [Mn], mitochondrial Carriage of the nonsynonymous SNP (rs4880, encoding Ala16Val) has been associated with advanced hepatic fibrosis in 
NAFLD in both Japanese (Namikawa et al., 2004) and European (Al-Serri et al., 2012) cohorts.  
Endotoxin response 
TLR4 Toll-like receptor 4 Study of a spontaneous Tlr4 null mutation in C3H/J mice has established the contribution of TLR4/endotoxin to NAFLD 
pathogenesis in the laboratory (Spruss et al., 2009). 
TLR4 polymorphisms (rs4986791 and rs4986790) influence hepatitis-C-related fibrosis (Huang et al., 2007; Guo et al., 
2009), but no association with NAFLD and either TLR4 or NOD2 (bacterial cell wall peptidoglycan receptor) variants has 
been found. 
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CD14 Monocyte differentiation antigen CD14 CD14 is a lipopolysaccharide receptor expressed on monocytes, macrophages and neutrophils that enhances TLR4 
endotoxin signaling. An association with a promoter-region polymorphism (–159C>T, rs2569190) that increases CD14 
expression has been reported (Baldini et al., 1999; Day et al., 2006). 
Cytokines 
TNF Tumour necrosis factor A TNF (–238G>A, rs361525) promoter polymorphism has been associated with NASH (Valenti et al., 2002; Tokushige et 
al., 2007), suggesting a primary role in the transition from steatosis to steatohepatitis; a separate study, found that two 
other promoter region polymorphisms (–1031T>C, rs1799964 and –863C>A, rs1800630) were more common in NASH 
than steatosis, but were no more common in NAFLD than a control population (Tokushige et al., 2007). 
 
IL6 Interleukin 6 An IL6 promoter region polymorphism (–174G>C, rs1800795) has been associated with NASH (Carulli et al., 2009). 
 
Fibrosis 
AGTR1 Type-1 angiotensin II receptor Two studies have linked the ATGR1 rs3772622 SNP with grade of steatohepatitis and stage of fibrosis, with the most 
recent study also suggesting an interaction with PNPLA3 genotype (Yoneda et al., 2009; Zain et al., 2013). 
KLF6 Kruppel-like factor 6 The KLF6–IVS1 –27G>A (rs3750861) SNP has been associated with milder NAFLD-related hepatic fibrosis in three 
separate European cohorts (Miele et al., 2008). 
 
MBOAT7/ 
LPIAT1 
Membrane bound O-acyltransferase domain 
containing 7 (also known as Lysophosphatidylinositol 
acyltransferase-1) 
A recent study with two large cohort sets (Dalles Heart Study, n=3854 and Liver Biopsy Cross-Sectional Cohort, n=1,149) 
reported the rs641738 SNP in MBOAT7 was associated with increased risk in developing steatosis, severe necro-
inflammation and advanced fibrosis (Mancina et al., 2016). The effect of rs641738 variant on NAFLD/NASH development 
may be mediated by alterations in the hepatic phosphatidylinositol acyl-chain remodeling (Mancina et al., 2016). 
 
Adapted and slightly modified from (Liu et al., 2016b).  
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1.7.3.6 Biological relevance of PNPLA3  
Ever since the association of PNPLA3 with NAFLD was identified by the first GWAS-
like study in NAFLD (Romeo et al., 2008), this association has been validated across 
multiple patient cohorts. The link between PNPLA3 and NAFLD was established in 
radiologically phenotyped cohorts however such studies are unable to assess the 
presence of features such as NASH or stage of liver fibrosis that can only be 
detected histologically. This deficiency reflects the difficulty in assembling sufficiently 
large patient cohorts that have undergone invasive testing by liver biopsy to provide 
a well-powered fully phenotyped cohort and means that the majority of GWAS 
studies are radiologically based and so ‘phenotype limited’ to detecting variations in 
HTGC. Candidate-gene disease association studies in histologically characterised 
patient cohorts have therefore been necessary to establish whether genetic variants 
identified by GWAS, such as PNPLA3, do indeed influence disease progression 
towards the more clinically relevant phenotypes.  
The PNPLA3 rs738409 variant has been shown to increase the risk of NASH and 
advanced liver fibrosis, independent of potential confounding factors such as age, 
BMI or T2DM (Valenti et al., 2010a; Anstee and Day, 2013). This variant has also 
been associated with increased HCC risk in alcohol-related liver disease (Nischalke 
et al., 2011; Trepo et al., 2012; Guyot et al., 2013; Trepo et al., 2014) and, more 
variably, in chronic viral hepatitis (Falleti et al., 2011; Nischalke et al., 2011; Valenti 
et al., 2011b; Guyot et al., 2013; Trepo et al., 2014). Data has also been presented 
showing an association with HCC in morbidly obese patients (Burza et al., 2012) and 
a mixed-aetiology cohort (Hassan et al., 2013). Although it may be hypothesised that 
these latter associations are related to underlying NAFLD, prior to the studies within 
this thesis, no studies had specifically addressed the effect of PNPLA3 rs738409 
C>G carriage on HCC risk in a NAFLD cohort.  
As a strong genetic risk factor for NAFLD, the biological function of PNPLA3 has 
been extensively studied. The PNPLA3 gene encodes a 481 amino acid protein (also 
referred to as adiponutrin) that belongs to a family of lipid hydrolases (patatin-like 
phospholipase domain containing proteins, PNPLA1-9) (Park et al., 1983). Among 
the human PNPLA proteins, PNPLA3 is structurally related to adipose triglyceride 
lipase (ATGL, also known as PNPLA2), the major triglyceride hydrolase in adipose 
tissue (Zimmermann et al., 2004; Kienesberger et al., 2009). Hence, PNPLA3 was 
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first thought to possess a similar function as ATGL. However, in contrast to the 
excessive TG accumulation that occurs following ATGL loss in mice, PNPLA3 knock-
out mice do not show increased hepatic TG content (Zimmermann et al., 2004). 
Similarly, reduced TG content was not seen when the PNPLA3 (I148) wild-type 
variant was overexpressed whereas this did occur with ATGL overexpression (He et 
al., 2010). These studies both suggest that the function of PNPLA3 differs 
substantially from ATGL. Evidence established so far suggests that there are some 
differences in tissue distribution of PNPLA3 expression between humans and mice 
which has made functional study of PNPLA3 more difficult. Amongst metabolically 
active organs, PNPLA3 is mainly expressed in the liver of humans (Wilson et al., 
2006) whilst adipose tissue expression dominates in mice (Lake et al., 2005). The 
expression of PNPLA3 is controlled in a nutrition-dependent manner: on fasting, 
expression is down-regulated whilst consumption of a high-carbohydrate diet up-
regulates expression (Dubuquoy et al., 2011). PNPLA3 is regulated by ChREBP 
under hyperglycaemia resulting in increased hepatic glycolysis and lipogenesis 
(Rae-Whitcombe et al., 2010; Perttila et al., 2012b). Insulin also controls postprandial 
PNPLA3 expression through liver X receptor–retinoid X receptor (LXR-RXR) and 
SREBP-1c that also promotes de novo lipogenesis (Shimomura et al., 1999a; Huang 
et al., 2010).  
Despite the plethora of genetic evidence for an effect, the physiological role of 
PNPLA3 and how it is perturbed by carriage of the rs738409 (I148M) variant has 
remained elusive. Although some progress has been made, the data is at times 
conflicting and there remains some debate as to whether the variant is a true loss-of-
function mutation or not. In vitro studies with both wild-type and mutant isoforms of 
recombinant adiponutrin indicate that PNPLA3 mediates hydrolysis of acylglycerols 
and that maximal hydrolytic activity is towards any of the three major glycerolipids 
(triacylglycerol, diacylglycerol and monoacylglycerol) as substrates, with a strong 
preference for oleic acid as the acyl moiety (He et al., 2010; Huang et al., 2011). 
Compared to the PNPLA3 wild-type protein, the I148M variant possesses 
substantially reduced enzymatic activity but there does not appear to be any change 
in substrate affinity (He et al., 2010; Huang et al., 2011). These findings are 
consistent with the results of stable isotope tracer studies in overweight or obese 
men and in vitro studies which show that carriage of the rs738409 (I148M) variant 
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reduces VLDL secretion, an effect attributed to failure to mobilize TG from 
intracellular lipid droplets (Pirazzi et al., 2012). Arguing against a simple loss-of-
function effect however, PNPLA3 knockout mice do not develop steatosis (Basantani 
et al., 2011). Indeed, others have suggested that the l148M substitution acts as a 
gain-of-function mutation with the variant form possessing some lysophosphatidic 
acid acetyltransferase activity, leading to an increase of TG synthesis (Kumari et al., 
2012). Supporting this, murine overexpression of wild-type PNPLA3 does not induce 
steatosis but overexpression of the variant (I148M) form does (Li et al., 2012). A 
recent study with PNPLA3 I148M knockin mice showed that HTGC level was normal 
on a chow diet but increased 2 to 3-fold compared to wild-type littermates with high 
sucrose diet. This increased fat was accompanied by a 40-fold increase in PNPLA3 
on hepatic lipid droplets, without increase in hepatic PNPLA3 messenger RNA 
(mRNA). Similar results were observed when inactivating the catalytic dyad of 
PNPLA3 by substituting the catalytic serine with alanine (S47A), suggesting that the 
catalytically inactive PNPLA3 protein is necessitate to drive NAFLD pathogenesis 
instead of a complete absence of PNPLA3 activity (Smagris et al., 2015).Taken 
together, the currently available data would suggest that the PNPLA3 I148M variant 
alters TG remodelling in lipid droplets within hepatocytes (Li et al., 2012; Ruhanen et 
al., 2014). 
Beyond steatosis, the underlying mechanisms through which PNPLA3 influences 
progression to NASH and hepatic fibrosis still remained uncertain. Recent data 
suggests that PNPLA3 may have a role in retinol metabolism, acting as retinyl-
palmitate hydrolase in human HSCs which are dominant players in fibrogenesis 
(Pirazzi et al., 2014). Overexpressed wild-type PNPLA3 in HSCs resulted in a 
substantial reduction of lipid droplets, an effect that was lost with I148M. However, 
how this alters HSC activation and affects collagen deposition and fibrosis is not 
known however it does suggest that PNPLA3 may have specific roles in different cell 
types and metabolic conditions which each contribute to the progression of NAFLD 
from steatosis to fibrosis. Thus, challenges remain in which cell types to target and 
what kinds of experimental conditions should be applied in order to investigate the 
comprehensive role of PNPLA3 in NAFLD. 
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1.7.3.7 Biological aspects of TM6SF2 
Reflecting the recent nature of the discoveries mentioned in section 1.7.3.4, little is 
currently known about the biological function of TM6SF2. It was first described as a 
multi-pass membrane protein in 2000 (Carim-Todd et al., 2000), and was later 
discovered to be highly expressed in liver, kidney and intestines (Kozlitina et al., 
2014; Surakka et al., 2015). In vitro study using confocal microscopy, GFP-tagged 
TM6SF2 was mainly localized to the endoplasmic reticulum (ER) and ER-Golgi 
intermediate compartments (ERGIC) (Mahdessian et al., 2014). In the same study, 
TM6SF2 siRNA inhibition led to a reduction of lipid secretion (triglycerides (TG) and 
Apolipoprotein B (ApoB)) and an increase in the number and overall size of lipid 
droplets, which represented as a manifestation of cellular triglyceride accumulation. 
On the contrary, overexpression of TM6SF2 caused a decrease in the lipid droplet 
contents (Mahdessian et al., 2014). Prediction of mouse knockout phenotype by 
analysis of coexpressed gene profiles based on Mouse Genome Informatics (MGI) 
Database, TM6SF2 is linked to abnormal lipids levels (decreased total cholesterol 
(TC), low-density lipoprotein-cholesterol (LDL-C) and VLDL) and may act as lipid 
transporter and interact with proteins involved in intestinal absorption (Surakka et al., 
2015). In vivo studies may provide more clues for above statements; adenovirus-
mediated short hairpin RNA knockdown of Tm6sf2 in mice has been shown to 
increase hepatic triglyceride content and reduce plasma cholesterol and VLDL 
secretion, suggesting that TM6SF2 activity is necessary for normal VLDL secretion 
and that impaired TM6SF2 function causally contributes to NAFLD (Kozlitina et al., 
2014). On the other hand, transient overexpression of Tm6sf2 in C57BL/6J mice 
resulted in a significant increase of serum TC, LDL-C and TG. These in vivo (Holmen 
et al., 2014; Kozlitina et al., 2014) and in vitro (Holmen et al., 2014; Kozlitina et al., 
2014; Mahdessian et al., 2014) functional studies indicate that TM6SF2 has effects 
on fat retention in the liver, lipid efflux and alteration in the number and average size 
of lipid droplets. However, the genetic and biological studies previously mentioned 
only focused on relevance to hepatic steatosis. Whether the effect of TM6SF2 is 
limited to steatosis or has broader clinical relevance, affecting susceptibility to both 
steatohepatitis and fibrosis as has already been shown for PNPLA3, remains 
undetermined. Further research is needed to establish the precise function of the 
TM6SF2 protein and to determine how this knowledge can be exploited clinically. 
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1.8 Aims  
NAFLD is best considered a complex disease trait in which subtle inter-patient 
genetic variations and environmental factors interact to determine disease 
phenotype and progression. Recent technical advances have led to the identification 
of important genetic modifiers, in particular non-synonymous gene variants in 
PNPLA3 (I148M) and TM6SF2 (E167K) that are associated with NAFLD. The aims 
of this thesis are to identify and validate candidate genes/SNPs based on the 
aforementioned literature that confer progression of NAFLD to its progressive 
stages, principally the PNPLA3 and TM6SF2 genes.  
The work of this thesis can be divided into two parts: case-control association 
studies (the majority of the thesis) and functional studies: 
 Case-control association studies: 
 To validate the PNPLA3 association in the FLIP GWAS cohort 
(n=1,005) to confirm its relevance to disease spectrum of NAFLD 
(steatosis, steatohepatitis and fibrosis) 
 To validate and expand the relevance of TM6SF2 to NAFLD severity   
 To investigate the relevance of PNPLA3 and TM6SF2 to NAFLD-
related HCC 
 With the available genetic data, pilot studies investigating the function of 
PNPLA3 were subsequently conducted: 
 To explore biological differences caused by the amino-acid substitution 
in vitro, mainly focused on the investigation of the correlation between 
PNPLA3-I148M and lipid metabolism in different cultured cells 
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2 Chapter 2. Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
51 
 
2.1 Patients 
The patients involved in this project can be divided into two cohorts: 1) the patients 
recruited from Newcastle, UK and 2) the patients from a FP7 project (FLIP, Fatty 
liver: Inhibition of Progression) funded by European Commission. These samples 
were collected at NAFLD clinics and bariatric surgery clinics across Europe. 
 Newcastle-based patients: Patients with biopsy-proven NAFLD were recruited 
from the Freeman hospital NAFLD clinic. 
 FLIP-based patients: Patients were recruited from hepatology clinics at 
several European specialist centres: the Freeman Hospital, Newcastle-upon-
Tyne, UK; Addenbrooke’s Hospital, Cambridge, UK; Queen’s Medical Centre, 
Nottingham, UK; Inselspital Hospital, Bern, Switzerland; Pitié-Salpêtrière 
Hospital, Paris, France; and Antwerp University Hospital, Belgium.  
 
All the necessary ethical approvals were obtained for this project and all participants 
gave informed consent. In all cases, alternative diagnoses were excluded, including 
excess alcohol intake (alcohol consumption < 20g/day for women; < 30g/day for 
men), chronic viral hepatitis (hepatitis B and hepatitis C), autoimmune liver diseases, 
hereditary hemochromatosis, α1-antitrypsin deficiency, Wilson’s disease and drug-
induced liver injury. Clinical and laboratory data were collected at the time of 
diagnosis including basic anthropometrics so that body mass index (BMI) could be 
calculated, and relevant co-morbidity including the presence of type 2 diabetes 
mellitus (fasting glucose ≥7.1 mmol/L [≥128 mg/dl] or treatment with anti-diabetic 
drugs) and evidence of underlying cirrhosis was recorded. 
 
2.2 Liver biopsy 
Liver biopsy was performed under radiological guidance. Specimens (at least 1.6 cm 
length and 1.5 mm thick) were fixed in 10% neutral formalin for evaluation and 
embedded in paraffin for histological examination. Tissue sections were stained with 
hematoxylin and eosin, impregnated with silver for visualizing reticulin framework 
and stained with Sirius Red Fast Green for visualizing collagen. Liver biopsies for 
Newcastle samples were reviewed by two expert liver pathologists: Alastair Burt and 
Dina Tiniakos. Liver biopsies for FLIP samples were performed by the collaborators 
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at each participating centre. Liver histology scoring was performed according to 
Kleiner et al. (Kleiner et al., 2005) and this provided a NAFLD activity score (NAS) 
which covers the degree of steatosis (0-3), hepatocyte ballooning (0-2) and lobular 
inflammation (0-3), and a separate fibrosis stage (0-4). A recently released scoring 
system, the validated semi-quantitative SAF score, is similar to the NAS score but 
separates the degree of steatosis from those of inflammation/ballooning to prove 
three separate measures of NAFLD severity. On this system, NAFLD is classified 
into the degree of steatosis (0-3), activity of steatohepatitis (A0-4) and stage of 
fibrosis (F0-4) (Bedossa and Consortium, 2014). This SAF score system was also 
considered in this study. Comparison of the SAF Score and the NAFLD Kleiner 
Score for the histological grading and staging of NAFLD/NASH is shown in Table 
1.1. 
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2.3 Laboratory methods 
2.3.1 Materials 
Materials and methods described in this chapter is relevant to several different 
chapters. More specific methods sections are provided in Chapters 3, 4, 5 and 6. 
Suppliers of materials commonly used in this work are shown in Table 2.1 or 
otherwise stated in the text. The composition of stock solutions commonly used is 
listed in Table 2.2. 
 
Table 2.1: List of suppliers and addresses. 
Suppliers Address 
Applied Biosystems California, USA 
Bioline London, UK 
Bio-Rad Hemel Hempstead, UK 
Fisher scientific Loughborough, UK 
Greiner Bio-One Stonehouse, UK 
Lonza Slough, UK 
New England Biolabs (NEB) Hitchin, UK  
QIAGEN  Crawley, UK  
Sigma Aldrich Gillingham, UK  
Thermo Scientific  Loughborough, UK 
 
Table 2.2: Compositions of commonly used stock solutions. 
Solution Composition 
10X TAE (Tris-acetate-EDTA) buffer per litre  10 mM Tris-base 48.4 g/L 
17.4 M Glacial acetic acid 11.4 ml/L 
10 mM EDTA 3.7 g/L 
DNA loading buffer 0.25% (w/v) bromophenol blue 
0.25% (w/v) xylene cyanol 
30 % glycerol 
2X protein sample loading buffer 0.125 M Tris-HCl pH 6.8 
4% SDS 
20% glycerol 
0.004% bromophenol blue 
10% β-mercaptoethanol 
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2.3.2 DNA extraction from blood samples 
Venous blood was collected from each patient and DNA was prepared from 
peripheral blood lymphocytes using a perchlorate-chloroform isolation method (Daly 
et al., 1996). Briefly, 35 ml lysis buffer (10 mM Tris-HCl (pH 8.0), 320 mM Sucrose, 5 
mM Magnesium Chloride, 1% Triton X-100) was added to 5 ml venous blood in a 50 
ml polypropylene centrifuge tube. After mixing, the tube was centrifuged at 3000G for 
10 min. The supernatant was discarded and the cell pellet was re-suspended in 2 ml 
of solution B (400 mM Tris-HCl (pH 8.0) 60 mM EDTA, 150 mM NaCl, 1% SDS). 500 
µl of sodium perchlorate (5 M) was added and the sample was mixed at room 
temperature for 15 min before incubating in a preheated hot block at 65oC for 30 
min. Next, 2 ml chloroform was added and the sample was further mixed for 10 min 
at room temperature. Having been centrifuged at 1400G for 10 min, the upper and 
clear DNA-containing phase was transferred to a new 15 ml polypropylene tube. 
Cold ethanol (7 ml) was added to the aqueous phase and the tube was gently 
inverted until the DNA precipitated. The DNA was spooled by using a soft plastic 
sterile loop and allowed to air dry for 20 min. DNA was then re-suspended in 200 µl 
of 5 mM Tris-HCl solution (pH 8) followed by the incubation at 60oC overnight. 
Samples were quantitated and quality assessed by absorbance measurements at 
260 and 280 nm. Some DNA preparation on Newcastle samples was performed by 
Julian Leathart and Julia Patch (Newcastle University, ICM). DNA isolation from FLIP 
samples was performed locally by the collaborators.  
 
2.3.3 Polymerase chain reaction (PCR) 
Lyophilised primers were purchased from Sigma Aldrich (UK). Forward primers were 
designed approximately 180 base pairs upstream from the polymorphism of interest, 
while reverse primers were around 100 base pairs downstream. Primers were re-
suspended in sterile water for stock purpose (200 μΜ). Further dilutions (25 μΜ) 
were performed during each work. Stock primers and working dilutions were stored 
at -20°C and 4°C, respectively. A total reaction volume of 25 µl of polymerase chain 
reaction was performed in a 200 µl sterile tube, reagents used including 0.1 mM 
dNTPs, 0.25 μΜ for both forward and reverse primers, 0.025 units of Taq DNA 
polymerase, 1X ThermoPol reaction buffer, and genomic DNA (typically 0.2 μg). 
Standard cycling conditions were used with varying annealing temperature according 
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to different nature of primers. 8 µl of PCR products were mixed with 3 µl of DNA 
loading buffer (Table 2.2) and viewed on 2% agarose gel (Table 2.4) at 50 mA for 30 
min. Materials and suppliers used for PCR are listed in Table 2.3. 
 
 
Table 2.3: Reagents used for PCR. 
Name Supplier Concentration 
100X dNTP mix solution Bioline, London, UK 0.1 mM  
100X forward and reverse primers Sigma Aldrich, Gillingham, UK 25 μM 
200X Taq DNA polymerase New England Biolabs, Hitchin, UK 0.025 units 
10X Thermopol Reaction Buffer New England Biolabs, Hitchin, UK 1X 
DNA Samples listed in section 2.1 0.2 μg  
Sterile water Braun Medical Supplies, Inc. 
Melsungen, Germany 
 
 
Table 2.4: Composition of 2% agarose gel. 
Composition  
2% Agarose gel 2 g Agarose powder  
100 ml 1X TAE buffer  
0.5 μg/ml ethidium bromide 
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2.3.4 Genotyping 
Genotyping was performed without knowledge of clinical status or histology of 
patients using two methods: digestion of PCR products by restriction fragment length 
polymorphism (PCR-RFLP) and TaqMan SNP genotyping assay. The method used 
depended on the individual polymorphism being studied. 
 
2.3.4.1 Digestion of PCR products by restriction fragment length polymorphism (PCR-
RFLP)  
Restriction fragment length polymorphism (RFLP) is a technique that genotypes for 
polymorphisms by using highly locus-specific restriction enzymes which digest one 
variant only. Following digestion, fragments are separated according to their size by 
gel electrophoresis. Digestion was performed in a total reaction volume of 22 µl, 
containing 17 µl PCR product, 3 units restriction enzyme (NEB, UK), and digestion 
buffer (NEB, UK). Samples were incubated at 37°C at least for 3 hours but usually 
overnight. Digested products (8 µl) were mixed with DNA loading buffer (3 µl) and 
electrophoresed on 2% agarose gel (Table 2.4) at 50 mA for an hour. Various sizes 
of DNA ladders were included for reference. Agarose gels were visualized and 
photographed on a transilluminator (GENi documentation system, Cambridge, UK). 
 
2.3.4.2 TaqMan SNP genotyping assay 
Genotyping was also performed by TaqMan SNP Genotyping Analysis (Applied 
Biosystems, USA). TaqMan SNP genotyping is a fast, simple and high-quality 
approach to genotyping a large number of samples. Each TaqMan assay was 
supplied as a solution (20X or 40X, 188 µl) containing unlabelled forward and 
reverse primers (1X final concentration was 900 nM) and two reporter probes (1X 
final concentration was 200 nM): VIC dye is linked to the 5´ end of the Allele 1 
sequence while fluorescein amidite (FAM) dye is linked to the 5´ end of the Allele 2. 
The 3´ end of each probe is incorporated with minor groove binder (MGB) 
technology, which the manufacturers assert delivers superior allelic discrimination. A 
2X TaqMan universal master mix (Applied Biosystems, USA) including AmpliTaq 
Gold® DNA polymerase, dNTPs and a passive internal reference based on 
proprietary ROX™ dye for the Applied Biosystems® real-time PCR instrument 
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(StepOne Real-Time PCR system) was also used. Materials and background 
TaqMan chemistry are displayed in Figure 2.1. 
The PCR was performed using a 48-well reaction plate (Applied Biosystems, USA). 
Enough reaction mix was made for 50 samples to avoid volume loss in pipetting. 20X 
working solution (12.5 ul) of SNP Genotyping Assay (6.25 µl for 40X) were added to 
273.5 µl 2X universal master mix. After briefly vortexing, 5 µl of the mixture were 
then transferred into each well of a 48-well plate already containing 5 µl of genomic 
DNA (5 ng/µl) diluted in sterile H2O. Quality controls were also included in each plate 
(duplicate of negative, homozygous wild-type, homozygous mutant, and 
heterozygous controls). The plate was sealed and briefly centrifuged at 300 rpm for 1 
min to avoid air bubbles, and further inserted into the StepOne Real-Time PCR 
machine. A standard 40 cycles of PCR was performed. Each PCR cycle was started 
with a hold mode at 95°C for 10 min, the denaturation process was run at 92°C for 
15 sec, and stages of annealing and extension were performed at 60°C for 1 min. 
Allelic discrimination plots were generated by the proprietary StepOne software. 
Well-distributed clusters were displayed on a XY axis chart based on the different 
fluorescence signals each genotype defined. A cluster located horizontally at the 
bottom end of X axis represented homozygosity of one allele (XX), whereas a cluster 
of homozygous of the other allele (YY) located vertically toward to Y axis. The cluster 
located in between indicated heterozygotes (XY) (Figure 2.2).  
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Figure 2.1: Allelic discrimination is achieved by the selective annealing of TaqMan® MGB 
probes extracted from 
(https://products.appliedbiosystems.com/ab/en/US/adirect/abcmd=catNavigate2&catID=601283
&tab=Literature). 
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Figure 2.2: Example of an allelic discrimination plot of TaqMan SNP genotyping assay. 
 
 
 
 
 
 
 
 
Homozygous Allele 2 (FAM signal) 
Heterozygotes Allele 1 + Allele 2 (VIC + FAM signal) 
Homozygous Allele 1 (VIC signal) 
No DNA template control 
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2.3.5 Statistical analysis 
Statistical analyses were performed using SPSS version 22.0 (IBM, USA) and PLINK 
version 1.07 (Purcell et al., 2007) (via the gPLINK version 2.050 GUI) to collate and 
analyze cohort phenotype data. Continuous variables were analyzed by independent 
two samples t-test and presented as means and standard deviations. Categorical 
variables were analysed by Chi-squared test unless otherwise stated. Multivariate 
logistic regression analysis was conducted incorporating biologically relevant 
covariates that were associated with risk of NAFLD development (age, gender, BMI 
and presence of T2DM) to test the genetic association. An additive genetic model 
best fitted the data and was reported. Results were expressed as beta β ± SEM for 
continuous parameters or odds ratio (OR) for categorical variables, with 95% 
confidence intervals (CI) as appropriate. Significance was taken as P value < 0.05 
throughout.  
 
2.4 Tissue culture 
2.4.1 Cell culture conditions 
All cell lines were cultured in 75cm2 sterile filtered flasks (Greiner Bio-One, 
Stonehouse, UK), and were incubated at 37°C in an atmosphere with 5% humidified 
CO2. Subculture was performed when cells reached to 80-90% confluence with cells 
normally were split into 1:3 ratio. All the solutions for cell culture were filter-sterilized 
by 0.22 μm filter (Merck Millipore, Hertfordshire, UK). When harvesting cultured cells, 
cells were washed by 1X PBS (Lonza, Slough, UK; Cat. No BE17-516F) once and 
were incubated with 1X trypsin for 10 min for cells detachment from flasks. All 
suspension was transferred into a 15 ml sterile tube and the sample was centrifuged 
twice (1st: fresh medium to deactivate trypsinization; 2nd: PBS, to wash the cells 
again) at 400G for 5 min. After centrifugation, cultured cell pellets were ready for 
further experimental purpose. For frozen stock purpose, cell pellets were re-
suspended in freezing medium (5% (v/v) dimethyl sulfoxide (Sigma Aldrich) in filtered 
FBS), kept in freezing container (Nalgene, Thermo Scientific) and stored in liquid 
nitrogen. 
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2.4.2 DNA/RNA isolation from cultured cells 
2.4.2.1 DNA extraction 
DNA extraction was performed by using the DNeasy blood and tissue kit from 
QIAGEN, UK (Cat.no 69504) according to the manufacturer’s instructions. Cells 
were detached by trypsin, then transferred into a 15 ml sterile tube and centrifuged 
twice at 400G for 5 min (1st: fresh medium to deactivate trypsinization; 2nd: PBS, to 
wash the cells again). The supernatant (PBS) of the final cell pellet was discarded 
and the pellet was re-suspended in 200 μl fresh PBS. The pellet was further mixed 
with 20 μl of proteinase K and 200 μl of Buffer AL, following a thorough mix by 
vortexing and an incubation at 56°C water bath for 10 min. The mixture was again 
thoroughly mixed with ethanol (96-100%) by vortexing.  
In the following steps, the mixture underwent centrifugation four times. Firstly, the 
mixture was transferred into the DNeasy mini spin column in a 2 ml collection tube 
(provided in the kit) and was centrifuged at 6000G for 1 min. The flow-through and 
the collection tube were discarded.  
The DNeasy mini spin column was placed in a new 2 ml collection tube, the Buffer 
AW1 (500 μl) was added to the mixture followed by the second centrifugation at 
6,000G for 1 min. The flow-through and the bottom tube were discarded.  
The third time, centrifugation was performed after adding 500 μl Buffer AW2 to the 
mixture and centrifuged at 20,000G to dry the DNeasy membrane, the flow-through 
and the bottom tube was discarded. For the last centrifugation, the DNeasy mini spin 
column was placed in a clean 1.5 ml microfuge tube (not provided in the kit) and 
mixed with 200 μl Buffer AE directly onto the DNeasy membrane. The mixture was 
further incubated at room temperature for 1 min followed by the centrifugation at 
6,000G for 1 min (materials in Table 2.5). The final flow-through would be the DNA 
itself. The concentration and the purity of extracted DNA were measured by using 
absorbance 260/280 and 260/230 ratios provided in Nanodrop spectrophotometer 
software (version: 3.5.2). The DNA product was stored at 4°C. 
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2.4.2.2 RNA isolation 
Cultured cell pellet was prepared as described in section 2.4.1. The pellet was re-
suspended with 1 ml TRI reagent (Sigma Aldrich, Gillingham, UK) and the liquid was 
transferred into a sterile microfuge tube. The tube was allowed to stand at room 
temperature for 5 min. Chloroform (200 μl) was then added to the mixture which 
underwent vigorous shaking for 15 sec to ensure all reagents were mixed 
thoroughly. The tube was allowed to stand at room temperature for 10 min, followed 
by a centrifugation at 12,000G for 15 min at 4°C to separate the mixture into three 
phases: a red organic phase (containing protein), an interphase (containing DNA) 
and a colourless supernatant (RNA). 
The upper aqueous phase (RNA containing) was carefully transferred into a new 
sterile microfuge tube, mixed with 500 μl isopropanol, and allowed to stand at room 
temperature for 5 min. The mixture was centrifuged at 18,000G for 10 min at 4°C to 
precipitate the RNA as a pellet on the side and bottom of the tube. The supernatant 
was discarded. The pellet was further washed by 1 ml of 75% ethanol and vortexed 
thoroughly, followed by a 5-min centrifugation at 8,500G at 4°C to yield the final RNA 
pellet. The RNA pellet was dissolved in 50 μl of RNAse-free water. Samples were 
quantitated and quality assessed by absorbance measurements at 260 and 280 nm 
using Nanodrop spectrophotometer software (version: 3.5.2). RNA was stored at -
80°C for further use (materials used in Table 2.6). 
 
2.4.2.3 Reverse transcription and gene expression analysis 
The RNA was thawed on ice and a master mix of oligo dT primers (0.4 μg), dNTPs 
(10 mM each) and DEPC water (make the volume up to 8 μl) was made. RNA from 
the samples (1 μg) was then mixed with the above reagents (total volume of 10 μl) 
followed by a 10-minute incubation at 65oC. After cooling on ice for 2 min, the 
mixture was further mixed with a second master mix containing 4 units RNAse 
inhibitor, 50 units of reverse transcriptase enzyme, 2 μl 10X reverse transcriptase 
reaction buffer, and DEPC water (total volume up to 10 μl). The RNA was reverse 
transcribed in a total reaction volume of 20 μl. The final mixture was incubated at 
37oC for 50 min and then at 70oC for 15 min to inactivate any remaining enzyme. All 
reagents and suppliers are listed in Table 2.7. The cDNA was then used immediately 
for gene expression analysis or stored at -20oC. 
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Quantitative analysis of gene expression was performed using TaqMan gene 
expression assays (Applied Biosystems). A 20X assay for gene of interest was 
delivered in a tube (250 μl) contains two unlabelled primers (1X final concentration is 
900 nM) and a FAM-dye labelled on 5´ end of the MGB probe (250 nM, final 
concentration). Another 20X assay (250 μl) used for an endogenous housekeeping 
gene contains a VIC-dye labelled on 5´ end of the MGB probe (250 nM) and two 
unlabelled primers (150 nM, primer-limited). Each MGB probe is labelled with non-
fluorescent quencher on 3´ end. 2X TaqMan universal master mix (described in 
section 2.3.4.2) and RNAse-free water were also applied. 
A duplex gene expression analysis was performed using a 48-well plate. Each well 
contained a total reaction volume of 20 μl: 1 μl from the assay of target gene (FAM-
dye labelled), 1 μl from the assay of housekeeping gene (VIC-dye labelled, primer-
limited), 10 μl of 2X TaqMan universal master mix, 4 μl of RNAse-free water, and 4 
μl of cDNA template (1-100 ng). Each sample was run in triplicate and negative 
control (no cDNA template) was included in each experiment. The plate was sealed 
and briefly centrifuged at 300 rpm for 1 min to avoid air bubbles, and was further 
inserted into the StepOne Real-Time PCR machine. PCR performance was 
described in section 2.3.4.2.  
The comparative Ct (cycle threshold) method of PCR data analysis was generated 
by StepOne software version 2.1 (ABI-Biosystems, 1997). Basically, Ct values of 
different samples are directly normalised to an endogenous gene to generate ΔCt 
values. Next, ΔCt values of all samples are normalised to a reference sample (also 
known as calibrator sample) when performing relative quantification. The given 
equation is ΔΔCt = average ΔCt (sample of interest) – average ΔCt (reference 
sample).  
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Table 2.5: DNeasy Blood & Tissue Kit contents abstracted from the QIAGEN manual provided. 
DNeasy Blood & Tissue Kit (50) (250) 
Catalogue Number 69504 69506 
DNeasy mini spin columns (colourless) in 2 ml collection tubes 50 250 
Collection tubes (2 ml) 100 500 
Buffer ATL 10 ml 50 ml 
Buffer AL 12 ml 54 ml 
Buffer AW1 (concentrate) 19 ml 95 ml 
Buffer AW2 (concentrate) 13 ml 66 ml 
Buffer AE 22 ml 2 x 60 ml 
Proteinase K 1.25 ml 6 ml 
 
Table 2.6: Materials used for RNA isolation. 
 
Table 2.7: Reagents used for reverse transcription. 
 
Name Supplier Cat. No./Lot No. 
Tri-reagent (100 ml) Sigma Aldrich, Gillingham, UK T9424 
Chloroform (2.5 L) Fisher Scientific,  Loughborough, UK Code: C/4920/17, Lot:1203452 
Propan-2-ol (1 L) Fisher Scientific,  Loughborough, UK Code: P/7500/15, Lot:1202163 
Ethanol, absolute  Fisher Scientific,  Loughborough, UK Code: E/0650DF/17, 
Lot:1349671 
RNAse-free water (1 L) Fisher Scientific,  Loughborough, UK Code: 10245203, Lot:120135 
Name Supplier Concentration Cat. No. 
Oligo dT primers  QIAGEN, Crawley, UK 0.4 µg/μl 79237 
dNTPs  QIAGEN, Crawley, UK 10 mM each  201901 
DEPC water Fisher Scientific,  
Loughborough, UK 
- BP5611 
Reverse transcriptase 
Reaction Buffer 
New England Biolabs, 
Hitchin, UK 
10X B0253S 
RNase inhibitor New England Biolabs, 
Hitchin, UK 
40,000 units/ml M0307S 
Reverse transcriptase 
enzyme 
New England Biolabs, 
Hitchin, UK 
200,000 units/ml M0253S 
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2.4.3 Western-blot analysis 
The procedure of Western blotting consists of several steps: protein extraction, 
protein concentration determination, polyacrylamide gel electrophoresis, 
electrophoretic transfer of protein, blocking, probing and immunodetection of protein 
blots, and membrane staining. Materials used in these procedures are listed in Table 
2.8. 
 
2.4.3.1 Protein extraction 
A refrigerated centrifuge was precooled to 4oC. A cultured cell pellet was prepared 
as described in section 2.4.1. The cell pellet was washed in 1X PBS (Lonza) and 
transferred into a microfuge tube followed by a 5-min centrifugation at 400G. The 
supernatant was discarded. The cell pellet was re-suspended in chilled CelLytic M 
buffer (Sigma Aldrich) with protease inhibitor (Roche, Welwyn Garden City, UK). The 
mixture was further vortexed moderately till fully dissolved and was left on ice for 10 
min. After centrifugation was performed at 18,000G for 10 min at 4oC to remove cell 
debris, the supernatant (the protein extracts) was transferred to a new microfuge 
tube without disturbing the pellet. The protein extracts were ready to be used for 
Western blotting or frozen at -80oC long-term.  
 
2.4.3.2 Protein concentration determination 
Concentrations of solubilized protein were determined using Coomassie Plus Assay 
Kit (Thermo Scientific, UK) based on the method of Bradford (Bradford, 1976). 10 µL 
of protein sample was added to 250 μl of Coomassie Plus Assay Reagent solution in 
each well of a single 96-well plate, mixed well on a plate shaker with 30 sec and 
incubated at room temperature for 10 min. The absorbance was measured at 595 
nm. A standard curve was created using bovine serum albumin (BSA stock, 2 mg/ml) 
provided in the Coomassie Plus (Bradford) Assay Kit, diluted in PBS with working 
range from 0 to 2000 µg/ml protein. All standard curves and unknown samples were 
performed in triplicate.  
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2.4.3.3 Polyacrylamide gel electrophoresis of protein samples 
Electrophoresis was carried out on a 12.5% polyacrylamide mini-gels containing 
30% acrylamide, 0.378 M Tris/HCl (pH 8.8), 0.1% (w/v) SDS, 0.1% (w/v) ammonium 
persulphate and 0.05% TEMED. The separating gel was poured between glass 
plates (100 mm x 100 mm x 0.75 mm) to within 40 mm of the top. A few drops of 
butanol was applied on the top of the gel to ensure the gel was flatten. The gel was 
allowed to polymerise for 30 min. The butanol was gently removed by water. Next, 
the stacking gel solution (30% acrylamide, 0.126 M Tris/HCl (pH 6.8), 0.1% (w/v) 
SDS, 0.1% (w/v) ammonium persulphate and 0.05% TEMED) was added onto the 
polymerized separating gel, and a comb to form wells was inserted immediately. 
All the samples were mixed with 2X or 4X sample loading buffer (Table 2.2) to reach 
a final dilution of 1X (62.5 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 0.002% 
bromophenol blue, and 5% β-mercaptoethanol) at an equivalent volume (20 μl). The 
mixtures were then heated at 95oC for 5 min, and immediately applied to a 12.5% 
SDS-PAGE gel for size-fractionation. Electrophoresis was performed at 40 mA for 50 
min in running buffer (25 mM Tris, 0.2 M glycine, 0.1% SDS). 
 
2.4.3.4 Electrophoretic blotting procedure of proteins separated by SDS-PAGE 
Electrophoretic transfer of protein from polyacrylamide gel to polyvinylidene fluoride 
(PVDF) membrane was carried out based on a method described by (Towbin et al., 
1979), using an Amersham Biosciences TE 22 Mighty Small Transphor. The physical 
assembly of electrophoretic blotting sandwich is shown in Figure 2.3. A sheet of 
PVDF (0.45 µm pore size) is pre-wetted with methanol briefly and soaked in transfer 
buffer (1X CAPS (3-(Cyclohexylamino)-1-propanesulfonic acid) buffer: 0.01 M CAPS, 
10% (v/v) methanol and 80% (v/v) H2O). The membrane was laid on two sheets of 
thick filter paper with a foam sponge underneath with the sponge supported by a stiff 
plastic grid. The gel to be blotted was removed carefully from the gel electrophoresis 
tank and layered onto the membrane, avoiding air bubbles. A second set of filter 
papers, foam sponge and a stiff plastic grid in the same order as described above 
was applied to the top of the gel. All items were kept submerged with transfer buffer 
to avoid any dryness. The blotting sandwich was inserted into the support holder of 
the transfer tank with the orientation from gel side/cathode (-) to membrane 
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side/anode (+). Electrophoretic blotting was conducted in the same transfer buffer at 
50 mA (overnight) or 250 mA (one hour) alternatively. 
 
2.4.3.5 Blocking, probing and immunodetection of protein blots  
The membranes were rinsed by PBST buffer (1X PBS and 0.1% Tween 20) twice. 
An incubation of membranes in blocking solution (5% dried skimmed milk in PBST 
buffer) was performed at room temperature for 1 hour to achieve blocking of non-
specific binding by the primary antibody. After the primary antibody and anti-GAPDH 
(1:25000) were diluted in the blocking solution, the membranes were incubated with 
the blocking solution at 4oC overnight on a shaker. On the following morning, 
membranes were washed four times for 5 min each in PBST buffer. The goat anti-
rabbit IgG conjugated to horseradish peroxidase was incubated with membranes in a 
dilution of 1:5000 for 1 hour at room temperature with shaking. Membranes were 
subjected to four washes in PBST buffer. Immunoblots were visualised using Super 
Signal West Pico chemiluminescent substrate (Thermo scientific) and blue X-ray film 
(CL-Xposure film, Thermo scientific). To measure protein expression levels, 
intensities of specific bands, and corresponding to the proteins of interest, 
densitometric analyses of the blots were performed using a GS-800 calibrated 
densitometer (Bio-Rad), and signal intensities were analysed using Quantity One – 
4.2.3 software (GraphPad Prism version 5.0a, San Diego, USA). Images of the blots 
were imported into the software, the area around each band was selected by 
drawing a tight boundary around them. The signal intensities of bands were then 
displayed in an excel format which can be exported for statistical analyses, graphic 
representation as mean ± S.E.M. 
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2.4.3.6 Staining of the PVDF membrane 
Membranes were stained by 0.05% copper solution for 1 min on a shaker. Next, 
membranes were rinsed three times in 10 mM HCl to remove unbound dye. 
Membranes were left to dry at room temperature and stored as a loading reference. 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: The assembly of electrophoretic blotting sandwich. A) PVDF membrane, B) 
Polyacrylamide gel, C) two sheets of thick filter paper, D) foam sponges, E) stiff plastic grids, 
F)cathode (-), G) anode (+). 
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Table 2.8: Materials used for Western blotting. 
Protein extraction Supplier Cat. No. 
CelLytic M buffer Lysis buffer  Sigma Aldrich, Gillingham, UK C2978 
Protease inhibitor Roche, Welwyn Garden City, UK 11 836 170 001 
Protein measurement Supplier Cat. No. 
Pierce Coomassie Plus Assay and  Thermo Scientific, Loughborough, UK 23236 
SDS-PAGE Supplier Cat. No. 
30% Acrylamide Sigma Aldrich, Gillingham, UK A3699 
Ammonium persulphate Sigma Aldrich, Gillingham, UK A3678 
SDS Sigma Aldrich, Gillingham, UK L3771 
Tris-base Sigma Aldrich, Gillingham, UK T1503 
TEMED Sigma Aldrich, Gillingham, UK T9281 
Butanol BDH Laboratory Supplies,  
Leicestershire, UK 
275006E 
Electrophoretic  transfer Supplier Cat. No. 
TE 22 Mighty Small Transphor Amersham Biosciences, 
Buckinghamshire, UK 
80-6204-26 
PVDF membrane Merck Millipore, Hertfordshire, UK IPVH00010 
CAPS Sigma Aldrich, Gillingham, UK C2632 
Glycine Sigma Aldrich, Gillingham, UK G8898 
Blocking, probing and 
immunodetection 
Supplier Cat. No. 
Methanol VWR Chemicals, Leicestershire, UK 67-56-1 
10X PBS Lonza, Slough, UK BE17-517Q 
Tween 20 Sigma Aldrich, Gillingham, UK P2287 
Rabbit polyclonal anti-PNPLA3 Abcam, Cambridge, UK ab81874 
Rabbit polyclonal anti-GAPDH Santa Cruz Biotechnology, Inc. sc-25778 
Horseradish peroxidase conjugated 
secondary antibody  
Sigma Aldrich, Gillingham, UK A6154 
SuperSignal West Pico 
chemiluminescence 
Thermo Scientific, Loughborough, UK 23236 
CL-Xposure film Thermo scientific, Loughborough, UK 34089 
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3 Chapter 3. Candidate Gene Association Study between PNPLA3 
and Severity of NAFLD in FLIP Cohort 
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3.1 Introduction  
The basis for the effect of PNPLA3 on genetic susceptibility to NAFLD up to the 
present has been described in detail in Chapter 1. Given the numerous gene 
association studies that had been performed for PNPLA3, and that its association 
has already been extensively replicated worldwide, there are limitations to be 
mentioned. The majority of genome-wide association studies (GWAS) reported to 
date are radiology-based but the diagnostic gold standard that can reliably assess 
NAFLD severity is liver biopsy. Although a few GWAS and candidate gene 
association studies reporting the PNPLA3 association were histology-based, many 
have weaknesses in study design and have very limited cohort size. Lack of 
statistical power due to relatively small sample size could easily produce 
misinterpretation of both false positive and false negative results. To validate the 
genetic correlation between the PNPLA3 gene and severity of NAFLD and to 
perform a better and more reliable genetic analysis, a large unrelated cohort of 
European-Caucasian descent (n=1,005) with histologically characterized NAFLD 
(representing the full spectrum of disease from simple steatosis through 
steatohepatitis to advanced fibrosis and cirrhosis) was assembled from centres 
across Europe by the FLIP consortium. This cohort was analysed by a GWAS using 
the Illumina OmniExpress chip platform however the PNPLA3 rs738409 SNP, that is 
considered to be the causative variation, is not represented on this chip so direct 
genotyping was needed. 
In addition to performing a candidate-gene association study upon the major SNP 
rs738409 in the PNPLA3 gene using the FLIP cohort, another SNP rs139051 was 
also tested. This polymorphism has been reported to be associated with obesity and 
NAFLD (Johansson et al., 2009; Peng et al., 2012). A Swedish study with a total 
number of 466 obese children and adolescents compared to 491 non-obese 
reference group first demonstrated that carriage of the minor allele (A) of rs139051 
was linked to obesity (P=0.014) but this effect was attenuated after adjustment for 
age and gender (P>0.05) (Johansson et al., 2009). The other study was performed in 
a Han Chinese population with 553 ultrasonography diagnosed NAFLD patients 
(Peng et al., 2012). When a dominant model was adapted, Peng et al. reported that 
the rs139051 homozygous mutant (AA) carriers were significantly associated with 
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increased risk of NAFLD in a multivariate analyses including gender, age, body mass 
index and other clinical characteristics (Peng et al., 2012).  
Little is known about this rs135091 polymorphism. This variant is an intronic 
polymorphism, located in intron 2 of PNPLA3 causing a single nucleotide substitution 
from guanine (G) to adenine (A). The rs135091 SNP is 51bp upstream of rs738409 
and 28bp away from the intron-exon boundary. A recent study using a locus-wide 
expression quantitative trait (eQTL) approach to assess SNPs that might be relevant 
to transcriptional regulation of PNPLA3 conducted by a collaborator, Prof. Wanqing 
Liu (Purdue University, USA), has suggested that rs135091 influences hepatic 
PNPLA3 expression with the A variant associated with increased gene expression 
(Liu et al., 2016a). HapMap data (CEU, Northern Europeans in Utah) indicates that 
rs738409 and rs135091 are in relatively low linkage disequilibrium, the D’ (coefficient 
of linkage disequilibrium) value is 0.61. 
The aims of the studies described in this chapter were:  
 Firstly, to validate the PNPLA3 rs738409 association with histologically 
characterised NAFLD in the FLIP cohort.  
 Secondly, to assess the relationship between the PNPLA3 rs139051 
polymorphism and severity of NAFLD in view of the recent eQTL result.  
 Thirdly, to also investigate the relevance of combined genotypes for 
rs738409/rs139051 to severity.  
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3.2 Methods  
3.2.1 Patients 
A large cohort of unrelated patients of European-Caucasian descent with biopsy-
proven NAFLD was recruited from centres across Europe. These patients were 
enrolled in a FP7 project (FLIP, Fatty liver: Inhibition of Progression) funded by 
European Commission. The centers that involved in FLIP cohort recruitment are 
described in section 2.1. Baseline characteristics of the cohort are shown in Table 
3.1. 
 
3.2.2 Liver biopsy 
Liver biopsy performance is described in section 2.2. Liver biopsies for Newcastle 
samples were reviewed by two expert liver pathologists: Alastair Burt and Dina 
Tiniakos. Liver biopsies for other FLIP samples were performed by the collaborators 
at each participating centre. The criteria adapted for biopsy assessment includes 
NAFLD activity score (NAS) designed by Kleiner (Kleiner et al., 2005), and semi-
quantitative SAF score (Bedossa and Consortium, 2014; Dyson et al., 2014). The 
histological phenotypes including degree of steatosis, stages of steatohepatitis and 
fibrosis were listed in Table 3.1. 
 
3.2.3 DNA preparation from blood samples 
DNA extraction from blood samples was described in section 2.3.2. DNA preparation 
from some Newcastle samples was performed by Julian Leathart and Julia Patch 
(Newcastle University, ICM). DNA samples from cases enrolled at other centres 
across Europe were prepared locally by the collaborators. 
 
3.2.4 PNPLA3 SNPs genotyping  
Assays for the two SNPs, PNPLA3 rs738409 (reference number: C___7241_10, Cat. 
#4351379) and rs139051 (reference number: C_176091868_10, Cat. #4351379) 
were purchased from Applied Biosystems Inc., USA. Genotypes for these SNPs 
were determined by allelic discrimination using TaqMan reagents according to the 
manufacturer’s protocol. Procedures were described in section 2.3.4.2. Control 
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samples of known genotype were also included in every 48-well plate (blank, 
homozygous wild-type, homozygous mutant and heterozygous). 
 
3.2.5 Statistical analysis  
Statistical analyses were performed using SPSS v19.0 (IBM, USA) and PLINK v1.07 
(Purcell et al., 2007) (via the gPLINK v2.050 GUI). Initially, univariate chi-squared 
analysis was performed followed by multivariate linear/logistic regression analysis 
incorporating biologically relevant covariates that were associated with risk of 
NAFLD (age, gender, BMI, and presence of T2DM) to test the genetic association. 
An additive genetic model best fitted the data and was used throughout this chapter. 
Results were expressed as beta (β ± SEM) or odds ratio (OR) with 95% confidence 
intervals (CI) as appropriate. P<0.05 was considered as the statistically significant 
level. Advanced haplotype analyses examining interactions between the SNPs 
(rs738409 and rs139051) and NAFLD-related phenotypes were performed in 
collaboration with Professor Heather Cordell (Institute of Genetic Medicine, 
Newcastle University) and Professor Wanqing Liu (Department of Medicinal 
Chemistry and Molecular Pharmacology, Purdue University) using the software 
programs R, PLINK (Purcell et al., 2007) and UNPHASED (Dudbridge, 2008; 
Dudbridge et al., 2011).  
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Table 3.1: Clinical characteristics of FLIP cohort. 
 Newcastle (UK) Nottingham (UK) Cambridge (UK) Paris (France) Antwerp (Belgium) Bern 
(Switzerland) 
OVERALL 
Number 311 56 32 292 254 60 1005 
Age, years 50.23 ± 12.7 51.52 ± 11.54 51.43 ± 12.32 47.71 ± 12.07 44.87 ± 12.31 52.7 ± 11.16 48.4 ± 12.48 
Gender (% Female) 124 (39.9%) 24 (42.9%) 14 (43.8%) 174 (59.6%) 164 (64.6%) 20 (33.3%) 520 (51.7%) 
BMI, kg/m2 34.29 ± 5.18 30.41 ± 4.95 32.87 ± 4.79 41.77 ± 10.88 39.03 ± 6.56 31.99 ± 4.94 37.26 ± 8.44 
DM (YES %) 129 (41.5%) 11 (19.6%) 14 (43.8%) 132 (45.2%) 30 (11.8%) 30 (50.0%) 346 (34.4%) 
ALT 81.97 ± 59.23 90.27 ± 54.37 70.97 ± 39.07 54.28 ± 33.05 47.63 ± 23.62 86.10 ± 62.53 65.60 ± 47.34 
AST# 53.57 ± 34.90 - 52.64 ± 36.50 38.27 ± 22.28 33.91 ± 17.01 66.37 ± 39.63 44.05 ± 29.23 
Steatosis* 
S0 4 (1.3%) 1 (1.8%) 0 (0.0%) 8 (2.7%) 51 (20.1%) 0 (0.0%) 64 (6.4%) 
S1 88 (28.3%) 13 (23.2%) 12 (37.5%) 63 (21.6%) 91 (35.8%) 20 (33.3%) 287 (28.6%) 
S2 150 (48.2%) 20 (35.7%) 11 (34.4%) 114 (39.0%) 61 (24.0%) 27 (45.0%) 383 (38.1%) 
S3 68 (21.9%) 19 (33.9%) 9 (28.1%) 107 (36.6%) 51 (20.1%) 13 (21.7%) 267 (26.6%) 
Activity score (composite hepatocyte ballooning and necro-inflammation scores)* 
A0 90 (28.9%) 2 (3.6%) 5 (15.6%) 58 (19.9%) 41 (16.1%) 12 (20.0%) 208 (20.7%) 
A1 57 (18.3%) 7 (12.5%) 13 (40.6%) 63 (21.6%) 42 (16.5%) 12 (20.0%) 194 (19.3%) 
A2 88 (28.3%) 17 (30.4%) 6 (18.8%) 100 (34.2%) 53 (20.9%) 36 (60.0%) 300 (29.9%) 
A3 48 (15.4%) 15 (26.8%) 6 (18.8%) 48 (16.4%) 80 (31.5%) 0 (0.0%) 197 (19.6%) 
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*Steatosis and Activity score data incomplete in 4 (0.4%) and 11 (1.1%) of samples respectively. #Phenotypes of AST levels were not obtained by the 
collaborators. 
 
A4 20 (6.4%) 13 (23.2%) 2 (6.3%) 22 (7.5%) 38 (15.0%) 0 (0.0%) 95 (9.5%) 
Fibrosis 
F0 109 (35.0%) 14 (25.0%) 8 (25%) 75 (25.7%) 157 (61.8%) 15 (25.0%) 378 (37.65) 
F1 77 (24.8%) 9 (16.1%) 14 (43.8%) 91 (31.2%) 42 (16.5%) 9 (15.0%) 242 (24.1%) 
F2 52 (16.7%) 22 (39.3%) 3 (9.4%) 77 (26.4%) 33 (13.0%) 13 (21.7%) 200 (19.9%) 
F3 47 (15.1%) 5 (8.9%) 5 (15.6%) 34 (11.6%) 21 (8.3%) 5 (8.3%) 117 (11.6%) 
F4 (Cirrhosis) 26 (8.4%) 6 (10.7%) 2 (6.3%) 15 (5.1%) 1 (0.4%) 18 (30.0%) 68 (6.8%) 
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3.3 Results 
3.3.1 PNPLA3 rs738409 genotype analyses  
3.3.1.1 Increased PNPLA3 rs738409 C>G minor allele carriage in NAFLD 
The PNPLA3 rs738409 genotypes in the overall NAFLD cohort showed borderline 
agreement with the Hardy-Weinberg equilibrium (P=0.048). The minor allele 
frequency was 0.34 which is significantly higher than that observed in a reference 
Northern European population sample (MAF 0.22, http://browser.1000genomes.org). 
This result provides some initial evidence for an association between this variant and 
NAFLD generally. There was a gene-dosage effect for this variant in the cohort with 
the incidence of NAFLD increasing with the number of minor alleles possessed (Χ2 
for trend, P<0.0001), Table 3.2. The relationship between the rs738409 SNP and 
specific histological components of the NAFLD disease phenotype were assessed 
individually. 
 
 
Table 3.2: Genotype frequency of PNPLA3 rs738409 in FLIP NAFLD Cohort vs. the 1000 
Genomes European Caucasian population. 
ChiSq for trend p<0.0001 (X2=36.04, df=1). 1000 Genomes MAF (EUR) = 0.22 
(http://browser.1000genomes.org) 
 
 
 
 
 
PNPLA3 
rs738409 
Genotypes 
FLIP NAFLD   
n=1005 (%) 
EUR Pop. 
n=379 (%) 
OR (95% CI) P-value 
CC 455 (45.3%) 233 (61.5%) - - 
CG 421 (41.8%) 128 (33.8%) 1.68 (1.38-2.17) <0.0001 
GG 129 (12.8%) 18 (4.7%) 3.67 (2.19-6.16) <0.0001 
78 
3.3.1.2 PNPLA3 rs738409 C>G polymorphism is associated with steatosis  
The PNPLA3 rs738409 association with hepatic steatosis diagnosed either by 
radiology or histology was reported by several studies (Romeo et al., 2008; Valenti et 
al., 2010a). In the FLIP cohort, carriage of the PNPLA3 rs738409 minor allele was 
significantly associated with degree of steatosis in the univariate analysis (β 
0.256±0.039, P=1.18x10-12). This strong effect remained significant after adopting an 
additive model and adjusted for age at biopsy, gender, BMI and presence of T2D (β 
0.308±0.038, 95%CI 0.23-0.38, P=5.4x10-15). When the patients were classified into 
mild steatosis (S0-1) compared to advanced steatosis (S2-3), the PNPLA3 rs738409 
C>G minor allele was associated with increased risk of greater steatosis in an 
additive model (OR 1.87, 95%CI 1.52-2.29, P=2.98x10-9), Table 3.3.  
 
 
Table 3.3: Multivariate analysis of association between PNPLA3 rs738409 genotype and 
histological steatosis.
 
 
 
 
 
 
Variables Steatosis (S0-S3) 
 
Steatosis (S0-1 vs. S2-3) 
 
OR (95% CI)                  P-value β (95% CI) P-value 
rs738409 
genotype 
0.3 (0.23-0.38) 5.4 x10-15 1.87 (1.52-2.29) 2.98 x10-9 
Age -0.002 (-0.007-0.001) 0.22 0.99 (0.98-1.006) 0.29 
Gender 
(Female) 
-0.16 (-0.27- -0.05) 0.0034 0.51 (0.38-0.68) 6.8 x10-6 
BMI 0.018 (0.01-0.02) 8.45 x10-8 1.05 (1.03-1.07) 2.18 x10-6 
T2DM 0.22 (0.1-0.33) 0.0001 1.59 (1.17-2.15) 0.003 
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3.3.1.3 PNPLA3 rs738409 C>G polymorphism is associated with NASH 
The NAS scoring system covers the degree of steatosis (0-3), hepatocyte ballooning 
(0-2) and lobular inflammation (0-3), and a separate fibrosis stage (0-4) (Kleiner et 
al., 2005). This scoring system aimed to provide a numerical order for assessing 
those patients who most likely to have NASH. The association with steatohepatitis 
activity was then tested using NAS score. The PNPLA3 rs738409 was associated 
with severity of steatohepatitis in the FLIP cohort by both univariate (β 0.45±0.08, 
P=4.32x10-8) and multivariate analysis. The modifier effect remained strong after 
adjustment for gender, age at biopsy, BMI, and presence of T2DM (β 0.48±0.008, 
95%CI 0.32-0.64, P=5.24x10-9). The other NASH scoring system, the validated 
semi-quantitative SAF score, is similar to the NAS score but separates the degree of 
steatosis from those of inflammation and ballooning to provide three separate 
domain measures of NAFLD severity (Bedossa and Consortium, 2014). The 
association with steatohepatitis activity was secondly tested using a composite score 
incorporating severity of necroinflammation and ballooning hepatocyte degeneration, 
generating the activity score (A0-A4). Similar results were found in the second 
analyses using SAF score. PNPLA3 rs738409 was associated with severity of 
steatohepatitis in the FLIP cohort by both univariate (β 0.172±0.06, P=0.004) and 
multivariate analysis. The modifier effect remained strong after adjustment with 
gender, age at biopsy, BMI, and presence of T2DM (β 0.174±0.059, 95%CI 0.056-
0.291, P=0.0037), Table 3.4. Beta coefficients instead of odds ratio were applied due 
to the nature of continuous variables. 
Table 3.4: Multivariate analysis of association between PNPLA3 rs738409 genotype and 
histological steatohepatitis. 
Variables SAF activity score (A0-A4) 
 
NAS (0-8) 
 
β (95% CI)                     P-value β (95% CI) P-value 
PNPLA3 
genotype 
0.17 (0.05-0.29) 0.004 0.48 (0.32-0.64) 5.24 x10-9 
Age 0.13 (0.006-0.02) 0.0001 0.01(0.001-0.02) 0.02 
Gender 
(Female) 
-0.04 (-0.21-0.12) 0.58 -0.2 (-0.43-0.02) 0.07 
BMI 0.01 (0.004-0.02) 0.004 0.03 (0.01-0.05) 4.41 x10-6 
T2DM 0.1 (-0.06-0.28) 0.22 0.33 (0.09-0.56) 0.006 
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3.3.1.4 PNPLA3 rs738409 C>G polymorphism is associated with fibrosis 
The association with NAFLD fibrosis stage were tested using linear and binary 
parameters. When a linear parameter of fibrosis score (F0-4) was applied, carriage 
of the minor allele of PNPLA3 rs738409 was significantly associated with stage of 
fibrosis; univariate (β 0.22±0.06, P=9.87x10-5), and linear regression analysis with 
major covariates included (gender, age at biopsy, BMI, and presence of T2DM) (β 
0.22±0.05, 95%CI 0.11-0.32, P=4.67x10-5). When patients were subdivided into mild 
fibrosis (F0-1) and advanced fibrosis (F2-4), individuals with the minor allele were at 
higher risk of developing NAFLD-related fibrosis in an additive model (OR 1.38, 
95%CI 1.14-1.66, P=0.0008). A significant result was also found in the multivariate 
analysis adopting an additive model adjusted for gender, age at biopsy, BMI, and 
presence of T2DM (OR 1.4, 95%CI 1.15-1.7, P=0.0006), Table 3.5. 
 
 
Table 3.5: Multivariate analysis of association between PNPLA3 rs738409 genotype and 
histological fibrosis.
 
 
 
 
 
Variables Fibrosis (F0-F4) 
 
Fibrosis (F0-1 VS. F2-4) 
 
OR (95% CI)                  P-value β (95% CI) P-value 
PNPLA3 
genotype 
0.3 (0.11-0.32) 4.67 x10-5 1.41 (1.16-1.70) 0.0005 
Age -0.02 (0.01-0.02) 1.99 x10-11 1.03 (1.01-1.03) 2.01 x10-5 
Gender 
(Female) 
-0.26 (-0.41~-0.1) 0.0006 0.67 (0.51-0.89) 0.007 
BMI 0.02 (0.01-0.03) 1.06 x10-5 1.03 (1.02-1.05) 1.42 x10-5 
T2DM 0.58 (0.4-0.73) 2.7 x10-12 2.27 (1.70-3.00) 1.77 x10-8 
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3.3.2 PNPLA3 rs139051 genotype analyses 
3.3.2.1 PNPLA3 rs139051 genotype distributions between NAFLD patients and general 
population   
The PNPLA3 rs139051 genotypes were confirmed to be in Hardy-Weinberg 
equilibrium (P=0.08) with a minor allele frequency of 0.40. This MAF is slightly higher 
than that observed in the same reference population as mentioned in section 3.3.1.1 
(MAF 0.38, http://browser.1000genomes.org). However, the genotype distributions of 
PNPLA3 rs139051 in the FLIP cohort and Northern European population were very 
similar, and did not show statistical significance (Χ2 for trend, P=0.46), Table 3.6. 
 
Table 3.6: Genotype frequency of PNPLA3 rs139051 in FLIP NAFLD Cohort vs. the 1000 
Genomes European Caucasian population. 
ChiSq for trend p=0.47 (X2=0.53, df=1). 1000 Genomes MAF (EUR) = 0.38 
 (http://browser.1000genomes.org) 
 
 
3.3.2.2 PNPLA3 rs139051 G>A polymorphism and histological NAFLD severity 
To investigate whether rs139051 contributes to NAFLD risk, the relationship between 
rs139051 and NAFLD phenotypes in FLIP cohort was then tested. A significant effect 
was observed between carriage of rs139051 G>A polymorphism and severity of 
NAFLD, including steatosis (β 0.13±0.04, P=0.003), and steatohepatitis (P=0.02 and 
P=0.002 for SAF score and NAS score, respectively) but not fibrosis (P=0.8) in the 
univariate analyses. These strong genetic modifier effects on hepatic steatosis and 
steatohepatitis remained significant in the multivariate analyses when adjusted for 
age at biopsy, gender, BMI and presence of T2D; P=2.0x10-4 and P=0.02 (for both 
SAF and NAS scoring systems), respectively. The association with stage of fibrosis 
remained non-significant after testing in a multivariate analysis (P=0.6).  
PNPLA3 
rs139051 
Genotypes 
FLIP NAFLD   
n=961 (%) 
EUR Pop. 
n=503 (%) 
OR (95% CI) P-value 
GG 330 (34.3%) 184 (36.6%) - - 
AG 489 (50.9%) 247 (49.1%) 1.10 (0.87-1.39) 0.43 
AA 142 (14.7%) 72 (14.3%) 1.10 (0.78-1.54) 0.31 
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Since the PNPLA3 rs738409 SNP is a well-known and well-replicated genetic 
modifier for NAFLD, another sets of multivariate analyses that included gender, age 
at biopsy, BMI, T2DM, and PNPLA3 rs738409 genotype were performed. 
Interestingly, the significant effects described above were completely abolished 
when the PNPLA3 rs738409 genotype was taken into account (P>0.05 for all 
phenotypes), suggesting that rs139051 is not independent of rs738409 as a risk 
factor for NAFLD, Table 3.7. 
 
3.3.2.3 Haplotype analyses of PNPLA3 SNPs in FLIP cohort 
As previously identified by our collaborator, Prof. Wanqing Liu, during his eQTL 
studies, rs139051 (51bp upstream of rs738409 in intron 2, and 28bp away from the 
intron-exon boundary) was the most significant cis-acting eQTL for PNPLA3 
transcription [P=6.6×10-8, false discovery rate (FDR) < 0.05] (Liu et al., 2016a). 
Detailed LD analysis of variants across the entire locus revealed that rs139051 was 
in low LD with all other significant eQTLs (r2 ≤ 0.50 for all tests). The data indicated 
that the minor (A) allele of rs139051 was associated with increased PNPLA3 gene 
expression. In contrast, after correcting for multiple testing, the rs738409 
polymorphism was not a significant eQTL for hepatic PNPLA3 expression (FDR > 
0.05) (Liu et al., 2016a).  
To investigate further whether rs139051 modifies the effect of rs738409 alleles in 
contributing to NAFLD risk, we tested the association between the rs139051-
rs738409 haplotype and aforementioned phenotypes. However, analyses examining 
the relative contribution of the SNP to the haplotype effect did not identify a 
statistically significant independent effect of rs139051 in the FLIP population. Indeed, 
the carriage of the A-G haplotype which combines both the high-expression 
rs139051 A allele and the disease-risk rs738409 G (148M) allele, conferred similar 
risk for NAFLD phenotypes as compared to the G-G haplotype which contains the 
rs738409 risk allele, but possesses a relatively lower expression level (P=0.51), 
Table 3.8 (Liu et al., 2016a). 
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Table 3.7: Multivariate analysis of association between PNPLA3 rs139051 genotype and 
histological NAFLD. 
 
 
 
 
Variables 
 
Steatosis 
Steatosis (S0-S3) 
 
Steatosis (S0-1 vs. S2-3) 
  
β (95% CI) P-value OR (95% CI)  P-value 
rs139051 genotype 0.02 (-0.06-0.21) 0.6 0.98 (0.78-1.23) 0.84 
Age -0.002 (-0.006-0.002) 0.35 0.99 (0.98-1.007) 0.39 
Gender (Female) -0.15 (-0.26~-0.04) 0.009 0.52 (0.39-0.70) 1.64 x10-5 
BMI 0.018 (0.012-0.026) 8.93 x10-8 1.05 (1.03-1.07) 2.23 x10-6 
T2DM 0.23 (0.11-0.35) 1.4 x10-4 1.62 (1.15-2.21) 0.003 
rs738409 genotype 0.29 (0.21-0.38) 4.18 x10-11 1.87 (1.48-2.37) 1.28 x10-7 
Variables 
 
 
Steatohepatitis 
SAF activity score (A0-A4) NAS (0-8) 
β (95% CI) P-value β (95% CI) P-value 
rs139051 genotype 0.08 (-0.05-0.22) 0.22 0.1 (-0.08-0.28) 0.29 
Age 0.014 (0.006-0.02) 1.4 x10-4 0.01 (0.002-0.02) 0.021 
Gender (Female) -0.06 (-0.23-0.11) 0.48 -0.21 (-0.44-0.02) 0.08 
BMI 0.013 (0.002-0.02) 0.013 0.03 (0.02-0.05) 1.52 x10-5 
T2DM 0.08 (-0.09-0.26) 0.36 0.03 (0.002-0.002) 0.01 
rs738409 genotype 0.13 (0.004-0.27) 0.042 0.43 (0.25-0.61) 2.93 x10-6 
Variables 
 
Fibrosis 
Fibrosis (F0-F4) 
 
Fibrosis (F0-1 vs. F2-4) 
 
β (95% CI) P-value OR (95% CI) P-value 
rs139051 genotype -0.08 (-0.2-0.04) 0.18 0.87 (0.69-1.01) 0.25 
Age 0.02 (0.01-0.03) 4.89 x10-12 1.03 (1.02-1.04) 7.64 x10-6 
Gender (Female) -0.27 (-0.42~-0.12) 5.56 x10-4 0.66 (0.49-0.88) 0.005 
BMI 0.02 (0.01-0.03) 2.92 x10-5 1.04 (1.02-1.06) 2.38 x10-6 
T2DM 0.54 (0.38-0.71) 1.10 x10-10 2.09 (1.56-2.80) 6.56 x10-7 
rs738409 genotype -0.27 (-0.43~-0.12) 9.78 x10-5 1.49 (1.19-1.86) 4.10x10-4 
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Table 3.8: Haplotype association with NAFLD histological features and effect of each 
haplotype on phenotype severity in the FLIP NAFLD Cohort (n=949). Adapted from (Liu et al., 
2016a). 
†Haplotype frequencies across entire NAFLD cohort: A-G 0.2425; G-G 0.09797; A-C 0.1628; G-C 0.4968. 
Estimated r2 between rs139051 and rs738409 = 0.20.  #Tests for the effect of each haplotype compared to A-G. 
*Tests for the effect of each haplotype compared to A-C. ‡Tests for the effect of each haplotype compared to 
all other haplotypes combined. *NAFLD histologically characterized using the semi-quantitative NASH CRN 
Score (Kleiner et al., 2005). The NAFLD Activity Score (NAS) equals the sum of the scores for steatosis, 
hepatocyte ballooning degeneration and lobular inflammation and reflects disease activity.  
 
Histological 
Phenotype* 
Haplotype† Added Value 
(95%CI)# 
P# P* Beta‡ P‡ 
Steatosis (0-3) A-G 0 - 9.85 x10-7 0.33 3.36x10-11 
G-G -0.08 (-0.31, 
0.16) 
0.51 3.78 x10-4 0.23 0.0014 
A-C -0.46 (-0.65, -
0.28) 
9.85 x10-7 - -0.15 0.0108 
G-C -0.46 (-0.60, -
0.32) 
1.33 x10-11 0.96 -0.23 3.15x10-8 
NAS (0-8) A-G 0 - 4.81 x10-4 0.56 4.27x10-8 
G-G -0.06 (-0.17, 
0.05) 
0.30 0.05 0.27 0.06 
A-C -0.16 (-0.25, -
0.07) 
4.81 x10-4 - -0.15 0.2 
G-C -0.18 (-0.25, -
0.12) 
2.66 x10-8 0.61 -0.4 2.45x10-6 
Fibrosis (0-4) A-G 0 - 0.04 0.17 0.01 
G-G 0.11 (-0.04, 
0.27) 
0.15 9.64 x10-4 0.32 0.0013 
A-C -0.14 (-0.28, -
0.008) 
0.04 - -0.15 0.06 
G-C -0.12 (-0.22, -
0.03) 
0.0089 0.74 -0.17 0.0092 
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3.4 Discussion 
Performing a case-control association study within a well-characterized population 
and with an appropriate sample size, we have validated the association between 
PNPLA3 rs738409 and severity of NAFLD. Carriage of the minor allele (G) is 
profoundly associated with disease severity across the entire NAFLD disease 
spectrum (steatosis, steatohepatitis, and fibrosis). As described in Chapter 5, we 
also investigated its association with NAFLD-related HCC, the ultimate stage of 
NAFLD.  
The other SNP rs139051 (G>A) which is 51bp upstream of rs738409 (Liu et al., 
2016a) has been suggested to be relevant to NAFLD susceptibility (Peng et al., 
2012). However, an earlier study demonstrated in obese children and adolescents 
provided opposite results (Johansson et al., 2009). It would be inappropriate to 
compare these two studies directly as their study aims (obesity vs. NAFLD) and 
population design (children and adolescents vs. adults) were totally different, as is 
the variation in ethnicities. Since NAFLD is closely associated with obesity, these 
findings should not be ignored entirely and require further investigations to be 
ascertain the relevance of rs139051 as a genetic risk factor.  
The rs139051 variant was identified as a strong eQTL, playing an independent role 
in regulating PNPLA3 transcription in man (Liu et al., 2016a). In our association 
analyses, a weaker but statistically significant association between rs139051 and 
steatosis, steatohepatitis but not fibrosis was observed. However, in the multivariate 
analysis with the rs738409 genotype included, the association was completely 
abolished (P>0.05 for all tests), suggesting that rs139051 is not independent of 
rs738409 as a risk factor for NAFLD. Furthermore, the apparent changes in hepatic 
PNPLA3 expression due to rs139051 carriage do not modify the effects of rs738409 
G-allele carriage in promoting NAFLD and related phenotypes. This was supported 
by the analysis of associations between rs139051-rs738409 haplotypes and 
histological features of NAFLD. While the A-G haplotype potentially represents an 
increased expression of the high-risk allele than the G-G haplotype, there was no 
significant difference between these two haplotypes in conferring risk to NAFLD or 
disease severity. A similar effect was observed between the A-C and G-C haplotype 
in conferring reduced risk for NAFLD. 
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As has already been discussed in section 1.7.1, a complex disease trait is a 
contribution of strong and weak genetic risk factors when combined together in the 
presence of a permissive environment (Hirschhorn and Gajdos, 2011). Taken 
Crohn’s disease as one of the examples for polygenic disease, several strong 
(P<5X10-8 with OR ≥1.8) genetic risk factors that have been identified and replicated: 
particularly, CARD15 (also known as NOD2, nucleotide binding oligomerization 
domain containing 2) on chromosome 16q12, IL23R (interleukin 23 receptor) on 
chromosome 1p31, and ATG16L1 (autophagy related 16 like 1) on chromosome 
2p37 are considered as the well-demonstrated SNPs associated with Crohn’s 
disease. Unlike Crohn’s disease, T2DM is best considered as a polygenic disease 
where multiple common variants with weak effects (P>5X10-4 with OR≤ 1.3) 
contribute to the outcomes and appear to combine in an additive manner to increase 
overall disease susceptibility, such as PPARG on chromosome 3q25 (peroxisome 
proliferator activated receptor gamma) and KCNJ11 (potassium voltage-gated 
channel subfamily J member 11) on chromosome 11q15. It has been estimated that 
only 10% of the genetic risk were identified in T2DM despite there have been 
intensive effort to identify the genetics of T2DM in the past two to three decades 
(Wellcome Trust Case Control, 2007; Donaldson et al., 2015). 
The effect size of the PNPLA3 rs738409 identified by the first GWAS-like study 
(P=5.9x 10-10) (Romeo et al., 2008) is even stronger than those identified in T2DM 
and Crohn’s disease, and to date it remains the strongest and the most widely 
replicated genetic risk factor for NAFLD (P<5X10-8 with OR≥1.8). In addition, there 
are multiple SNPs in the chromosome 22 region (22q13.31) on the Illumina chip that 
were reported to be associated with NAFLD but with weaker effect sizes compared 
to rs738409 even in a strong LD, the rs3761472 located in the neighbouring gene 
SAMM50 (SAMM50 sorting and assembly machinery component) would be an 
example, pointing that rs738409 is the true causative locus (Kawaguchi et al., 2012; 
Kitamoto et al., 2013).   
In summary, the rs738409 PNPLA3 polymorphism represents a biologically plausible 
candidate gene and remains the strongest genetic signal for NAFLD across the 
whole genome. However, the biological effect of rs738409 remains elusive as 
discussed in detail in section 1.7.3.6, investigation into the functional role of PNPLA3 
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on pathogenic mechanisms of NAFLD is therefore needed in order to possibly 
provide therapeutic approaches to NAFLD management in the future. 
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4 Chapter 4. TM6SF2 rs58542926 Influences Hepatic Fibrosis 
Progression in Patients with Non-Alcoholic Fatty Liver Disease 
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4.1 Introduction 
As described in section 1.7.3, genome-wide association studies (GWAS) (Romeo et 
al., 2008; Chambers et al., 2011; Speliotes et al., 2011) and candidate-gene studies 
(Dongiovanni et al., 2010b; Valenti et al., 2010a; Al-Serri et al., 2012; Aravinthan et 
al., 2014; Tan et al., 2014) have contributed greatly to the understanding of the 
genetic contribution to NAFLD pathogenesis and variability of prognosis (reviewed 
(Anstee and Day, 2013)). Amongst the loci identified, the non-synonymous SNP in 
PNPLA3 (rs738409 c.444 C>G, p.Ile148Met), has been validated across multiple 
patient cohorts (Romeo et al., 2008; Valenti et al., 2010a; Speliotes et al., 2011; 
Kawaguchi et al., 2012). Importantly, carriage of this SNP has been robustly 
associated not only with steatosis, but also with clinically relevant factors including 
severity of hepatic fibrosis/cirrhosis (Valenti et al., 2010a). However, its association 
with NAFLD-related HCC remains to be elucidated (Trepo et al., 2014). 
Recently, Kozlitina et al. showed that a non-synonymous SNP in TM6SF2 
(rs58542926 c.449 C>T, p.Glu167Lys (E167K)), transmembrane 6 superfamily 
member 2, a gene of unknown function on chromosome 19, was associated with 1H-
MRS quantified HTGC based on genotyping with a genome-wide exome chip 
(Kozlitina et al., 2014). This variant has also been associated with dyslipidaemia and 
cardiovascular risk (Holmen et al., 2014). The TM6SF2 rs58542926 SNP lies within 
50kb of an NCAN gene variant (rs2228603 c.274 C>T, p.Pro92Ser) that has 
previously been associated with HTGC in another GWAS (Speliotes et al., 2011; 
Gorden et al., 2013). Both SNPs are in strong linkage disequilibrium (D’=0.926, 
r2=0.798). Conditioning on the TM6SF2 variant abrogated the effect of the NCAN 
variant whilst the reverse did not occur, suggesting that TM6SF2 rs58542926 is 
more strongly associated with the HTGC phenotype. Homozygote TM6SF2 
rs58542926 minor (T) allele carriage was shown to be associated with a modest but 
statistically significant increase in 1H-MRS measured HTGC from 5.86±0.25% in CC 
homozygotes to 15.04±2.23% in TT homozygotes (Kozlitina et al., 2014).  
Limited knowledge has been established for the protein structure or the functional 
role of TM6SF2. The TM6SF2 rs58542926 c.449 C>T variant is a non-synonymous 
change producing a glutamate to lysine amino acid substitution at residue 167 
(Glu167Lys), which is highly conserved across mammals (Kozlitina et al., 2014). 
First descried as a multi-pass membrane protein in 2000 (Carim-Todd et al., 2000), 
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TM6SF2 was later discovered to be highly expressed in liver, kidney and intestines 
(Kozlitina et al., 2014; Surakka et al., 2015). In vitro study using confocal 
microscopy, GFP-tagged TM6SF2 was mainly localized to the endoplasmic reticulum 
(ER) and ER-Golgi intermediate compartments (ERGIC) (Mahdessian et al., 2014). 
In the same study, TM6SF2 siRNA inhibition led to a reduction of lipid secretion 
(triglycerides (TG) and Apolipoprotein B (ApoB)) and an increase in the number and 
overall size of lipid droplets, which represented as a manifestation of cellular 
triglyceride accumulation. On the contrary, overexpression of TM6SF2 caused a 
decrease in the lipid droplet contents (Mahdessian et al., 2014). Prediction of mouse 
knockout phenotype by analysis of coexpressed gene profiles based on Mouse 
Genome Informatics (MGI) Database, TM6SF2 is linked to abnormal lipids levels 
(decreased Total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C) and 
very-low-density lipoprotein (VLDL)) and may act as lipid transporter and interact 
with proteins involved in intestinal absorption (Surakka et al., 2015). In vivo studies 
may provide more clues for above statements, adenovirus-mediated short hairpin 
RNA knockdown of Tm6sf2 in mice has been shown to increased hepatic triglyceride 
content and reduced plasma cholesterol and VLDL secretion, suggesting that 
TM6SF2 activity is necessary for normal VLDL secretion and that impaired TM6SF2 
function causally contributes to NAFLD (Kozlitina et al., 2014). On the other hand, 
transiently overexpressed of Tm6sf2 in C57BL/6J mice resulted in a significant 
increase of serum TC, LDL-C and TG. These in vivo (Holmen et al., 2014; Kozlitina 
et al., 2014) and in vitro (Holmen et al., 2014; Kozlitina et al., 2014; Mahdessian et 
al., 2014) functional studies indicate that TM6SF2 has gene effects on fat retention in 
the liver, lipid efflux and alteration in the number and average size of lipid droplets. 
However, the genetic and biological studies previously mentioned only focused on 
the scope of hepatic steatosis. Whether the effect of TM6SF2 was limited to 
steatosis or had broader clinical relevance, possessing the susceptibility to 
steatohepatitis or fibrosis as has already been shown for PNPLA3, remains 
undetermined.  
The aim of the current study was firstly to determine whether the association with 
NAFLD reported by Kozlitina et al. (Kozlitina et al., 2014) could be independently 
validated; and secondly to establish whether the TM6SF2 rs58542926 variant was 
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associated with clinically important disease endpoints that have prognostic relevance 
(in particular stage of hepatic fibrosis).  
To address this, I performed a quantitative analysis within a well-characterised 
European Caucasian ‘discovery’ cohort with histologically characterised NAFLD, 
controlling for relevant co-morbidities and factors that have previously been linked 
with disease progression (age, gender, BMI, presence of T2DM and PNPLA3 
rs738409 genotype), and replicated our findings in a separate histologically 
characterised European Caucasian ‘validation’ cohort. The association between this 
SNP and development of NAFLD-related HCC was also examined (described in 
Chapter 5).  
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4.2 Methods 
4.2.1 Patients  
Patients were recruited from hepatology clinics at several European specialist 
centres, including UK, Switzerland, Belgium and France (details are listed in Table 
4.1). The study had all the necessary ethical approvals (Table 4.1). All participants 
gave informed consent. Criteria for NAFLD diagnosis and patients’ clinical and 
laboratory data are described in section 2.1.   
 An initial discovery cohort of 349 consecutive European Caucasian patients 
from the UK with histologically characterised NAFLD of different stages of 
disease. These were unrelated patients with histologically characterised 
NAFLD, derived from a patient population originally identified as having 
ultrasonographically detected bright liver and abnormal biochemical tests 
(ALT and/or GGT).  
 A validation cohort of 725 consecutive European Caucasian patients from 
centres in UK and mainland Europe with histologically characterised NAFLD 
of different stages of disease. Patients in this cohort were unrelated patients 
with histologically characterised NAFLD, derived from a patient population 
originally identified as having ultrasonographically detected bright liver and 
abnormal biochemical tests (ALT and/or GGT) or identified as having 
evidence of NAFLD at the time of bariatric surgery.  
Together, these comprised the combined cohort of 1,074 patients with histologically 
characterised NAFLD. Demographic and histological details are shown in Table 4.2. 
A description of the ‘healthy workers’ cohort recruited in the North East of the UK has 
previously been published (Velaga et al., 2004).  
 
4.2.2 Liver biopsy 
Liver biopsies for Newcastle samples were reviewed by two expert liver pathologists: 
Alastair Burt and Dina Tiniakos. Liver biopsies for FLIP samples were performed by 
the collaborators at each participating centre. Liver biopsy performance is written in 
section 2.2. The degree of steatosis (S0-3), activity of steatohepatitis (A0-4) and 
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stage of fibrosis (F0-4) were scored according to the validated semi-quantitative SAF 
score (Bedossa and Consortium, 2014; Dyson et al., 2014), Table 1.1. 
 
4.2.3 DNA preparation from blood samples 
DNA preparation from blood samples were descried in section 2.3.2. Some DNA 
preparation on Newcastle samples was performed by Julian Leathart and Julia Patch 
(Newcastle University, ICM). DNA isolation from FLIP samples was performed locally 
by the collaborators.  
 
4.2.4 TaqMan SNP genotyping assays 
The TaqMan SNP genotyping assays for TM6SF2 rs58542926 (reference number: 
C___8709053_10, Cat. # 4351379), NCAN rs2228603 (reference number: 
C___16171492_10, Cat. # 4351379) and PNPLA3 rs738409 (reference number: 
C___7241_10, Cat. # 4351379) were purchased from Applied Biosystems Inc., USA. 
Genotypes for these SNPs were determined by allelic discrimination using TaqMan 
reagents according to the manufacturer’s protocol. Procedures were described in 
section 2.3.4.2. Control samples of known genotype were also included in every 48-
well plate (blank, homozygous wild-type, homozygous mutant and heterozygous).  
 
4.2.5 Statistical analysis 
Statistical analyses were performed using SPSS v19.0 (IBM, USA) to collate and to 
analyze cohort phenotype data. Continuous variables were analysed using Student’s 
t-test/one-way ANOVA and categorical variables were analysed by Chi-squared test 
unless otherwise stated. PLINK v1.07  (Purcell et al., 2007) (via the gPLINK v2.050 
GUI) was used to conduct the genetic analysis. An initial univariate chi-squared 
analysis was performed. Subsequently, multivariate logistic regression analysis was 
conducted incorporating biologically relevant covariates that were associated with 
risk of NAFLD (age, gender, BMI, presence of T2DM and PNPLA3 rs738409 
genotype) to test the genetic association. An additive genetic model best fitted the 
data and was reported. Results were expressed as beta β ± SEM or odds ratio (OR) 
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with 95% confidence intervals (CI) as appropriate. P<0.05 was considered as 
statistically significant level. 
 
Table 4.1: Patients were recruited from hepatology clinics across Europe. 
 
 
 
 
 
 
 
 
 
 
 
 
Recruitment Centre Country  Ethical Approval 
Freeman Hospital Newcastle-upon-
Tyne, UK 
Newcastle & North Tyneside 1 REC 
[10/H0906/41] 
Addenbrooke’s Hospital Cambridge, UK Norfolk REC [06/Q0106/70] 
Nottingham University 
Hospitals NHS Trust 
Nottingham, UK Nottingham 2 REC [GM010201] 
Inselspital Hospital Bern, Switzerland Inselspital Bern Local Ethics Committee 
Antwerp University 
Hospital 
Belgium Antwerp University Hospital Ethics 
Committee 
Pitié-Salpêtrière Hospital Paris, France CPP (Comité de Protection des Personnes) 
Paris VI IDF Pitié - Salpêtrière Hospital 
95 
Table 4.2: Demographic characteristics of patient cohorts. 
*Steatosis and Activity score data incomplete in 8 (0.7%) and 15 (1.3%) of samples respectively. 
 
 
 
 
 Discovery Cohort Validation Cohort Combined cohort 
Number 349 725 1074 
Ethnicity European Caucasian European Caucasian European Caucasian 
Gender (Female) 147 (42.1%) 407 (56.1%) 554 (51.6%) 
Age, years 51 .5 ± 12.0 47.6 ± 12.4 48.9 ± 12.4 
BMI, kg/m2 34.5 ± 5.7 38.5 ± 9.1 37.2 ± 8.3 
T2DM (Yes) 161 (46.1%) 235 (32.4%) 396 (36.9%) 
Steatosis score* 
S0 5 (1.4%) 60 (8.3%) 65 (6.1%) 
S1 99 (28.4%) 206 (28.4%) 305 (28.4%) 
S2 166 (47.6%) 247 (34.1%) 413 (38.5%) 
S3 79 (22.6%) 204 (28.1%) 283 (26.4%) 
Activity score (composite hepatocyte ballooning and necro-inflammation scores)* 
A0 81 (23.2%) 132 (18.2%) 213 (19.8%) 
A1 65 (18.6%) 133 (18.3%) 198 (18.4%) 
A2 101 (28.9%) 214 (29.5%) 315 (29.3%) 
A3 64 (18.3%) 149 (20.6%) 213 (19.8%) 
A4 31 (8.9%) 89 (12.3%) 120 (11.2%) 
Fibrosis score 
F0 108 (30.9%) 277 (38.2%) 385 (35.8%) 
F1 90 (25.8%) 162 (22.3%) 252 (23.5%) 
F2 55 (15.8%) 161 (22.2%) 216 (20.1%) 
F3 66 (18.9%) 75 (10.3%) 141 (13.1%) 
F4 (Cirrhosis) 30 (8.6%) 50 (6.9%) 80 (7.4%) 
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4.3 Results 
4.3.1 Increased TM6SF2 rs58542926 C>T minor allele carriage in NAFLD 
In the NAFLD discovery cohort, the TM6SF2 rs58542926 genotypes were confirmed 
to be in Hardy-Weinberg equilibrium with a minor allele frequency of 0.12, 
significantly higher than that observed in a reference Northern European population 
sample (MAF 0.07, http://browser.1000genomes.org) or a cohort of 265 Caucasian 
self-reported ‘healthy workers’ recruited from offices and factories locally in the North 
East of England (MAF 0.07) and so supportive of an association between these 
variants and NAFLD. Indeed, a gene-dosage effect was observed for both variants in 
the discovery cohort with the incidence of NAFLD increasing with the number of 
minor alleles possessed (Χ2 for trend, P=0.0008), Table 4.3. A similar association 
was also confirmed for PNPLA3 rs738409, P=0.0001 (Table 4.4). Specific 
histological components of the NAFLD disease phenotype were next assessed 
individually. 
 
Table 4.3: Genotype frequency of TM6SF2 rs58542926 in Discovery Cohort NAFLD patients vs. 
the 1000 Genomes European Caucasian population. 
ChiSq for trend p=0.0008 (X2=11.34, df =1). 1000 Genomes MAF (EUR) = 0.07 
(http://browser.1000genomes.org). 
Table 4.4: Genotype frequency of PNPLA3 rs738409 in Discovery Cohort NAFLD patients vs. 
the 1000 Genomes European Caucasian population. 
ChiSq for trend p<0.0001 (X2=31.29, df =1). 1000 Genomes MAF (EUR) = 0.22 
(http://browser.1000genomes.org). 
 
TM6SF2 
Genotypes 
NAFLD   
n=349 (%) 
EUR Pop.  
n=379 (%) 
OR (95% CI) P-value 
CC 271 (77.6%) 328 (86.5%) - - 
CT 70 (20%) 49 (12.9%) OR 1.72 (1.16-2.57) 0.008 
TT 8 (2.3%) 2 (0.5%) OR 4.84 (1.01-22.9) 0.049 
PNPLA3  
Genotypes 
NAFLD   
N=349 (%) 
EUR Pop. 
N=379 (%) 
OR (95% CI) P-value 
CC 152 (43.5%) 233 (61.5%) - - 
CG 148 (42.4%) 128 (33.8%) OR 1.77 (1.29-2.42) 0.0003 
GG 49 (14%) 18 (4.7%) OR 4.17 (2.34-7.43) 3.04 x10-7 
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4.3.2 TM6SF2 and degree of histological steatosis 
As a positive control, and consistent with our previously reported analysis (Valenti et 
al., 2010a), carriage of the PNPLA3 rs738409 minor allele was significantly 
associated with degree of steatosis in multivariate analysis adopting an additive 
model adjusted for gender, age at biopsy, BMI and presence of T2DM (β 
0.192±0.056, 95%CI 0.082-0.301, P=6.74x10-4). However, in contrast to the report 
by Kozlitina et al., neither TM6SF2 rs58542926 (β 0.087±0.083, 95%CI -0.076-
0.250, P=0.296) nor NCAN rs2228603 (β 0.050±0.085, 95%CI -0.116-0.216, 
P=0.554) were found to be significantly associated with degree of histologically 
determined steatosis in the 349-patient discovery cohort. This was also the case in 
the 725-patient validation cohort (P=0.17). However, a trend towards significance 
was observed when the two cohorts were combined (β 0.111±0.059, 95%CI -0.0041-
0.2268, P=0.053), suggesting that an underlying effect on degree of steatosis may 
be present but of relatively small size. An effect became apparent when the 
multivariate analysis in the combined cohort was repeated after subdividing the 
cohort into those with mild steatosis (S0-1) and pronounced steatosis (S2-3). Here, 
carriage of each copy of the TM6SF2 rs58542926 C>T minor allele was associated 
with increased risk of greater steatosis (OR 1.379, 95%CI 1.019-1.865, P=0.037), 
although with a marginal level of significance (Table 4.5).  
 
4.3.3 TM6SF2 and severity of histological steatohepatitis  
Next, the association with steatohepatitis activity was tested using a composite score 
incorporating severity of necroinflammation and ballooning hepatocyte degeneration. 
TM6SF2 rs58542926, but not NCAN rs2228603, was associated with severity of 
steatohepatitis in the discovery cohort by multivariate analysis adopting an additive 
model adjusted for gender, age at biopsy, BMI, T2DM and PNPLA3 rs738409 
genotype (β 0.288±0.139, 95%CI 0.015-0.561, P=0.039). However, this effect was 
not replicated in the validation or combined cohorts (Table 4.6). Beta coefficients 
instead of odds ratio were applied due to the nature of continuous variables. 
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Table 4.5: Multivariate analysis of association between TM6SF2 rs58542926 genotype and steatosis stage S0-1 (mild) vs. S2-3 (advanced). 
Additive model including age, gender, BMI, T2DM and PNPLA3 rs738409 genotype as covariates.  
Discovery/Validation/Combined cohorts: Stage S0-1 (mild) n=104/266/370, Stage S2-3 (advanced) n=245/451/696. 
 
 
 
 
 
 
 
 
 
 
Variables 
 
Discovery cohort (n=349) Validation cohort (n=725) Combined cohort (n=1074) 
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value 
TM6SF2 genotype 1.39 (0.83-2.35) 0.202 1.32 (0.90-1.92) 0.15 1.38 (1.01-1.86) 0.037 
PNPLA3 genotype 1.51 (1.06-2.13) 0.021 2.02 (1.59-2.59) 1.66 x10-8 1.84 (1.51-2.25) 1.57 x10-9 
Age 0.97 (0.95-0.99) 0.022 0.99 (0.98-1.008) 0.41 0.99 (0.98-1.003) 0.137 
Gender (Male) 1.02 (0.61-1.71) 0.94 0.48 (0.34-0.68) 2.70 x10-5 0.57 (0.43-0.75) 7.53 x10-5 
BMI 1.03 (0.98-1.08) 0.174 1.05 (1.03-1.07) 1.04 x10-6 1.04 (1.02-1.06) 6.00 x10-6 
T2DM 1.40 (0.86-2.28) 0.175 1.43 (0.99-2.09) 0.058 1.52 (1.13-2.03) 5.01 x10-3 
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Table 4.6: Multivariate analysis of association between TM6SF2 rs58542926 genotype and steatohepatitis stage (Activity Score A0-4). 
 
Additive model including age, gender, BMI, T2DM and PNPLA3 rs738409 genotype as covariates. 
Variables 
 
Discovery cohort (n=349) Validation cohort (n=725) Combined cohort (n=1074) 
β±SEM (95% CI) P-value β±SEM (95% CI) P-value β±SEM (95% CI) P-value 
TM6SF2 genotype 0.288±0.139 (0.015-0.561) 0.039 0.01±0.11 (-0.207-0.22) 0.921 0.1±0.087 (-0.067-0.276) 0.236 
PNPLA3 genotype 0.19±0.096 (0.005-0.382) 0.044 0.17±0.07 (0.032-0.31) 0.016 0.17±0.057 (0.065-0.289) 0.002 
Age 0.017±0.006 (0.006-0.03) 0.0034 0.014±0.004 (0.006-0.02) 7.0 x10-4 0.014±0.003 (0.007-0.02) 2.87 x10-5 
Gender (Male) -0.005±0.146 (-0.29-0.28) 0.972 -0.146±0.1(-0.34-0.051) 0.146 -0.049±0.08 (-0.21-0.11) 0.546 
BMI 0.02±0.012 (-0.0028-0.04) 0.085 0.01±0.005 (-0.001-0.02) 0.108 0.013± 0.005(0.003-0.02) 0.006 
T2DM 0.463±0.137 (0.194-0.733) 0.0008 0.079±0.11 (-0.13-0.29) 0.477 0.189± 0.086(0.01-0.358) 0.029 
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4.3.4 TM6SF2 and stage of histological fibrosis 
Finally, the association with NAFLD fibrosis stage was tested. In the discovery cohort 
multivariate analyses adopting an additive model adjusted for gender, age at biopsy, 
BMI, T2DM and PNPLA3 rs738409 genotype found that TM6SF2 rs58542926 (β 
0.549±0.135, 95%CI 0.285-0.813, P=5.57x10-5) and NCAN rs2228603 (β 
0.419±0.138, 95%CI 0.148-0.689, P=0.0026) were both significantly associated with 
stage of fibrosis. The association between TM6SF2 rs58542926 and fibrosis stage 
persisted when analysis included both the NCAN rs2228603 and the PNPLA3 
rs738409 SNPs as co-variates (β 0.552±0.205, 95%CI 0.151-0.953, P=0.0074). 
However, the association with NCAN rs2228603 was lost when the analysis was 
conditioned on rs58542926. Thus, the association is driven by the TM6SF2 
rs58542926 variant and carriage of its minor allele confers significantly greater 
NAFLD-related hepatic fibrosis independent of gender, age at biopsy, BMI, T2DM, 
and PNPLA3 rs738409 genotype.  
This strong association between TM6SF2 rs58542926 and fibrosis stage was 
replicated independently in the validation cohort (β 0.238±0.097, 95%CI 0.047-0.428, 
P=0.014) and also clearly demonstrated in the combined cohort (β 0.357±0.079, 
95%CI 0.203-0.511, P=6.36 x10-6) using an additive model adjusted for gender, age 
at biopsy, BMI, T2DM and PNPLA3 rs738409 genotype in both cases. To illustrate 
the potential clinical relevance of this finding, when the multivariate analysis was 
repeated subdividing the NAFLD cohort into those with mild fibrosis (F0-1) and 
advanced fibrosis (F2-4), carriage of each copy of the TM6SF2 rs58542926 C>T 
minor allele was associated consistently with a significant increased risk of advanced 
fibrosis, independent of gender, age at biopsy, BMI, T2DM, and PNPLA3 rs738409 
genotype across each cohort studied (Table 4.7). 
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Table 4.7: Multivariate analysis of association between TM6SF2 rs58542926 genotype and fibrosis stage F0-1 (mild) vs. F2-4 (advanced). 
 
Additive model including age, gender, BMI, T2DM and PNPLA3 rs738409 genotype as covariates.  
Discovery/Validation/Combined cohorts: Stage F0-1 (mild) n=198/439/637, Stage F2-4 (advanced) n=151/286/437. 
 
 
 
Variables 
 
Discovery cohort (n=349) Validation cohort (n=725) Combined cohort (n=1074) 
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value 
TM6SF2 genotype 2.94 (1.76-4.89) 3.44x10-5 1.46 (1.03-2.09) 0.0362 1.88 (1.41-2.5) 1.63 x10-5 
PNPLA3 genotype 1.57 (1.21-2.19) 0.0086 1.32 (1.05-1.66) 0.0183 1.40 (1.16-1.69) 4.84 x10-4 
Age 1.03 (1.01-1.06) 0.0045 1.02 (1.01-1.04) 0.0041 1.03 (1.01-1.04) 1.57 x10-5 
Gender (Male) 1.05 (0.64-1.74) 0.8297 0.55 (0.39-0.77) 4.50 x10-4 0.69 (0.53-0.91) 0.0096 
BMI 1.05 (1.00-1.10) 0.0368 1.03 (1.01-1.05) 9.80 x10-4 1.04 (1.02-1.05) 3.78 x10-5 
T2DM 2.39 (1.49-3.84) 0.0003 2.73 (1.93-3.88) 1.68 x10-8 2.57 (1.95-3.39) 1.78 x10-11 
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4.4 Discussion 
A region on chromosome 19 (19p13.11) that contains multiple genes previously 
known as NCAN/CLIP2/PBX4/TM6SF2 has been reported to be associated with 
NAFLD (Speliotes et al., 2011; Gorden et al., 2013; Kozlitina et al., 2014) as well as 
variations in plasma cholesterol, triglyceride and low-density lipoprotein levels in 
several earlier studies (Kathiresan et al., 2008; Teslovich et al., 2010; Holmen et al., 
2014). In particular, a variant within the NCAN gene (rs2228603 C>T) that is in 
strong linkage disequilibrium (D’=0.926, r2=0.798) with TM6SF2 rs58542926 was 
reported to be associated with radiologically and histologically characterized NAFLD 
in both GWAS and candidate-gene studies (Speliotes et al., 2011; Gorden et al., 
2013). Prior to the recent publication by Kozlitina et al. (Kozlitina et al., 2014), 
examination of linkage disequilibrium patterns across the region had already brought 
that association into question (Anstee and Day, 2013). It was however the use of a 
genome-wide exome-chip genotyping approach, combined with detailed association 
analysis conditioning on previously published variants across the 19p13.11 region, 
which determined that the causative variant affecting HTGC was TM6SF2 
rs58542926 (Kozlitina et al., 2014). In clinical practice, simple steatosis is generally 
considered to have a benign course and so degree of HTGC is of limited prognostic 
relevance (Ekstedt et al., 2006; Anstee et al., 2011b; Anstee et al., 2013b). In 
contrast, progressive hepatic fibrosis leading to cirrhosis is the principal common 
pathway to hepatic failure and a liver-related death (Ekstedt et al., 2006; Musso et 
al., 2011). Using two large, well-characterised European Caucasian cohorts with 
biopsy-proven NAFLD I demonstrate that carriage of the TM6SF2 rs58542926 
variant is strongly associated with the presence of NAFLD and in particular with a 
significantly greater risk of developing advanced hepatic fibrosis/cirrhosis.  
Evidence to support a modifier effect of the TM6SF2 rs58542926 variant on 
histologically determined HTGC (steatosis), seen only when the 1,074-patient strong 
combined cohort was studied, is arguably more modest than might be expected. Our 
findings do support the previously reported association (Speliotes et al., 2011; 
Gorden et al., 2013; Kozlitina et al., 2014), although differences in sensitivity to 
subtle changes in HTGC between radiological and histological modalities may have 
reduced the power to detect this effect (McPherson et al., 2009). Kozlitina et al. 
reported that the maximal effect of the TM6SF2 variant in European Caucasians was 
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only a mean 9.2% increase in 1H-MRS quantified HTGC in TT homozygotes above 
the ~5.9% observed in CC homozygotes (Kozlitina et al., 2014). Histological 
assessment of hepatic steatosis uses broad microscopic categories reflecting the 
proportion of hepatocytes that are visibly steatotic (S0 <5%, S1 5-33%, S2 33-66%, 
S3 >66%) (Bedossa and Consortium, 2014). Based on data from previous 
comparative modality analysis (McPherson et al., 2009), the modest gene effect size 
reported by Kozlitina (less-than a 3-fold increase in HTGC above normal) would 
likely be encompassed within the histological S1 bracket and therefore may not be 
apparent histologically. Combined with the relatively low minor allele frequency in the 
background population, smaller cohorts may therefore have insufficient statistical 
power for an association to become evident.  
The modifier effect of the TM6SF2 variant on grade of steatohepatitis (disease 
activity) was apparent in the initial discovery cohort analysis however statistical 
significance was not reached in the subsequent validation analysis. The validation 
cohort comprised a mixture of patients recruited from both hepatology and bariatric 
services and, although the cohorts appear well matched histologically, the validation 
cohort exhibited higher mean BMI levels (38.5±9.1 vs. 34.5±5.7 kg/m2, P<0.0001), a 
younger mean age (47.6±12.4 vs. 51.5±12.0 years, p<0.0001), a greater female 
preponderance (56.1% vs. 32.1%, P<0.0001) and a lower prevalence of T2DM 
(32.4% vs. 46.1%, P<0.0001) than the discovery cohort (Table 4.2). These factors 
may have impacted on our ability to replicate the initial association with 
steatohepatitis in a multivariate analysis. Further study of the variant in other patient 
cohorts and exploration of the functional effects of TM6SF2 on inflammatory 
response will be needed to address this point.  
The key finding of the current study is that carriage of the TM6SF2 rs58542926 C>T 
minor allele is unequivocally associated with an increased risk of advanced NAFLD-
associated hepatic fibrosis. This highly significant effect was consistently 
demonstrated across all the cohorts studied and was independent of potentially 
confounding factors including gender, age at time of biopsy, BMI, T2DM, and 
PNPLA3 rs738409 genotype. Conditional analysis undertaken as part of the present 
study adds further weight to the assertion that the 19p13 signal is causally related to 
TM6SF2 and not NCAN, not only for HTGC as was previously reported (Kozlitina et 
al., 2014) but now also for stage of hepatic fibrosis. These findings therefore 
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establish a new and important clinical relevance to the recently described 
association between TM6SF2 and NAFLD and suggest that TM6SF2 should be 
considered alongside PNPLA3 (Romeo et al., 2008; Valenti et al., 2010a) and GCKR 
(Speliotes et al., 2011; Anstee et al., 2013a; Petta et al., 2014), as one of a handful 
of genes so far identified that are associated not only with variations in hepatic 
triglyceride accumulation but also with fibrogenesis (Anstee and Day, 2013). It is 
noteworthy that across all the cohorts studied, the odds ratio for advanced fibrosis 
conferred by each copy of the TM6SF2 variant carried was consistently of similar or 
up to 2-fold greater magnitude than that which was observed, or has previously been 
reported (Valenti et al., 2010a; Valenti et al., 2010b), for the widely-studied PNPLA3 
rs738409 variant (Table 4.7).  
After our findings were published in mid-2014, the role of genetic modifier of 
TM6SF2 rs58542926 variant on severity of NAFLD, particularly the stage of simple 
steatosis, was soon replicated in studies performed in adults (Dongiovanni et al., 
2015; Sookoian et al., 2015; Wang et al., 2015; Zhou et al., 2015) and in paediatric 
patients (Mancina et al., 2015; Goffredo et al., 2016; Grandone et al., 2016). One 
study with large European cohort identified that NAFLD patients with TM6SF2 
rs58542926 E167K variant are not only more steatotic but also more prone to have 
steatohepatitis (necroinflammation and lobular ballooning) and fibrosis which 
validated our key finding (Dongiovanni et al., 2015). Two studies from China (Wong 
et al., 2014) and Argentina (Sookoian et al., 2015) failed to replicate the effect of 
TM6SF2 rs58542926 variant upon hepatic fibrosis. The former study used a 
community-based cohort rather than selecting individuals afflicted by NAFLD, 
suggesting the cohort is more likely to be a representative of ‘healthy population’. 
Together with the given generally low minor allele frequency of TM6SF2 rs58542926 
(MAF 0.07), they reported that this variant has limited impact on NAFLD. Whereas 
the other Chinese group with a more appropriate study design (a case-control 
association study between equivalent numbers of healthy controls and biopsy-
proven NAFLD patients) demonstrated a positive association between NAFLD and 
rs58542926 (Wang et al., 2015). The latter Argentinian study only contained a cohort 
of 226 NAFLD cases with histologically characterised disease: 96 of them had 
simple steatosis and the remaining 130 exhibited relatively mild fibrosis (mean 
fibrosis stage of 1.4 out of 4). The statistical power of this low quality study would 
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therefore be questionable, and Type II error may often occur. Interestingly, this 
significant genetic influence of TM6SF2 E167K on fibrosis even remained in a 
GWAS recently published suggesting carrier of this variant increased susceptibility to 
alcohol-induced cirrhosis (Buch et al., 2015).  
When Kozlitina et al. first linked the TM6SF2 rs58542926 minor allele (T) to NAFLD, 
a separate GWAS published around the same time assessing modifiers of serum 
lipid levels and cardiovascular disease (CVD) revealed that carriage of the common 
allele (C) of the same SNP was strongly associated with raised circulating TG/LDL-
C/TC levels and increased risk of myocardial infraction/cardiovascular disease while 
carriage of the (T) minor allele was protective (Holmen et al., 2014). One study 
applied two separate groups (a NAFLD patient cohort from Italy and Finland and a 
Swedish obese population) reinforced above findings (Dongiovanni et al., 2015). In 
427 NAFLD patients evaluated carotid atherosclerosis, the minor allele carriers of 
E167K had lower risk of developing carotid plaques (OR 0.49, 95%CI 0.25-0.94) 
while decreased serum lipid levels (TC, non HDL-C and ApoB) and lower prevalence 
of cardiovascular events (hazard ratio 0.61, 95%CI 0.39-0.95) were found in E167K 
carriers among 1,819 obese subjects (Dongiovanni et al., 2015). Above findings 
suggest that TM6SF2 rs58542926 C-allele carriage increases circulating lipid profiles 
whilst T-allele carriage promotes hepatic triglyceride/cholesterol retention. Although 
hepatic steatosis is often accompanied by insulin resistance, this dual role of 
TM6SF2 rs58542926 on fatty liver and serum lipid profiles was not found to be 
correlated (Mancina et al., 2015; Zhou et al., 2015). In fact, TM6SF2 E167K carriers 
had a higher level of hepatic insulin sensitivity of glucose production and adipose 
tissue lipolysis than those wild-type subjects (Zhou et al., 2015).  
In vivo (Holmen et al., 2014; Kozlitina et al., 2014) and in vitro (Holmen et al., 2014; 
Kozlitina et al., 2014; Mahdessian et al., 2014) functional studies indicate that 
TM6SF2 has gene effects on fat retention in the liver, lipid efflux and alteration in the 
number and average size of lipid droplets. However, these studies were of too short 
a duration to adequately address the effects on steatohepatitis or fibrogenesis. 
Furthermore, previous experimental evidence has shown that hepatic triglyceride 
accumulation may not itself be directly hepatotoxic. This was elegantly demonstrated 
in mice by silencing hepatic gene expression of diacylglycerol O-acyltransferase 2 
(Dgat2), a key enzyme mediating the conversion of free fatty acids to triglyceride 
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(Yamaguchi et al., 2007). Rather than ameliorating steatohepatitis, the consequent 
reduction in hepatocyte triglyceride synthesis was associated with increased fatty 
acid oxidation, particularly through Cyp2e1, leading to greater oxidative stress, 
cellular damage and higher serum transaminase levels (Yamaguchi et al., 2007). It is 
therefore tempting to speculate that the function of TM6SF2 and the mechanism 
through which TM6SF2 drives NAFLD-associated hepatic fibrosis may be other than 
through increased triglyceride accumulation.  
In conclusion, the current study confirms that TM6SF2 is associated with 
histologically defined NAFLD and is the first demonstration that this gene serves as a 
powerful modifier of hepatic fibrogenesis. That this gene is also associated with 
disturbed cholesterol metabolism and so may modify risk of cardiovascular events 
including myocardial infarction (Holmen et al., 2014), suggesting that TM6SF2 may 
be an important determinant of clinical outcome across several facets of metabolic 
syndrome related end-organ damage. 
Based on the available data it appears that TM6SF2 is an important determinant of 
clinical outcome across several facets of metabolic syndrome related end-organ 
damage. It is tempting to speculate that TM6SF2 may act as a ‘switch’ with TM6SF2 
rs58542926 T-allele mediated hepatic retention of triglyceride and cholesterol 
predisposing to NAFLD-fibrosis whilst C-allele carriage promotes VLDL excretion, 
protecting the liver but at the expense of an increased risk of atherosclerosis and 
ultimately, cardiovascular disease (Figure 4.1). NAFLD is globally acknowledged to 
be associated with CVD which is the most common causes of mortality in NAFLD 
patients rather than malignancy and a liver-related death (Targher et al., 2007a; 
Rafiq et al., 2009; Angulo, 2013; Anstee et al., 2013b), therefore carriage of different 
alleles of TM6SF2 may dissociate this. The minor (T) allele of TM6SF2 rs58542926 
carriers may likely to experience liver-induced death while individuals carrying the 
major (C) allele are prone to afflicted by cardiovascular morbidity and mortality. 
These data surely mandate further mechanistic study to determine the physiological 
and pathophysiological role of this gene in various tissues and cell types as a 
modifier of fibrogenesis, and hopefully could develop a putative therapeutic target.  
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Figure 4.1: Outcomes of the metabolic syndrome: TM6SF2 dissociates NAFLD from cardiovascular disease. Adapted from (Kahali et al., 2015). 
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5.1 Introduction 
The rise in the burden of NAFLD coincides with a marked increase in the incidence 
of HCC in many countries (El-Serag and Rudolph, 2007; European Association For 
The Study Of The Liver and Cancer, 2012; Dyson et al., 2014). Worldwide, most 
HCC cases are related to chronic viral hepatitis; however, more than half of all HCC 
cases in developed countries occur in the viral hepatitis negative population (Parkin, 
2006; Baffy et al., 2012). Features of the metabolic syndrome, particularly obesity 
and T2DM (with gender, age and ethnicity), are well-known independent risk factors 
for HCC (Guzman et al., 2008; Starley et al., 2010) whilst the pathogenic processes 
that favour progression from steatosis to steatohepatitis are also pro-carcinogenic 
(El-Serag and Rudolph, 2007). Accumulating evidence suggests that a substantial 
proportion of HCC occurs in the absence of advanced fibrosis (Hashimoto et al., 
2009; Ascha et al., 2010; Sanyal et al., 2010; Ertle et al., 2011). 
Despite the high prevalence of NAFLD, only a minority of patients exhibit 
steatohepatitis, progress to significant fibrosis or experience associated morbidity 
and mortality (Anstee et al., 2013b). The reasons for the apparent variation in 
individual susceptibility to progressive NAFLD in general and NAFLD-related HCC in 
particular are incompletely understood (Baffy et al., 2012; Anstee and Day, 2013). 
NAFLD-related HCC develops through the complex interplay of environmental and 
genetic factors that determine individual risk ('EASL-EORTC clinical practice 
guidelines: management of hepatocellular carcinoma,' 2012; Valenti et al., 2013). 
The role of the PNPLA3 c.444C>G SNP (rs738409) is well recognized as a modifier 
of hepatic triacylglycerol accumulation and NAFLD progression (Romeo et al., 2008; 
Valenti et al., 2010a; Anstee and Day, 2013). This variant has been associated with 
increased HCC risk in alcohol-related liver disease (Nischalke et al., 2011; Trepo et 
al., 2012; Guyot et al., 2013; Trepo et al., 2014) and, more variably, in chronic viral 
hepatitis (Falleti et al., 2011; Nischalke et al., 2011; Valenti et al., 2011b; Guyot et 
al., 2013; Trepo et al., 2014). Data has also been presented showing an association 
with HCC in morbidly obese patients (Burza et al., 2012) and a mixed-aetiology 
cohort (Hassan et al., 2013). Although it may be hypothesised that these latter 
associations are related to underlying NAFLD, to date no studies have specifically 
addressed the effect of PNPLA3 rs738409 C>G carriage on HCC risk in a NAFLD 
cohort.  
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As part of the current project, the TM6SF2 association with NAFLD was expanded 
after Kozlitina et al. first linked the rs58542926 minor allele (T) to steatosis (Kozlitina, 
2014); this gene was also found to serve as a powerful modifier of hepatic 
fibrogenesis (Liu et al., 2014b). Whether the TM6SF2 SNP is also relevant to 
NAFLD-associated HCC was therefore tested. 
The aim of the current study was to determine whether carriage of the PNPLA3 
rs738409 C>G or TM6SF2 rs58452926 C>T polymorphisms confers an increased 
risk of NAFLD-related HCC, and whether that effect is independent of the presence 
of cirrhosis. To address this, I performed a case-control association study in a well-
characterised Northern European cohort with NAFLD-related HCC. 
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5.2 Methods 
5.2.1 Patients  
Patients were recruited from hepatology clinics at two European specialist centres, 
the Freeman Hospital, Newcastle-upon-Tyne, UK and Inselspital Hospital, Bern, 
Switzerland. The study had all the necessary ethical approvals in both the countries 
and all participants gave informed consent (Table 5.1). A cohort of 100 Northern 
European Caucasian patients, were recruited prospectively, with primary HCC 
arising on a background of NAFLD was identified (UK 82, Switzerland 18 patients). 
The diagnosis of HCC was established histologically or through non-invasive 
assessment according to the EASL-EORTC clinical practice guidelines ('EASL-
EORTC clinical practice guidelines: management of hepatocellular carcinoma,' 
2012). The presence of NAFLD was determined through histological assessment of 
non-tumour liver tissue or, when biopsy was not clinically appropriate, through 
radiological evidence of hepatic steatosis. As a comparator, a cohort of 275 UK 
patients recruited prospectively, with histologically characterised NAFLD of different 
stages of disease but without clinical evidence of HCC was assembled. These were 
unrelated patients with histologically characterised NAFLD, derived from a patient 
population originally identified as having ultrasonographically detected bright liver 
and abnormal biochemical tests (ALT and/or GGT). In all cases, alternative 
diagnoses were excluded, including excess alcohol intake (alcohol intake <20g/day 
for women; <30g/day for men), chronic viral hepatitis (hepatitis B and hepatitis C), 
autoimmune liver diseases, hereditary hemochromatosis, α1-antitrypsin deficiency, 
Wilson’s disease and drug induced liver injury.  
Clinical and laboratory data were collected at the time of diagnosis. These included 
basic anthropometrics so that body mass index (BMI) could be calculated. Relevant 
co-morbidity including the presence of diabetes mellitus (fasting glucose ≥7.1 
mmol/L [≥128 mg/dl] or treatment with anti-diabetic drugs) and evidence of 
underlying cirrhosis was recorded. Laboratory evaluation included routine liver 
biochemistry (alanine and aspartate aminotransferase, total bilirubin, albumin, 
alkaline phosphatase and gamma glutamyl transpeptidase); full blood count; total- 
and HDL-cholesterol and total triglycerides; viral serology for hepatitis B and C 
infection and autoantibodies. Demographic details of the cohorts are shown in Table 
5.1. 
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5.2.2 Liver biopsy 
Liver biopsy performance is described in section 2.2. The severity of steatosis, 
necroinflammatory grade and stage of fibrosis were scored according to the 
validated Kleiner criteria (Kleiner et al., 2005). This assessment allowed confirmation 
of a NAFLD diagnosis and assessment of fibrosis so that patients were classified as 
cirrhotic or non-cirrhotic. In 25 HCC patients, the diagnosis of HCC was confirmed 
histologically and staged according to Edmondson (Edmondson and Steiner, 1954), 
adapted for needle biopsy specimens.  
 
5.2.3 DNA preparation from blood samples 
DNA extraction from blood samples was described in section 2.3.2. DNA preparation 
from some Newcastle samples was performed by Julian Leathart and Julia Patch 
(Newcastle University, ICM). DNA samples from Bern were isolated locally by the 
collaborators. 
 
5.2.4 PNPLA3 rs738409 and TM6SF2 rs58452926 genotyping  
Genotypes for the two SNPs were determined by allelic discrimination using TaqMan 
reagents. TaqMan SNP genotyping assays for PNPLA3 rs738409 (reference 
number: C___7241_10, Cat. # 4351379) and TM6SF2 rs58542926 (reference 
number: C___8709053_10, Cat. # 4351379) were purchased from Applied 
Biosystems Inc., USA. Genotypes for these SNPs were determined by allelic 
discrimination using TaqMan reagents according to the manufacturer’s protocol. 
Procedures were described in section 2.3.4.2. 
 
5.2.5 Statistical analysis  
Statistical analyses was performed using SPSS v19.0 (IBM, USA) to collate and 
analyse cohort phenotype data. Continuous variables were tested using Student’s t-
test/one-way ANOVA and categorical variables were analysed by Chi-squared test 
unless otherwise stated. PLINK v1.07 (Purcell et al., 2007) (via the gPLINK v2.050 
GUI) was used to conduct the genetic analysis. An initial univariate chi-squared 
analysis was performed to determine whether PNPLA3 rs738409 C>G carriage 
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differed between the NAFLD-HCC and control NAFLD-Cohort. Subsequently 
multivariate logistic regression analysis was conducted, incorporating rs738409 
genotype and those biologically relevant covariates that were associated with risk of 
disease progression to HCC (age, gender, coexisting T2DM, BMI and presence of 
cirrhosis) to test the genetic association. Consistent with previous studies (Romeo et 
al., 2008; Sookoian et al., 2009b; Rotman et al., 2010), an additive genetic model 
best fitted the data and was reported. Results were expressed as odds ratio (OR) 
with 95% confidence intervals (CI). Significance was taken as p<0.05 throughout.  
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5.3 Results 
5.3.1 Cohort characteristics 
One hundred NAFLD-HCC patients and 275 histologically characterised NAFLD 
control patients were recruited. Characteristics of the NAFLD-HCC and NAFLD 
control populations are provided in Table 5.1. Patients with NAFLD-HCC were 
significantly older (mean age 70.3±8.0 vs. 50.9±12.4 years, P<0.0001) than a 
general NAFLD cohort. NAFLD-HCC patients were also significantly more likely to 
be male (82% vs. 59%, P<0.0001) and to be diabetic (68% vs. 43%, P<0.0001). The 
presence of NAFLD-HCC was also significantly associated with underlying advanced 
fibrosis/cirrhosis (Kleiner F4 67% vs. 9%, P<0.0001). NAFLD-HCC patients exhibited 
a lower mean BMI than the NAFLD control population.  
 
 
Table 5.1: Details of NAFLD-HCC and NAFLD Cohorts. 
Categorical values are shown as n (%). Continuous variables are shown as mean ± SD. *Fibrosis 
stage distribution in NAFLD Cohort: F0 89 (32.4%), F1 97 (35.3%), F2 37 (13.5%), F3 26 (9.5%), F4 
26 (9.5%).
 
Phenotype NAFLD-HCC Cohort 
n=100 
NAFLD Cohort 
n=275 
P-Value 
 
PNPLA3 rs738409  
G-Allele Frequency 
0.505 0.333 <0.0001 
Age (Mean±SD) 70.3±8.0 50.9±12.4 <0.0001 
Male Gender (%) 82 (0.82) 161 (0.59) <0.0001 
BMI (Mean±SD) 32.0±6.6 34.4±5.2 0.0003 
Diabetes (%) 68 (0.68) 117 (0.43) <0.0001 
Cirrhosis (%) 67 (0.67) 26 (0.09)* <0.0001 
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5.3.2 PNPLA3 rs738409 C>G polymorphism carriage is associated with 
increased risk of HCC relative to a tertiary centre NAFLD cohort 
To determine whether carriage of the PNPLA3 rs738409 C>G allele influenced 
susceptibility to NAFLD-related HCC, we studied a cohort of Northern European adult 
patients with established NAFLD. The total study population of 375 individuals (100 
NAFLD-HCC, 275 NAFLD only) was genotyped for PNPLA3 rs738409. PNPLA3 
rs738409 genotypes were confirmed to be in Hardy-Weinberg equilibrium. Reflecting 
the known association with NAFLD, the minor allele (G) frequency observed in the 
present study (G617: 0.38) was slightly higher than that observed in a population of 
North-Western European descent by the International HapMap project 
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=738409) but similar to that 
reported in previous NAFLD studies (International HapMap Consortium, 2003; 
Valenti et al., 2010a). Genotype frequencies are summarised in Table 5.2. 
Compared to a cohort of NAFLD patients with varying severity, carriage of the 
PNPLA3 rs738409 minor (G) allele (I148M variant) was strongly associated with the 
presence of NAFLD-related HCC (unadjusted OR 2.046, 95%CI 1.47-2.84, Χ2 18.50, 
P<0.0001) and exhibited a gene-dosage effect with the incidence of HCC increasing 
with the number of G alleles present (Cochran-Armitage Χ2 for trend 16.92, 
P<0.0001). Adopting an additive model relative to the NAFLD patient cohort, an 
approximate doubling of HCC risk was observed for each copy of the minor (G) allele 
carried (unadjusted OR 1.95, 95%CI 1.40-2.70, P<0.0001). The unadjusted odds 
ratio increased to 3.92 (95%CI 2.06-7.48, P=0.0001) when only homozygotes were 
considered (Table 5.2). The relationship between PNPLA3 genotype and a number 
of relevant patient-specific and clinical parameters is summarised in Table 5.3. 
Amongst those samples where HCC was histologically characterised, carriage of the 
rs738409 C>G polymorphism was associated with the presence of more poorly 
differentiated tumour (Fisher’s Exact Test P=0.018), (Table 5.3).  
 
5.3.3 PNPLA3 rs738409 C>G polymorphism carriage in NAFLD-HCC relative to 
an unselected population cohort 
The published PNPLA3 rs738409 C>G minor allele frequency in a UK general 
population sample (the MRC/Wellcome Trust UK 1958 Birth Cohort, 
http://www.b58cgene.sgul.ac.uk/) is 0.23 (95%CI 0.21-0.24) with genotype 
frequencies of CC 0.59, CG 0.36, GG 0.05. Carriage of the rs738409 C>G 
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polymorphism was increased in the NAFLD-HCC cohort relative to this unselected 
population (Table 5.2). As limited phenotype data is available on the population 
cohort only unadjusted odds ratios could be calculated however, adopting an additive 
model relative to the UK general population, a greater than 3-fold increased HCC risk 
was observed for each copy of the minor (G) allele carried (OR 3.43, 95%CI 2.54-
4.62, P<0.0001). When only homozygotes were considered an odds ratio of 12.19 
(95%CI 6.89-21.58, P<0.0001) for GG over CC was observed.   
 
 
 
 
 
117 
Table 5.2: PNPLA3 rs738409 genotype frequencies and their relationship to risk of HCC development. 
♯ Odds ratio for HCC relative to CC genotype adjusted for age, gender, diabetes, BMI and cirrhosis. 
† The MRC/Wellcome Trust UK 1958 Birth Cohort. 
Genotype NAFLD-HCC 
n(%) 
NAFLD 
Cohort 
n(%) 
Unadjusted 
OR (95%CI) 
P-value Adjusted 
OR 
(95%CI)♯ 
P-value UK Popn. 
n(%)† 
Unadjusted OR 
(95%CI) 
P-value 
CC 28 (0.28) 125 (0.46) - - - - 871 (0.59) - - 
GC 43 (0.43) 117 (0.42) 1.64  
(0.96-2.81) 
0.072 2.35  
(0.90-6.13) 
0.082 531 (0.36) 2.52  
(1.55-4.10) 
0.0002 
GG 29 (0.29) 33 (0.12) 3.92  
(2.06-7.48) 
<0.0001 5.05  
(1.47-17.29) 
0.01 74 (0.05) 12.19 
(6.89-21.58) 
<0.0001 
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Table 5.3: Comparison of selected characteristics according to PNPLA3 rs738409 genotype within NAFLD-HCC and NAFLD Cohorts. 
Categorical values are shown as n (%). Continuous variables are shown as mean ± SD.  
† Comparison between PNPLA3 genotypes within each study cohort (chi-squared test used for categorical variables and one-way ANOVA for continuous 
variables unless otherwise stated).  
* 25 cases had histologically characterised HCC. Results expressed as n (%) of cases with ‘well differentiated’/’moderate-poorly differentiated’ tumour. P-
value calculated by Fisher’s Exact Test.
 NAFLD-HCC Cohort NAFLD Cohort 
Genotype  
n(%) 
CC 
n = 28 (0.28) 
CG 
n = 43 (0.43) 
GG 
n = 29 (0.29) 
P-Value† CC 
n = 125 (0.46) 
CG 
n = 117 (0.42) 
GG 
n = 33 (0.12) 
P-value† 
Age (Mean±SD) 73.6±8.1 68.9±7.9 69.2±7.4 0.034 50.9±12 51±12 50±15.2 0.906 
Male Gender (%) 23 (0.82) 36 (0.84) 23 (0.79) 0.892 75 (0.60) 74 (0.63) 12 (0.36) 0.020 
BMI (Mean±SD) 30.4±6.7 31.9±4.5 33.6±8.9 0.201 34.4±4.8 34.6±5.7 33.9±4.8 0.765 
Diabetes (%) 18 (0.64) 31 (0.72) 19 (0.66) 0.744 51 (0.41) 56 (0.48) 10 (0.30) 0.171 
Cirrhosis (%) 13 (0.46) 30 (0.70) 24 (0.83) 0.012 11 (0.01) 9 (0.01) 6 (0.18) 0.181 
Histological Grade of 
HCC* 
5 (0.45) /  
6 (0.54) 
8 (0.80) /  
2 (0.20) 
0 (0.00) /  
4 (1.00) 
0.018 - - - - 
119 
5.3.4 Contribution of the PNPLA3 rs738409 C>G polymorphism to NAFLD-
HCC risk is independent of presence of cirrhosis 
Given the previous reports demonstrating a role for rs738409 C>G as a modifier of 
disease progression and fibrosis in NAFLD, and the association between presence 
of age, T2DM, obesity and cirrhosis with HCC, a multivariate logistic regression 
analysis using an additive model was performed to control for any potential 
confounding effects. Along with genotype, gender, age at diagnosis, presence of 
advanced fibrosis/cirrhosis, T2DM and BMI were included in the analysis. PNPLA3 
genotype (OR 2.26, 95%CI 1.23-4.14, P=0.0082), gender, age and presence of 
cirrhosis were independent predictors of NAFLD-HCC (Table 5.4). Of these factors, 
male gender (OR 11.11, 95%CI 4.17-33.33, P<0.0001) and the presence of 
underlying cirrhosis (OR 9.37, 95%CI 3.82-23.00, P<0.0001) conferred the greatest 
risk. The presence of T2DM or raised BMI were not significant predictors of HCC risk 
in this analysis, although a trend towards significance was observed for T2DM (OR 
2.33, 95%CI 0.93-5.81, P=0.070). No significant interactions were identified within 
the regression model. The results of multivariate analysis correcting for age, gender, 
T2DM and BMI but not cirrhosis are shown in Table 5.5 and Table 5.6.  
 
Table 5.4: Multivariate analysis of the effect of PNPLA3 genotype on NAFLD-related HCC risk. 
Variables OR (95% CI) P-value 
PNPLA3 rs738409 genotype 2.26 (1.23-4.14) 0.0082 
Age 1.24 (1.17-1.32) <0.0001 
Gender (Male) 11.11 (4.17-33.33) <0.0001 
BMI 0.94 (0.87-1.02) 0.148 
Diabetes 2.33 (0.93-5.81) 0.070 
Cirrhosis 9.37 (3.82-23.00) <0.0001 
Additive Model including age, gender, BMI, diabetes and cirrhosis as covariates.
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Table 5.5: Multivariate analysis of the effect of PNPLA3 genotype on NAFLD-related HCC risk 
adjusted for age, gender, BMI and diabetes but not cirrhosis. 
Additive Model including age, gender, BMI and diabetes (but not cirrhosis) as covariates.  
 
 
 
Table 5.6: PNPLA3 rs738409 genotype frequencies and their relationship to risk of HCC 
development adjusted for age, gender, BMI and diabetes but not cirrhosis.  
♯ Adjusted odds ratio for HCC relative to CC genotype (covariates age, gender, T2DM and BMI).  
  
 
 
 
 
Variables OR (95% CI) P-value 
PNPLA3 rs738409 genotype 3.06 (1.76-5.29) <0.0001 
Age 1.28 (1.21-1.36) <0.0001 
Gender (Male) 9.52 (3.85-23.26) <0.0001 
BMI 0.98 (0.91-1.05) 0.593 
Diabetes 2.71 (1.19-6.17) 0.018 
Genotype NAFLD-HCC 
n(%) 
NAFLD Cohort  
n(%) 
Adjusted Odds Ratio 
(95%CI)♯ 
P-value 
CC 28 (0.27) 125 (0.46) - - 
CG 43 (0.43) 117 (0.42) 2.50 (1.03-6.08) 0.043 
GG 29 (0.3) 33 (0.12) 9.61  (3.21-28.75) <0.0001 
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NAFLD-HCC patients carrying the G allele on average developed HCC at a younger 
age than those that do not (Table 5.3). When NAFLD-HCC patients were stratified by 
median age (</>70 years) a significant enrichment in G allele carriage was present in 
the younger HCC patients over the older ones (MAF Young 0.59 vs. Old 0.42, Χ2 
5.76, P=0.016). Similarly, when compared to the NAFLD-Cohort control group, the 
effect of rs738409 carriage was statistically significant in those younger than the 
median age (OR 2.85, 95%CI 1.85-4.37, Χ2 24.09, P<0.0001) but not in those older. 
Consistent with previous reports (Valenti et al., 2010a), carriage of the rs738409 
C>G polymorphism was also significantly associated with the presence of NAFLD-
related cirrhosis (OR 2.33, 95%CI 1.66-3.27, Χ2 24.8, P<0.0001) across the entire 
375 patient NAFLD cohort and exhibited a gene-dosage effect with the incidence of 
cirrhosis increasing with the number of G alleles present (Cochran-Armitage Χ2 for 
trend 22.68, P<0.0001). To further examine the effect of PNPLA3 on HCC risk 
independent of degree of fibrosis, only those patients with coexistent cirrhosis were 
studied (NAFLD-HCC n=67, NAFLD-Cohort n=26). Study-group sizes were relatively 
small in this sub-analysis however carriage of the rs739409 C>G polymorphism 
remained significantly associated with NAFLD-HCC (OR 2.06, 95%CI 1.07-3.94, Χ2 
4.78, P=0.029) in patients with cirrhosis. Adopting an additive model incorporating 
genotype, gender, age at diagnosis, T2DM and BMI, PNPLA3 remained significantly 
associated with HCC (OR 3.41, 95%CI 1.39-8.37, P=0.0074) amongst patients with 
cirrhosis. The effect did not reach statistical significance in the non-cirrhotic cohort, 
but for HCC this group included only 23 cases. 
 
5.3.5 TM6SF2 rs58542926 C>T polymorphism and risk of hepatocellular 
carcinoma 
We also sought to determine whether TM6SF2 rs58542926 had a similar effect to 
PNPLA3 rs738409. TM6SF2 rs58542926 allele and genotype frequencies in this 
cohort were compared to the NAFLD cohort described above. In the univariate 
analysis, homozygote carriage of the TM6SF2 rs58542926 minor allele was 
associated with an increased risk of NAFLD-HCC with respect to CC (OR 1.922, 
95%CI 1.31-2.81, P=6.81 x10-4), however significance was lost in the multivariate 
analysis incorporating known risk factors including age, gender, BMI, T2DM and 
presence of cirrhosis (P=0.42).
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5.4 Discussion 
Using a large, well-characterised Northern European cohort with biopsy-proven 
NAFLD we show a strong association between PNPLA3 rs738409 genotype and 
HCC risk, but not with TM6SF2 rs58542926 genotype. This highly significant effect 
between the PNPLA3 rs738409 SNP and HCC risk was independent of potentially 
confounding factors including age, gender, co-existent diabetes, obesity and the 
presence of cirrhosis. Although PNPLA3 rs738409 is principally recognised as a 
disease risk factor in NAFLD (Anstee and Day, 2013), studies thus far reporting 
associations with HCC have been in individuals with viral hepatitis (Falleti et al., 
2011; Nischalke et al., 2011; Valenti et al., 2011b; Guyot et al., 2013), alcoholic liver 
disease (Nischalke et al., 2011; Trepo et al., 2012; Guyot et al., 2013) or obesity 
(Burza et al., 2012) (reviewed (Valenti et al., 2013; Trepo et al., 2014). We report the 
first NAFLD study in which multivariate analysis relative to a well-characterised 
NAFLD population demonstrates that carriage of each G allele is associated with a 
doubling of HCC risk (adjusted OR 2.26, 95% CI 1.23-4.14, P=0.0082).  
As they were recruited in a tertiary centre, our NAFLD cohort is likely to represent a 
more severe spectrum of disease than is present in an unselected population cohort, 
and so is likely to be enriched for rs738409 C>G minor allele carriage. We therefore 
also compared the NAFLD-HCC cohort with a UK general population sample (the 
MRC/Wellcome Trust funded UK 1958 Birth Cohort) to provide a measure of effect 
relative to an unselected background population. Although additional phenotype data 
for this secondary analysis was limited and so only univariate comparisons could be 
made, the results were striking. Carriage of the G allele was strongly associated with 
HCC with the homozygote GG genotype being associated with an unadjusted odds 
ratio for HCC of 12.19 (95%CI 6.89-21.58) over CC. By its nature, this secondary 
analysis cannot control for potential confounders including age, gender, co-existent 
diabetes, obesity and the presence of cirrhosis as these data are not available for 
the 1958 Birth Cohort and so care should be taken not to over-interpret the estimates 
of effect-size in this comparison. However, taken together with the results of our 
primary analysis comparing NAFLD-HCC with histologically characterised NAFLD, 
the results consistently demonstrate significantly increased HCC risk with PNPLA3 
rs738409 C>G minor allele carriage and suggest that the effect-size reported by our 
primary analysis using a tertiary centre NAFLD cohort may be a conservative 
123 
estimate. These results have implications for our understanding of HCC 
pathogenesis in NAFLD and, if supported by further validation, are also potentially of 
clinical relevance.  
In keeping with established predictors of progression from steatosis to NASH and 
fibrosis, and the recognised independent associations of HCC with both cirrhosis and 
T2DM (El-Serag et al., 2004; Anstee et al., 2013b), we show that NAFLD-HCC 
patients are likely to be older males with T2DM and underlying cirrhosis. In contrast, 
although NAFLD-HCC patients were generally obese, at the time of HCC diagnosis 
the mean BMI was lower than that of the reference NAFLD population. The reason 
for this is not clear however this observation is possibly attributable to HCC induced 
cachexia.  
A key finding in the current study is that the influence of rs738409 C>G on HCC risk 
was greater than can be accounted for by the associated increased risk of 
progression to cirrhosis. This was demonstrated both in the multivariate analysis, 
where the effect of cirrhosis was controlled by inclusion as a covariate, and also in a 
sub-analysis with the cohort stratified according to presence of cirrhosis. Amongst 
cirrhotics, rs738409 C>G remained a highly significant factor even after the other 
covariates were included in the model (OR 3.41, 95%CI 1.39-8.37, P=0.0074), 
indeed the adjusted odds ratio increased. Thus, supporting the conclusions of the 
multivariate regression analysis, HCC risk conferred by PNPLA3 genotype is not 
mediated solely through progression to advanced fibrosis. The effect of PNPLA3 did 
not reach significance in the non-cirrhotic sub-group and so it is tempting to 
speculate that the effect of rs738409 on HCC risk is largely confined to those with 
cirrhosis; however, only 23 HCC patents were included in that analysis and overall G 
allele carriage was low, severely limiting statistical power and so the negative result 
should be interpreted with caution. Furthermore, no significant interaction between 
genotype and cirrhosis was identified in the logistic regression model making this 
interpretation less likely. Validation in a larger NAFLD-HCC cohort will be required to 
clarify this point; irrespective of this our data supports the view that HCC promotion 
by PNPLA3 in NAFLD is independent of its role in fibrosis progression.  
It is noteworthy rs738409 C>G polymorphism carriage was associated with a mean 
4-year younger age at tumour presentation than the CC genotype (Table 5.3). 
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Consistent with a recent report that PNPLA3 genotype may have a greater impact on 
hepatic fibrosis progression at younger onset of alcohol consumption (Burza et al., 
2013), our observation that minor allele carriers were younger at HCC diagnosis 
possibly suggests the influence of genetic factors on HCC risk diminishes with age, 
whilst acquired exposure to environmental factors exerts a greater effect. 
Stratification by median age showed the greatest effect of PNPLA3 in those aged 
less than seventy and so would support this view however, as discussed earlier, 
such an interaction is not supported by the multivariate analysis and so further 
studies in larger cohorts will be needed to address this.  
The PNPLA3 gene encodes a protein that is closely related to adipose triglyceride 
lipase (ATGL/PNPLA2), the major TAG hydrolase in adipose tissue (Zimmermann et 
al., 2004; Romeo et al., 2010). PNPLA3 represents one of a small number of genes 
that has been consistently identified as a modifier of NAFLD severity (reviewed 
(Anstee and Day, 2013)). Notably, the variant has also been associated with 
inflammation and fibrosis independent of TAG accumulation (Sookoian et al., 2009b; 
Rotman et al., 2010; Valenti et al., 2010a; Al-Serri et al., 2012). The pathogenesis of 
HCC in NAFLD has been the subject of recent reviews, highlighting the likely 
contributions of lipotoxicity (Baffy et al., 2012), metabolic or stress response 
pathways (Michelotti et al., 2013), gut microbiota, bile acid receptors, vitamin D, 
senescence and autophagy in hepatic stellate cells as well as progenitor cell 
dysregulation (Lade et al., 2014). However, our findings suggest that the contribution 
of PNPLA3, probably in the context of these proposed mechanisms, warrants further 
study. 
In terms of lipotoxicity, the phenomenon called ‘adipose tissue expansion’ - is a 
compensatory response to an overwhelming uptake of fat/nutrition when obesity 
occurs. This process releases several cytokines, typically leptin, tumour necrosis 
factor alpha (TNF-α) and interleukin-6 (IL-6), promoting a pro-inflammatory and pro-
fibrotic environment through activation of JAK/STAT, PI3K/Akt, mTOR and Nf-KB 
signalling pathways (Saxena et al., 2007; Baffy et al., 2012; Nakagawa et al., 2014). 
Sustained lipid/nutrition overloading results in an increase in de novo lipogenesis 
coincident with a decrease in excretion of VLDL and a reduction in free fatty acids 
(FFA) clearance. Aberrant level of circulating FFA could induce ER stress and JNK-
dependent hepatocyte lipoapoptosis (Malhi et al., 2006; Wei et al., 2006). In the 
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context of overwhelmed fatty acid oxidation, reactive oxygen species (ROS) can 
therefore be produced at high levels. These free radicals target DNA, RNA, proteins 
and lipids, causing inflammation, damage to genomic DNA and other 
macromolecules, mitochondrial dysfunction, ER stress and apoptosis, forming a 
fundamental process for oncogenesis (Hussain et al., 2003; Malhi et al., 2006; Wei 
et al., 2006). Because PNPLA3 is known to be expressed in the liver and adipose 
tissue, suggested to be localized in the ER and in lipid droplets and possibly 
functioning as a lipid hydrolase (Pirazzi et al., 2012), it is tempting to speculate that 
mutation of PNPLA3-I148M may stimulate or accelerate the conditions described 
above by means of loss of function. Namely, the mutated protein causes excess fat 
retention within lipid droplets via a reduced activity of lipid hydrolysis and an impaired 
secretion of VLDL in the ER. Hence, PNPLA3-I148M may profoundly promote the 
effects of adipose tissue remodelling and following cascades of lipotoxicity.  
Moreover, insulin resistance (IR) and hyperinsulinemia are essential elements in 
obesity-associated conditions. The actions of insulin involve a complex signalling 
network, with insulin receptor-mediated tyrosine phosphorylation of insulin receptor 
substrates (IRS), activation of PI3K/Akt pathway, and enzymatic regulators for 
glucose uptake, glycogen and lipid synthesis (Saltiel and Kahn, 2001). Multiple 
insults driven by elevated circulating FFA and ROS may cause impaired insulin 
signalling, resulting in insulin resistance and hyperinsulinemia (Saltiel and Kahn, 
2001; Jou et al., 2008; Karagozian et al., 2014). Evidence indicates that consistently 
high levels of insulin, insulin-like growth factors (IGF) and IRS-1 are involved in the 
development of angiogenesis and HCC, by activating oncogenic pathways of 
PI3K/Akt, vascular endothelial growth factor (VEGF) and mitogen-activated protein 
kinase (MAPK) (Tanaka et al., 1997; Kim et al., 1998). Insulin also activates the 
gene expression of transcription factor steroid regulatory element-binding protein 
(SREBP) -1c  to promote hepatic de novo lipogenesis (Ferre and Foufelle, 2007). 
Increased activation of SREBP-1c due to insulin resistance/hyperinsulinemia would 
therefore worsen steatosis. Additionally, carbohydrate response element-binding 
protein (ChREBP) is another key transcription factor responsible for promotion of 
glycolysis and de novo lipogenesis (Iizuka and Horikawa, 2008). It has been 
demonstrated that the degree of steatosis was markedly improved by liver-specific 
inhibition of ChREBP in mouse, decreasing lipogenic rates and improving insulin 
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sensitivity in liver, skeletal muscles and adipose tissue (Dentin et al., 2006). Hence, 
PNPLA3 is very likely to share a part of the underpinning mechanisms of NAFLD-
HCC as it is regulated by both SREBP-1c and ChREBP (Rae-Whitcombe et al., 
2010; Perttila et al., 2012a). Besides, PNPLA3 also has been suggested to have 
retinyl-palmitate lipase activity in human hepatic stellate cells, which may explain its 
pathophysiological role in liver fibrosis (Pirazzi et al., 2014). 
Taken together with our data, the observation that carriage of the rs738409 GG 
genotype was associated with more poorly differentiated tumours amongst those 
with histologically characterised NAFLD-HCC, these findings suggest that PNPLA3 
genotype may directly influence tumour biology. Additional studies will be required to 
establish how these effects of PNPLA3 are mediated. However, the general concept 
of PNPLA3 in determining the susceptibility to NAFLD-related HCC could be that 
accumulating fat promoted by PNPLA3 I148M, oxidative stress and the low-grade 
inflammatory response present in NAFLD, favour a pro-carcinogenic milieu within the 
liver (Baffy et al., 2012). This interpretation would be consistent with previous studies 
that suggest a greater effect of the PNPLA3 variant on HCC risk in steatotic liver 
diseases (e.g. ALD, and here NAFLD) than that observed in non-steatotic conditions 
such as viral hepatitis (Sookoian and Pirola, 2013; Trepo et al., 2014).  
The high prevalence of NAFLD within the general population and the potential for 
disease progression both to cirrhosis and HCC poses a major challenge to existing 
healthcare infrastructure (Anstee et al., 2011b). Understanding the contribution of 
PNPLA3 to this process may theoretically have relevance to future preventive or 
therapeutic strategies targeting NAFLD-HCC. Ultrasonography and serological 
examinations (alpha-fetoprotein, AFP) ('EASL-EORTC clinical practice guidelines: 
management of hepatocellular carcinoma,' 2012) are presently used surveillance 
strategies, but even when targeting the cirrhotic population, their cost-effectiveness 
is debatable (Sarasin et al., 1996; Trevisani et al., 2007). Like most common 
diseases, NAFLD-related HCC is a complex disease trait with risk influenced by a 
combination of genetic and environmental factors. Whilst the odds ratios reported 
here are substantial and highly statistically significant, these do not mean that the 
PNPLA3 rs738409 variant is the sole driver for HCC or could alone be used to 
stratify individual HCC risk (Manolio, 2013). However, if the results of the current 
study are corroborated, PNPLA3 rs738409 genotype could potentially be included in 
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a broader multi-factorial risk assessment to help physicians to identify those amongst 
the expanding population of obese individuals with NAFLD at greatest risk of HCC, 
both in the presence and absence of cirrhosis (Baffy et al., 2012; Dyson et al., 2014). 
If the current findings are validated, a prospective economic evaluation of strategies 
incorporating assessment of PNPLA3 rs738409 C>G status to target surveillance to 
those at greatest HCC risk may be warranted.  
It should however be noted that the NAFLD-HCC cohort contained only 100 patients 
in the case-control analyses (NAFLD vs. NAFLD-HCC) for both PNPLA3 and 
TM6SF2. However, a significant association was only observed between the 
PNPLA3 rs738409 genotype and NAFLD-related HCC, not TM6SF2 rs58542926. 
One possible explanation for the differences between the two SNPs in the 
association with NAFLD-HCC could be due to their minor allele frequencies. In the 
Northern European population, minor allele frequencies of 0.22 and 0.07 were 
reported for PNPLA3 rs738409 and TM6SF2 rs58542926, respectively. The 
numbers increased slightly and were found to be 0.34 (rs738409) and 0.12 
(rs58542926) in our NAFLD cohort. Combined with a relatively modest TM6SF2 
rs58542926 minor allele frequency, the current study had approximately 70% power 
to detect an effect if an additive genetic model and risk similar to that seen for 
fibrosis (described in Chapter 4) is assumed (α=0.05) (Purcell et al., 2003). Failure to 
detect an association for TM6SF2 due to limited statistical power cannot therefore be 
completely excluded but would seem unlikely. Studies using larger cohorts of 
NAFLD-HCC patients than are presently available will be required to provide 
sufficient power to study this further. Alternatively, differences between the two 
proteins in overall function (e.g. the reported additional role for PNPLA3 in retinyl-
palmitate lipase activity) may explain the association of PNPLA3 with fibrosis and 
HCC but TM6SF2 with fibrosis only. 
In summary, we report a striking association between PNPLA3 rs738409 and the 
development of NAFLD-HCC, which is independent of other known risk factors. 
These data highlight the importance of understanding the contribution of PNPLA3 
I148M to NAFLD-HCC pathogenesis, and if validated, may contribute to a tailored 
approach to the cost effective surveillance and detection of NAFLD-HCC in those at 
greatest risk. 
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6.1 Introduction 
As described in Chapter 1, the two SNPs in the genes PNPLA3 (rs738409 c.444 
C>G, p.I148M) and TM6SF2 (rs58542926 c.449 C>T, p.E167K) are significantly 
associated with severity of NAFLD. Our statistical data in the previous Chapters also 
suggested that the PNPLA3 rs738409 SNP is a strong genetic risk factor associated 
with susceptibility to steatosis, inflammation and fibrosis using a well-characterised 
histologically proven NAFLD cohort. Moreover, we demonstrated the novel finding 
that this SNP was independently associated with the end-stage of NAFLD - 
hepatocellular carcinoma (data described in Chapter 5). Therefore, investigating the 
functional role of PNPLA3 in NAFLD pathogenesis is important, including how this 
variant may biologically influence development of steatosis and fibrosis.    
As described in detail in section 1.7.3.6, recent research suggests that PNPLA3 
mediates hydrolysis of acylglycerols and the I148M, which results in reduced 
enzymatic activity, causes fat accumulation in the liver. (He et al., 2010; Huang et al., 
2011). The PNPLA3 I148M variant has also been reported to alter hepatic lipid 
metabolism especially TG remodelling in lipid droplets within hepatocytes (Li et al., 
2012; Ruhanen et al., 2014). Beyond steatosis, its role in underlying biological 
mechanisms through which PNPLA3 influences progression to NASH and hepatic 
fibrosis still remain obscure. One study recently published by Pirazzi et al. has shed 
some light on the association between PNPLA3 I148M and hepatic fibrogenesis, 
demonstrating that PNPLA3 may possess a role of retinyl-palmitate hydrolase in 
human HSCs (Pirazzi et al., 2014). PNPLA3 was reported to be highly expressed in 
both the retina and the liver thus pointing to a key feature within the two organs, 
retinol metabolism. Retinol is converted into retinyl ester for storage in quiescent 
HSCs and is released during stellate cell activation (Lee and Jeong, 2012; Pirazzi et 
al., 2014). Pirazzi et al. further demonstrated that PNPLA3 is indeed highly 
expressed in HSCs, the dominant contributors to fibrogenesis. Incubation of primary 
human HSCs or immortalized human HSCs – LX-2 with retinol and palmitate up to 
48 hours showed that a time-dependent increase in lipid droplet accumulation 
coexisted with a down-regulation of PNPLA3 protein expression, suggesting that 
PNPLA3 expression may also be regulated by retinol availability in human HSCs. 
Additionally, overexpressed wild-type PNPLA3 in HSCs resulted in a substantial 
reduction of lipid droplet content, an effect that was lost with I148M. These findings 
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reinforce that PNPLA3 is a regulator of lipid metabolism influenced by retinol levels 
and the I148M variant is a loss-of-function mutation (Pirazzi et al., 2014). How 
activation of HSC, collagen deposition and fibrogenesis may be affected by this 
mutated protein remains unknown but however indicates that PNPLA3 may be 
expressed in multiple cell types. Thus, challenges remain in targeting relevant cell 
types and optimising experimental conditions to further investigate the key role of 
PNPLA3 in NAFLD. 
In respect of TM6SF2 rs58542926 SNP, unlike studies for PNPLA3, little is known in 
terms of the pathogenic role of TM6SF2 in NAFLD. The current understandings of 
this protein are that: 1) TM6SF2 is a multi-pass membrane protein (Carim-Todd et 
al., 2000), 2) is highly expressed in liver, kidney and intestines (Kozlitina et al., 2014; 
Surakka et al., 2015), 3) is mainly localized to the ER and ER-Golgi intermediate 
compartments (ERGIC) (Mahdessian et al., 2014), and 4) both in vivo (Holmen et al., 
2014; Kozlitina et al., 2014) and in vitro (Holmen et al., 2014; Kozlitina et al., 2014; 
Mahdessian et al., 2014) functional studies indicate that TM6SF2 has effects on fat 
retention in the liver, lipid efflux and alteration in the number and average size of lipid 
droplets. Taking the current knowledge of TMS6F2 together with our data in Chapter 
4 that the TM6SF2 rs58542926 polymorphism was strongly linked to hepatic fibrosis, 
it appears that this variant is an important determinant of clinical outcome across 
several facets of metabolic syndrome related end-organ damage.  
To investigate of the functional significance of the PNPLA3 rs738409 and TM6SF2 
rs58542926 in fatty liver disease, a series of studies were performed as described in 
this Chapter. In this preliminary investigation, I aimed to establish in vitro models to 
demonstrate the effect of fatty acid treatment on PNPLA3 and TM6SF2 expression. 
Commercially available human hepatoblastoma/hepatoma cell lines were 
characterised in detail and compared with primary hepatocytes. Additionally, the 
effect of retinol-palmitate treatment on PNPLA3 expression in the immortalized 
human HSCs – LX-2 was also investigated. 
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6.2 Methods 
6.2.1 Cell culture 
6.2.1.1 Cell lines employed and cell culture conditions 
Three human HCC cell lines (Hep3B, HUH-7 and SNU182), and one human 
hepatoblastoma cell line (HepG2) were obtained from Gillian Patman, Northern 
Institute for Cancer Research, Newcastle University. The human hepatic stellate cell 
line LX-2 was kindly provided by Prof. Fiona Oakley, Institute for Cellular Medicine, 
Newcastle University. Cell culture conditions and DNA/RNA isolation are described 
in section 2.4.1 and section 2.4.2, respectively. Materials used are listed in Table 6.1 
and Table 6.2. 
Cultured primary human hepatocytes were purchased from Biopredic International 
(Saint-Grégoire, France, catalogue number: HEP220). These primary hepatocytes 
were isolated from a single donor, 54-year old male Caucasian, who had been 
diagnosed with liver metastases from carcinoma of the colon. Alternative diagnoses 
were excluded, including excess alcohol intake, chronic viral hepatitis (hepatitis B 
and hepatitis C), hypertension, diabetes, cardiovascular disease, and human 
immunodeficiency virus infection (HIV).  
The isolation of hepatocytes was performed by the supplier using an undisclosed 
protocol (for commercial reasons). Primary hepatocytes were cultured by the 
supplier in a 6-well plate for one day after isolation with undisclosed culture 
conditions. Cell morphology was maintained and cell viability and culture confluence 
were reported to be 88% and 98%, respectively.  
The 6-well plate was dispatched and delivered on the second day after isolation. 
After arrival, the cells were washed once with 1X PBS (Lonza, Slough, UK; 
catalogue number: BE17-516F) and the culture medium was replaced by the basal 
hepatic cell medium (Biopredic International, Saint-Grégoire, France, catalogue 
number: MIL600, 100 ml) supplemented with the 10X long term culture medium 
(Biopredic International, Saint-Grégoire, France, catalogue number: ADD271, 11 ml). 
All the solutions for cell culture were filter-sterilized by 0.22 μm filter (Merck Millipore, 
Hertfordshire, UK). The cells were incubated at 37°C in an atmosphere with 5% 
humidified CO2. On the following morning, the hepatocytes were harvested for DNA 
(section 2.4.2.1), RNA (section 2.4.2.1) and protein extraction (section 2.4.2.3).  
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Table 6.1: Complete RPMI medium for growing HepG2, Huh-7, Hep3B and SNU182 cells. 
Name Supplier 
RPMI 1640 500 ml Lonza, Cat: BE12-167F 
Sodium Pyruvate 100 mM (5 ml) Lonza, Cat: BE13-115E 
L-glutamine 200 mM (5 ml) Lonza, Cat: BE17-605E 
Non-essential amino acids 100X (5 ml) Lonza, Cat: BE13-114E 
10% Foetal bovine serum FBS (50 ml) Lonza, Cat: DE14-801F 
Penicillin/ Streptomycin (5 ml) Lonza, Cat: DE17-603E 
 
 
Table 6.2: Complete RPMI medium for growing LX-2 cells. 
Name Supplier 
RPMI 1640 500 ml Lonza, Cat: BE12-167F 
Sodium Pyruvate 100 mM (5 ml) Lonza, Cat: BE13-115E 
L-glutamine 200 mM (5 ml) Lonza, Cat: BE17-605E 
Non-essential amino acids 100X (5 ml) Lonza, Cat: BE13-114E 
5% Foetal bovine serum FBS (50 ml) Lonza, Cat: DE14-801F 
Penicillin/ Streptomycin (5 ml) Lonza, Cat: DE17-603E 
 
 
6.2.1.2 Genotyping and gene expression 
Genotyping was conducted using TaqMan SNP genotyping assays for PNPLA3 
rs738409 (reference number: C___7241_10, Cat. # 4351379) and TM6SF2 
rs58542926 (reference number: C___8709053_10, Cat. # 4351379) purchased from 
Applied Biosystems Inc., USA. The procedure of genotyping is described in section 
2.3.4.2. TaqMan gene expression assays were purchased from Applied Biosystems 
Inc., USA for PNPLA3 (Hs00228747_m1, Cat: #4331182), TM6SF2 
(Hs00403495_m1, Cat: #4331182) and GAPDH (Dm01843827_s1, Cat. # 4331182) 
as the reference gene. Materials used and performance of reverse transcription and 
gene expression are described in section 2.4.2.3. Unpaired student T-test was 
adapted for statistical analyses using 2-^delta CT value.  
 
133 
6.2.1.3 Preparation of BSA-bound oleic acid 
Oleic acid (317 µl) was taken from the stock solution (SIGMA, Cat: O1008, 3.15M), 
and was added to 50 ml of a 0.15 M (8.76 mg/ml) NaCl solution at 70°C to reach a 
concentration of 20 mM. Another 25 ml of 3.4 mM (224 mg/ml) bovine serum 
albumin (BSA) already dissolved in Dulbecco's modified Eagle's medium-F12 
(DMEM-F12) at 37°C was prepared, filtered by 0.22 μm filter (Millex-GP), and kept at 
37°C. Once the 20 mM oleic acid solution was fully mixed, 25 ml of it was then 
added to 25 ml 3.4 mM BSA-DMEM solution at 70°C, under constant agitation to 
provide the final solution of BSA-bound oleic acid (10 mM). The final solution of BSA-
bound oleic acid was adjusted to pH 7.4, sterilized by 0.22 μm filter (Millex-GP), and 
stored at -20°C for fatty acid treatments on cell lines. Materials used are listed in 
Table 6.3. Selected cells were grown under the same culture conditions and treated 
with a final concentration of 1 mM oleic acid, loading for 8, 24 and 48 hours. 
 
 
 
Table 6.3: Materials used for BSA-bound oleic/palmitic acids. 
Name Supplier 
Oleic acid SIGMA, Cat: O1008 Mwt 282.46; Density 
0.891/ml 
Palmitate (palmitic acid) SIGMA, Cat: P9767 
BSA SIGMA, Cat: A7030 
DMEM F-12 
(Dulbecco's modified Eagle's medium-F12) 
500ml 
Lonza, Cat: BE12-719F 
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6.2.1.4 Retinol/palmitate treatment on LX-2  
25 mg of retinol powder purchased from Sigma (Cat: R7632) was first dissolved in 1 
ml of ethanol to make the original stock at 87.2 mM, 25.8 µl of it was then diluted in a 
45 ml of 5% BSA-PBS solution to make the 50 µM BSA-bound retinol stock solution. 
The stock solution was adjusted to pH 7.4 and was sterilized by a 0.22 μm filter.  
Sodium palmitate (palmitic acid) was purchased from SIGMA (Cat: P9767). 278 mg 
palmitate was first dissolved in a 50 ml of 0.15 M NaCl solution (8.76mg/ml) at 70°C 
for 1h to reach a concentration of 20 mM. 25 ml of the palmitate solution was then 
added to another 25 ml solution of 3.4 mM BSA (224 mg/ml) already dissolved in 
DMEM-F12 and stored at 37°C. The 50 ml mixture was under constant agitation at 
70°C to make the final BSA-conjugated palmitate solution (10 mM). Afterwards, the 
final solution was adjusted to pH 7.4, sterilized using 0.22 μm filter (Millex-GP), and 
stored at -20°C (materials are listed in Table 6.3).  
The study design and the procedure for retinol/palmitate treatment of LX-2 are 
shown in Figure 6.1- 6.4. Cells were divided into 4 groups depending on the culture 
conditions: untreated (group A), treated with retinol 10 µM alone (group B), with 
palmitate 300 µM alone (group C) and group D treated with both retinol (10 µM) and 
palmitate (300 µM). Four different time points were selected as read-out references 
(0 hour, 12 hours, 24 hours, and 48 hours). It has been suggested that an increased 
retinol uptake within HSCs occurred in the presence of palmitate pre-incubation prior 
to retinol loading (Randolph and Ross, 1991; Vogel et al., 2000). Except for the 
group A and B, group C and D were therefore pre-incubated with palmitate (300 µM) 
for 12 hours prior to further incubation of palmitate or a mixture of retinol and 
palmitate, thus the actual durations of palmitate loading for these two groups were 0 
hour, 24 hours, 36 hours, and 60 hours. All the standard media or conditioned media 
(supplemented with either retinol, palmitate or both) were changed at the same time 
to minimise variations. Once the experiment was complete, cells were washed twice 
by 1X PBS and harvested for Western blotting, gene expression analysis and Oil red 
O staining. 
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Figure 6.1: Layout of study design and purposes for retinol or/and palmitate treatment on LX-2. 
PA, palmitate; RA, retinol. 
 
 
 
Figure 6.2: Study procedure for group B, LX-2 treated with retinol (10 µM) alone. 
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Figure 6.3: Study procedure for group C, LX-2 treated with palmitate (300 µM) alone. 
 
 
 
Figure 6.4: Study procedure for group D, LX-2 treated with both retinol (10 µM) and palmitate 
(300 µM). 
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6.2.1.5 Western-blotting 
A series of Western-blotting procedures including protein extraction, protein 
concentration determination, polyacrylamide gel electrophoresis of protein samples, 
electrophoretic blotting procedure of proteins separated by SDS-PAGE, blocking, 
probing and immunodetection of protein blots, and staining of the PVDF membrane 
are described thoroughly in section 2.4.3. The rabbit polyclonal anti-PNPLA3 was 
purchased from Abcam, Cambridge, UK (ab81874, with 1:900 dilution) and the rabbit 
polyclonal anti-GAPDH was purchased from Santa Cruz Biotechnology, Inc. (sc-
25778, with 1:25000 dilution). Two commercial anti-TM6SF2 were employed, the 
mouse polyclonal anti-TM6SF2 from Abcam (ab169629) and the rabbit polyclonal 
anti-TM6SF2 from ANTYBODY VERIFY (AAS00444C). 
 
6.2.1.6 Oil Red O staining  
Oil Red O is a fat-soluble dye used for staining of neutral triglycerides and lipids on 
frozen or paraffin tissues. Cells were fixed overnight using a 10% formalin solution 
(VWR, prolabo, Cat: 361387P), and were then incubated with 60% isopropanol 
(VWR, prolabo, Cat: 20842.330) for 5 min at room temperature after washing with 1 
ml of sterile water twice. Having been dried completely, cells were loaded with 1 ml 
of 60% Oil Red O working solution (6 parts of Oil Red O purchased from SIGMA 
(Cat: O-0625) and 4 parts of 100% isopropanol) and left on the bench for 10 min 
incubation at room temperature. At the final stage, cells were washed 4 times by 
sterile water, and all images were acquired under the microscope.  
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6.3 Results 
6.3.1 The role of PNPLA3 polymorphism rs738409 in vitro  
6.3.1.1 PNPLA3 rs738409 genotypes of selected cell lines 
To investigate the effect of PNPLA3-I148M in vitro three human hepatoma cell lines 
(Hep3B, HUH-7 and SNU182), one hepatoblastoma cell line (HepG2), primary 
human hepatocytes and one human hepatic stellate cell line (LX-2) were employed. 
Each cell line was genotyped for PNPLA3 rs738409. Interestingly, 50% of cell lines 
targeted are homozygous mutant (GG). Subsequently, the basal expression of 
PNPLA3 (both RNA and protein levels) among these cell lines were investigated and 
compared to primary human hepatocytes. Genotypes of PNPLA3 (rs738409) in 
these cell lines are listed in Table 6.4. 
 
6.3.1.2 Basal mRNA levels and protein expression of PNPLA3  
Primary hepatocytes and the five cell lines were characterized for PNPLA3 mRNA 
expression in triplicate. It should be noted that the primary hepatocytes used in this 
gene expression analysis were technical replicates (n=3) as they were isolated from 
a single donor whilst the other commercial cell lines were biological replicates (n=3). 
However, primary human hepatocytes showed the highest expression of PNPLA3, 
whereas the lowest level was found in LX-2. Using primary hepatocytes as the 
reference, PNPLA3 is highly expressed in primary hepatocytes compared to HepG2 
(P=0.001), HUH-7 (P=0.038), SNU182 (P=0.001), and LX-2 (P=0.02). No significant 
difference was found between Hep3B and primary hepatocytes (P=0.43). With 
regard to expression of PNPLA3, it is highly expressed in primary human 
hepatocytes compared to the others which shared a similar level, Figure 6.5 (this 
preliminary data contains a low n-value, n=1).  
 
 Table 6.4: PNPLA3 rs738409 genotypes of the selected cell lines. 
CC for homozygous wild-type and GG for homozygous mutant. 
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Figure 6.5: Basal messenger RNA levels and protein expression of PNPLA3 in HepG2, Hep3B, 
HUH-7, SNU182, LX-2 and primary human hepatocytes. (A) Basal mRNA levels of PNPLA3 (n=3) 
and (B) Western blot analysis of PNPLA3 (n=1) in the selected cell lines. (C) Densitometry 
based on Western blot results. Unpaired student T-test was used as the test for statistical 
significance test using 2-^delta CT values, with human hepatocytes as the reference. * 
represents p value <0.05. 
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6.3.2 The effect of oleic acid treatment on PNPLA3 expression in vitro 
To investigate differences in expression of PNPLA3 following fat loading in cells of 
different genotypes, two cell lines which possess two copies of common (C) or minor 
(G) allele respectively were selected: Hep3B homozygous wild-type CC and HUH-7 
homozygous mutant GG. Hep3B and HUH-7 were treated with the same culture 
condition, the medium supplemented with 1 mM BSA-bound oleic acid, and were fat-
loaded for the same time points of 8, 24, and 48 hours, Figure 6.6. 
For the experiments performed by using Hep3B (homozygous wild-type, CC), protein 
intensities were quantified by densitometry at three exposure times, 2, 5, and 17 
minutes (Figure 6.6. A). An increased expression of PNPLA3 was observed in 
Hep3B compared to the control 8 hours after start of treatment. However, this result 
could be affected by a bubble between the SDS gel and the blotting membrane, 
therefore no firm conclusion could be made upon this. Distinct alterations in 
expression of PNPLA3 were not detectable when comparisons were made between 
the untreated and the treated groups at the 24- and 48-hour time points.  
For the results of fat-loading on HUH-7 displayed in Figure 6.6 (B), the densitometric 
analyses were performed by three different exposure times, 15, 30 seconds, and 2 
minutes. Once again, no major differences could be identified in the protein level of 
PNPLA3 between each groups at the three time points.    
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Figure 6.6: Effect of oleic acid on expression of PNPLA3 in the selected cell lines. (A) Hep3B and (B) HUH-7 cells were treated for 8 hours, 24 hours, 
and 48 hours with 1 mM Oleic acid (n=1). The expression of PNPLA3 were visualised by Western blot analysis and quantified using densitometry 
at different time exposures (+ represents treated condition, CTL, control). 
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6.3.3 The effect of retinol/palmitate treatment on PNPLA3 expression in LX-2 
A recent study reported that PNPLA3 may be involved in retinyl-palmitate hydrolysis 
in hepatic stellate cells (HSC/LX-2), by demonstrating that a decreased expression 
of PNPLA3 coexisted with an increased lipid droplet accumulation in the presence of 
retinol and palmitate incubation for up to 48 hours (Pirazzi et al., 2014). To 
investigate the role of PNPLA3 in a fibrogenic cell type, I therefore performed a 
similar study to that from Pirazzi et al. but with LX-2 employed only to test the effect 
of retinol/palmitate treatment upon expression of PNPLA3. 
As described in section 6.2.1.4 (methods), this study is composed of 4 groups 
(untreated, treated with retinol or palmitate alone, and with both) for 4 time points (0, 
12, 24, 48 hours). The study design and procedure is shown in Figure 6.1.-6.4. At 
each time point, cells were harvested for RNA/protein extraction and Oil red O 
staining.  
Before reporting our results, the limitations of these preliminary data should be 
noted. A key limitation is that the cells were overly stressed by the incubations with 
palmitate (alone or in combination with retinol) due to the nature of saturated fat 
toxicity. In fact, the viability of LX-2 could only be maintained for 24 hours of 
incubation. Beyond this time point, the LX-2 were severely stressed and cell 
death/cell detachment from the flasks could be easily observed. The palmitate 
treatment of the LX-2 cells resulted in a strongly reduced RNA 280/260 ratio (data 
not shown) due to a large loss of cell numbers. Therefore, I focussed on analysing 
protein expression rather than gene expression as a more acceptable amount of 
protein extracted from the cells allowed Western blotting to be performed (results are 
displayed in Figure 6.7).  
Taken the results from those blots and densitometric data, an increased expression 
of PNPLA3 was found in the untreated controls and those treated with palmitate 
alone. The expression of PNPLA3 in those treated with retinol alone increased 
slightly at the beginning followed by a trend towards a decrease. Treatment with 
combined retinol and palmitate showed a reduced level of PNPLA3 in a time-
dependent manner, similar to the findings published by (Pirazzi et al., 2014).  
Lastly, Oil Red O staining was used to visualise intracellular neutral lipid content in 
LX-2 incubated with palmitate, retinol or both combined (Figure 6.8). No major 
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differences were detectable for the group incubated with retinol alone (Figure 6.8 - 
B). In regard to the groups treated with palmitate only (Figure 6.8 - C) or in 
combination with retinol (Figure 6.8 - D), it is clear that both palmitate and combined 
treatments induced intracellular lipid uptake in a time-dependent manner. However, 
reduced cell viability and cell loss after 24 hours incubation were observed with 
treatment by palmitate or both compounds during the experiment thus quantification 
of intracellular lipid accumulation was not comparable. Also noteworthy is that the 
study described in this section has only been conducted once, hence all data should 
be interpreted with caution.
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Figure 6.7: Effect of retinol/palmitate treatment on expression of PNPLA3 in LX-2 for 0, 12, 24, and 48 hours. (A) Exposure time for 50 seconds, and 
(B) exposure time for 2 minutes. The signal intensities presented by densitometric analyses with different time exposures are shown underneath. 
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Figure 6.8: Oil red O staining of LX-2 at 4 time points. (A) Untreated control, (B) LX-2 treated with 10 µM retinol alone, (C) LX-2 treated with 300 µM 
palmitate alone, (D) LX-2 treated with 10 µM retinol and 300 µM palmitate. Arrows showed above are the examples of stained lipids within the cells.
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6.3.4 The role of TM6SF2 rs58542926 polymorphism in vitro 
6.3.4.1 TM6SF2 rs58542926 genotypes of each cell line 
The functional study of TM6SF2-E167K is covered briefly in this thesis as it is an 
ongoing study. Primary human hepatocytes, human hepatoma and hepatic stellate 
cell lines (HepG2, Hep3B, HUH-7, SNU182 and LX-2) were genotyped for TM6SF2 
rs58542926 (results displayed in Table 6.5). All of them are homozygous wild-type 
(CC) except the SNU182 cells are heterozygotes (CT). A high genotype frequency of 
homozygous wild-type identified in the cell lines is conceivable as the minor allele 
frequency of this SNP is only 0.07, observed in a Northern European population 
(http://browser.1000genomes.org). Interestingly, the low frequency of minor allele (T) 
carriage among these cell line is also in line with the non-statistically significant 
association between rs58542926 C>T and NAFLD-related HCC (already described 
in Chapter 5).  
 
6.3.4.2 Basal mRNA levels and protein expression of TM6SF2
To get a general idea of TM6SF2 expression, quantitative gene expression (n=1) 
and Western blot analyses were used to investigate mRNA levels and protein 
expression of this gene in the aforementioned cell lines. All the cell lines used in this 
gene expression analysis were technical replicates. Primary human hepatocytes 
showed the highest expression level of TM6SF2, whereas HUH-7 are the second 
highest and the others shared a similar level of TM6SF2 mRNA (Hep3B, LX-2 and 
SNU182), Figure 6.9. The expression of TM6SF2 of these cell lines was tested by 
Western blot analysis. However, the two commercial antibodies employed in this 
study failed to detect the protein (data not shown).    
 
Table 6.5: TM6SF2 rs58542926 genotypes of the selected cell lines. 
CC for homozygous wild-type and CT for heterozygous. 
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Figure 6.9: Basal expression levels of TM6SF2 mRNA in the selected cell lines, n=1.  
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6.4 Discussion  
To investigate the functional significance of PNPLA3 (mainly) and TM6SF2, a series 
of preliminary in vitro studies were described in this chapter, including genotyping for 
both PNPLA3 rs738409 and TM6SF2 rs58542926 SNPs, the quantitative gene 
expression of endogenous mRNA levels and immunoblotting for protein expressions 
of the two genes, and fatty acids treatments with oleic acid/retinol/palmitate using 
human hepatoma, hepatoblastoma, and hepatic stellate cell lines.  
Regarding the study for PNPLA3 rs738409, 50% of the cell lines were identified as 
homozygous mutant (GG) whilst only 30% in homozygous wild-type (CC). Although 
the sample number of the cell lines employed is quite small, only 3 hepatoma cell 
lines and the primary hepatocytes were obtained from only one individual, enriched 
G-allele in these cell lines roughly mirrors the statistical association between the 
rs738409 variant and liver cancer. Investigations on mRNA/protein expression of 
PNPLA3 were subsequent performed to test any variations by different genotypes. 
Relatively high levels of PNPLA3 mRNA were observed in primary hepatocytes and 
Hep3B (homozygous wild-type for both) compared to the others either are 
heterozygous CG (SNU182) or homozygous mutant (HepG2, HUH-7, and LX-2). For 
the protein levels, PNPLA3 is once again highly expressed in the primary 
hepatocytes while the other cell lines possess a similar but lower level. Notably, the 
levels of PNPLA3 mRNA varied among the commercial cell lines however no major 
differences in expression of PNPLA3 were detected. This discrepancy of the 
expression patterns between mRNA and protein of PNPLA3 in those cell lines may 
be explained by the following points: 1) Cancer cells or artificial immortalized cells 
(LX-2) may have alterations in transcription/translation/metabolism process 
compared to primary cells. Several biological factors have been suggested may 
influence translational efficiency, including RNA secondary structure, weak Shine-
Dalgarmo sequence (imperfect complementarity to ribosomal RNA), blocking 
translation by regulatory proteins (i.e. R-protein) and small RNA, low ribosome 
occupancy, and codon bias. Additionally, protein turnover may also influence the 
correlation between mRNA and protein abundances as individual protein half-lives 
vary from seconds to hours (Maier et al., 2009). 2) Technical factors: varied sensitivity 
in methodology used for quantitative analysis of mRNA and protein. Real time PCR 
provides fast, precise and accurate results, by collecting data as the reaction is 
proceeding not measured at End-Point (plateau) as traditional PCR does. An 
increase in reporter fluorescent signal is directly proportional to the number of 
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amplicons generated thus it is more sensitive for DNA and RNA quantitation. On the 
contrary, Western blot is a semiquantitative technique with several processing-steps 
for protein detection. Various parameters during the processing steps may influence 
sensitivity of the results: blot transfer conditions, blot irregularities, concentration of 
antibodies and ECL substrate, exposure time, camera sensitivity, colour format and 
adjustments, band definition and background correction (Heidebrecht et al., 2009). 3) 
Ethnicity, genetic background may be one of the determinants which exert different 
levels of PNPLA3 expression, as HepG2 cells are derived from a Caucasian patient 
while Hep3B, HUH-7, SNU182 are from African American, Japanese, and Korean, 
respectively. Notably, LX-2 is a transfected cell line which was made immortal for 
research purposes (Xu et al., 2005), and the origin of this cell line remains elusive. 4) 
Complex disease trait is a phenotype contributed from more than one SNP, therefore 
other SNPs near rs738409 may also have effects on the expression of PNPLA3. 5) A 
coding SNP is generally considered to slightly alter function of a protein rather than 
changing expression. Though there is growing evidence for the significant role of 
PNPLA3 in severity of NAFLD, it is uncertain that whether under this amino acid 
substitution of PNPLA3-I148M, the other ‘rescue’ pathways in human body are 
activated to cover this subtle defect so as to maintain the original function or 
metabolic role that PNPLA3 is involved in.  
The next step after characterization of the cell lines for PNPLA3 rs738409 was to 
investigate whether any alteration/activation of PNPLA3 expression could be 
observed in response to fat loading by different genotypes as FFA metabolism is one 
of the key elements for NAFLD development (Ricchi et al., 2009), and PNPLA3 was 
suggested to mediate hydrolysis of acylglycerols with a strong preference for oleic 
acid as the acyl moiety (He et al., 2010; Huang et al., 2011). Additionally, studies 
also revealed that a decreased unsaturated/saturated fatty acid ratio in serum, fat 
and liver tissue was found in obese NAFLD patients (de Almeida et al., 2002; Videla 
et al., 2004). An in vitro study also reported that oleic acid (unsaturated FFA) was 
more steatogenic but less toxic than palmitate (saturated FFA) (Ricchi et al., 2009). 
Therefore, a preliminary study of oleic acid treatments on Hep3B (wild-type, 
PNPLA3-148I) and HUH-7 (mutant isoform, PNPLA3-148M) was performed with time 
points of 8, 24 and 48 hours selected. 
Although the previous in vitro studies on PNPLA3 showing an inactivated TG 
hydrolysis coexisted with intracellular fat deposition resulted from overexpression of 
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PNPLA3-148M under fat loading (He et al., 2010; Perttila et al., 2012a), no apparent 
effect on expression of PNPLA3 was in either the homozygous wild-type or 
homozygous mutant cells after treatment with oleic acid in the present study. Once 
again, this preliminary study has low n-value (n=1) thus no firm conclusion could be 
made, and the present data is not comparable to those studies mentioned above as 
the study designs such as cell type employed and procedure of overexpression are 
totally different. Replicate studies are definitely required, including further 
optimization of experimental conditions. These include the concentration and 
components of fatty acids applied and the duration of treatment. Other co-culture 
variables such as glucose or insulin could also be considered as PNPLA3 is 
regulated by ChREBP and SREBP-1c under hyperglycaemia and hyperinsulinemia, 
respectively, to promote de novo lipogenesis (Shimomura et al., 1999b; Rae-
Whitcombe et al., 2010; Perttila et al., 2012b).  
As PNPLA3 is highly expressed in HSCs, which have a key role in hepatic 
fibrogenesis and are the main reservoir of retinoids stored in lipid droplets (Senoo et 
al., 2010), and suggested to be regulated by retinol availability in human HSCs 
(Pirazzi et al., 2014), other fat loading experiments using retinol/palmitate/combined 
treatment on immortalized LX-2 cells were also performed in the present work to 
demonstrate the role of PNPLA3 in a fibrogenic cell type. In particular this was to 
further investigate the underlying mechanisms of the association between the 
PNPLA3 rs738409 variant and fibrosis. The study design is similar to the work by 
Pirazzi et al. with the difference that LX-2 cells were not only treated with retinol and 
palmitate but also with the palmitate separately. Our results showed that treatment 
with palmitate alone induced increased expression of PNPLA3 whilst a reduced level 
was found in the combined treatment with no effect was detectable under incubation 
with retinol alone. Although our data shares a similar trend with the work 
demonstrated by Pirazzi et al., the limitations of this present study should be 
considered; reduced cell viability due to palmitic toxicity together with low n-value of 1  
and it is therefore inappropriate to make a solid conclusion. Replicate experiments 
with optimised procedures are required to clarify whether PNPLA3 expression can be 
induced by retinol, palmitate or a combined effect as Pirazzi et al. only reported the 
combined effect of retinyl-palmitate on expression of PNPLA3 in primary human 
HSCs. Nonetheless, they stated that the same results were found in LX-2 with these 
data not included in the publication, though the absence of these data makes a direct 
comparison difficult. However, studies recently published provided more information 
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for the functional role of PNPLA3 in fibrogenesis; overexpression of wild-type 
PNPLA3 induced a reduction in secretion of proteins involved in extracellular matrix 
formation and remodelling, secretion of matrix metallopeptidase 2 and tissue inhibitor 
of metalloproteinase 1 and 2 (Pingitore et al., 2016). Conversly, PNPLA3-I148M 
potentiates the fibrogenic features of HSCs (Bruschi et al., 2017). 
To date, the majority of studies examining the functional role of PNPLA3 or TM6SF2 
in NAFLD involve either overexpression or knock-down of the protein, resulting in 
alterations in the entire protein level, which cannot completely reflect functional 
effects due to a SNP mutation. CRISPR/Cas9 may be a possible approach to 
address this issue, it is a nuclease guided by small RNAs through Watson-Crick base 
pairing with target DNA, representing a system that is markedly easier to design, 
highly specific, efficient and well-suited for high-throughput and multiplexed gene 
editing for a variety of cell types and organisms (Ran et al., 2013). By adopting 
CRISPR/Cas9, the ease of customization, higher targeting efficiency and the ability 
to facilitate multiplex genome editing (simply knock-in the SNP of interest), a greater 
precision and prediction in functional effect of one SNP could be easily achieved. 
Other challenges remain in targeting different organs or cell types to establish in vitro 
models for NAFLD. Lipotoxicity-mediated inflammation and prolonged liver injury by 
oxidative stress triggers proliferation/activation of hepatic progenitor cells which can 
differentiate into hepatocytes and cholangiocytes. Activated progenitor cells are 
correlated to ductular reaction initiating fibrosis via epithelial-mesenchymal transition 
contributing to the portal myofibroblast pool or production of chemotactic agents for 
inflammatory cells activating progenitor cells (Wruck et al., 2017). Macrophage-
derived foam cells due to excessive lipid deposition are also presented in 
progression to NASH (Walenbergh et al., 2013). By future work targeting cell types 
not only involving hepatocytes and HSCs but also hepatic progenitor cells or 
macrophages (Kupffer cells in the liver), and optimized experimental variables (fatty 
acid compositions and their saturation degree for instance) in combination with 
CRISPR/Cas9, the functional roles of PNPLA3 and TM6SF2 in NAFLD progression 
may be better assessed.  
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7.1   General discussion 
Non-alcoholic fatty liver disease represents a spectrum of progressive liver disease 
characterised by increased HTGC in the absence of excess alcohol consumption. It 
incorporates NASH, fibrosis and ultimately cirrhosis and is strongly associated with 
features of the metabolic syndrome (obesity, insulin resistance/T2DM and 
dyslipidaemia) (Anstee et al., 2013b). NAFLD is best considered as a complex 
disease trait resulting from a combination of environmental exposures acting on a 
susceptible polygenic background (Altshuler et al., 2008; Hirschhorn and Gajdos, 
2011; Anstee and Day, 2013). Although NAFLD is estimated to affect approximately 
one-third of the population in many developed countries, only a minority of patients 
exhibit progressive steatohepatitis leading to cirrhosis and/or hepatocellular 
carcinoma (HCC), suggesting that inter-patient genetic variations may exert a greater 
effect upon the pathogenesis of NAFLD (Anstee et al., 2013b; Loomba and Sanyal, 
2013). Therefore, investigation into the genetic contribution to NAFLD may be useful 
to determine those are at high risk in developing severe disease and possibly provide 
tailored surveillance. 
This thesis reports a series of studies examining the association of genetic variations 
in two genes patatin-like phospholipase domain-containing 3 (PNPLA3, rs738409 
c.444 C>G, p.I148M) and transmembrane 6 superfamily member 2, (TM6SF2, 
rs58542926 c.449 C>T, p.E167K) with severity of NAFLD and risk of NAFLD-
associated hepatocellular carcinoma (HCC). The patient cohort used is the largest 
histologically characterised NAFLD cohort assembled up to date and represents the 
full spectrum of disease from simple steatosis through steatohepatitis to advanced 
fibrosis and cirrhosis. Patients are of European-Caucasian descent (n=1,005) and 
were assembled during the FLIP (Fatty liver: Inhibition of Progression) project funded 
by the European Commission. To test the association between SNPs of interest and 
the end stage of NAFLD, another cohort of 100 Northern European Caucasian 
patients with primary HCC arising on a background of NAFLD was identified and 
were recruited from UK and Switzerland. As a comparator with NAFLD-related HCC 
population, a cohort of 275 biopsy-proven NAFLD patients of different stages of 
disease but without clinical evidence of HCC was also assembled. Healthy controls 
were not studied due to the invasive nature of liver-biopsy, hence the analyses were 
conducted comparing severity of disease within the NAFLD spectrum. This approach 
differs from most case-control studies where comparison is made to a normal healthy 
population. However, in the absence of non-invasive methods to establish absence 
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of NAFLD this would have required the conduct of liver biopsy in heathy people and 
so was not ethically appropriate or feasible.  
Using candidate gene association studies in the FLIP cohort to address first the role 
of PNPLA3, the rs738409 variant was significantly associated with steatosis (OR 
1.87, 95%CI 1.52-2.29, P=2.98x10-9), steatohepatitis (β 0.174±0.059, 95%CI 0.056-
0.291, P=0.0037) and fibrosis (OR 1.4, 95%CI 1.15-1.7, P=0.0006), independent of 
age at biopsy, gender, BMI and presence of T2DM. Our data supports the well-
established assertion that the PNPLA3 rs738409 is a major genetic determinant for 
susceptibility to NAFLD. Subsequently, adopting a case-control analysis in a cohort 
of 100 NAFLD-associated HCC and a cohort of 275 NAFLD patients without HCC, 
carriage of the rs738409 minor (G) allele was shown to significantly associate with an 
increased risk of developing NAFLD-associated HCC, independent of potential 
confounding factors including gender, age at diagnosis, T2DM, BMI, and presence of 
advanced fibrosis/cirrhosis (OR 2.26, 95%CI 1.23-4.14, P=0.0082). As 22-54% of 
NAFLD-HCC occur in the absence of cirrhosis (Sanyal et al., 2010; Ertle et al., 2011), 
the effect of PNPLA3 on HCC risk independent of degree of fibrosis was further 
examined selecting those patients with coexistent cirrhosis (NAFLD-HCC n=67, 
NAFLD-Cohort n=26). Here, although the study-group sizes were relatively small in 
this sub-analysis, the effect of rs739409 variant remained significantly associated 
with NAFLD-HCC (OR 2.06, 95%CI 1.07-3.94, Χ2 4.78, P=0.029). When the non-
cirrhotic group were studied however, the effect did not attain statistical significance, 
although this may be due to insufficient statistical power given that only 23 cases 
were available in non-cirrhotic HCC group.  
The work in this thesis not only confirms the association between PNPLA3 with 
NAFLD severity but also provides the most robust evidence to date of its association 
with HCC risk which was published in 2014 (Liu et al., 2014a). Several studies have 
validated the PNPLA3 effect on NAFLD-related HCC (Casper et al., 2016; 
Vespasiani-Gentilucci et al., 2016). It is well-acknowledged that NAFLD as a complex 
disease trait, unlike Mendelian disorders, is often considered an outcome attributed 
from multiple genetic modifiers, where each genetic variant may alone be insufficient 
to cause disease (Hirschhorn and Gajdos, 2011; Anstee and Day, 2013). Strikingly, a 
12-fold increased risk of HCC was demonstrated in our work for rs738409 minor (G) 
allele homozygotes relative to C-allele homozygotes (OR 12.19, 95%CI 6.89-21.58, 
P<0.0001), when comparing the genotype frequencies between the NAFLD-HCC 
155 
patients and an unselected UK general population sample (the MRC/Wellcome Trust 
UK 1958 Birth Cohort). In response to our data, Krawczyk et al. compared the effect 
of PNPLA3 to the monogenic condition hereditary haemochromatosis due to HFE 
rs1800562 (A>G, p.C282Y) as the rs738409 SNP carries such strong genetic effect. 
Their detailed comparison demonstrated that carriage of either variant confers a 
similar risk of HCC (Krawczyk et al., 2015). Although statistical techniques to assess 
proportion of variability explained by genetic variations are imperfect (Witte et al., 
2014), our data indicates a Population Attributable Risk (PAR) of PNPLA3 rs738409 
for HCC of 55% and an area under the receiver operator characteristics curve 
(AUROC) of 0.68 attributable to this variant (Liu et al., 2014a). Further supporting the 
independent role of PNPLA3 rs738409 as a risk factor for HCC, it is telling that other 
genetic variants that are strong modifiers of NAFLD severity and fibrosis progression 
such as TM6SF2 (Liu et al., 2014b), do not appear to confer an additional, 
independent increased risk of HCC (Liu et al., 2014b; Dongiovanni et al., 2015). We 
agree with Krawczyk et al. that PNPLA3 is an important genetic risk factor for liver 
disease. For the moment, we would however caution against a move towards 
considering “PNPLA3-associated NAFLD”, or by extension “PNPLA3-associated 
HCC”, as distinct, monogenic conditions analogous to HFE in haemochromatosis but 
rather suggest that PNPLA3 should be considered a strong modifier within a 
complex, polygenic disease trait that is subject both to genetic and substantial 
environmental influence (e.g. due to dietary factors and the intestinal microbiota) 
(Anstee et al., 2013b).  
Given the mounting evidence of an association between PNPLA3 and HCC (Burza et 
al., 2012; Trepo et al., 2014), it is timely to consider the clinical utility of PNPLA3 
genotyping to assist in patient risk stratification. It has been suggested that, 
assuming a sensitivity of 80%, an odds ratio of >50 is required to control false-
positive rates to an acceptable level of <10% (Manolio, 2013). A re-analysis of the 
data from our previously published article (Liu et al., 2014a) to assess 
sensitivity/specificity is shown in Table 7.1. Based on these data, the use of PNPLA3 
genotyping alone to positively predict risk of HCC is unlikely to be tenable. However, 
even in this HCC-enriched dataset, the negative predictive value was substantially 
greater, both within the NAFLD vs. NAFLD-HCC comparison and the NAFLD-HCC vs. 
unselected background population comparison, and so it may be that knowledge of 
PNPLA3 rs738409 genotype has utility to select out those individuals least likely to 
develop HCC and therefore least likely to benefit from surveillance. As Krawczyk et al. 
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suggest, studies addressing the interaction between PNPLA3 and HFE in 
determining HCC risk would be of great interest. Given the increasing prevalence of 
NAFLD-HCC and consequent clinical need for improved risk-stratification care 
pathways (Dyson et al., 2014), we would also suggest that large, prospective studies 
are needed urgently to validate our findings and to determine the utility and health-
economic merits of a multi-factorial risk stratification that incorporates PNPLA3 
rs738409 genotype along with other recognised risk factors for HCC.  
Recently, a novel non-synonymous SNP in TM6SF2 (rs58542926 c.449 C>T, 
p.Glu167Lys (E167K) was identified to be associated with 1H-MRS quantified HTGC 
by an exome-wide association study (Kozlitina et al., 2014). This variant has also 
been associated with dyslipidaemia and cardiovascular risk (Holmen et al., 2014). It 
was therefore pertinent to determine whether this variant also affected risk of 
steatohepatitis or fibrosis in NAFLD. Using the aforementioned cohorts (FLIP and 
NAFLD-HCC ones), our data demonstrated the first time that, in addition to its 
association with steatosis, the rs58542926 SNP is significantly associated with stage 
of fibrosis in NAFLD. P-values are P=5.57 x10-5, P=0.014, and P=6.36 x10-6 for our 
discovery (n=349), validation (n=725), and combined cohort (n=1,074), respectively 
(Liu et al., 2014b). Our data once again confirmed that the causal SNP showing a 
strong genetic signal on 19p13.11 region for steatotic association would actually be 
the TM6SF2 rs58542926 variant rather than the NCAN gene (rs2228603 C>T) that is 
in strong LD (D’=0.926, r2 =0.798) with TM6SF2 rs58542926.  
After our findings were published, this genetic effect of TM6SF2 rs58542926 has 
been well replicated, including a recent study carriage of this variant increased 
susceptibility to alcohol-induced cirrhosis (Buch et al., 2015). Relevance to simple 
steatosis has been confirmed in studies performed in adults (Dongiovanni et al., 2015; 
Sookoian et al., 2015; Wang et al., 2015; Zhou et al., 2015) and in paediatric patients 
(Mancina et al., 2015; Goffredo et al., 2016; Grandone et al., 2016). This variant not 
only influences initiation of steatosis but also steatohepatitis (necroinflammation and 
lobular ballooning) and our key finding - its effect upon fibrosis was also validated 
(Dongiovanni et al., 2015). Two studies from China (Wong et al., 2014) and 
Argentina (Sookoian et al., 2015) disagreed with our data by reporting no 
associations between rs58542926 and stage of fibrosis. The former study only used 
a community-based cohort rather than selecting individuals afflicted by NAFLD, given 
generally low MAF of TM6SF2 rs58542926 (MAF 0.07), they reported that this variant 
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has limited impact on NAFLD. Whereas the other Chinese group with a more 
appropriate study design demonstrated a positive association between NAFLD and 
rs58542926 (Wang et al., 2015).  
The current thesis confirms the association of PNPLA3 with NAFLD severity and 
provides novel evidence of its association with HCC risk. In addition, it demonstrates 
for the first time that TM6SF2 is associated with NAFLD-fibrosis severity. Certainly, 
our data needs further validation such as GWAS or candidate gene association study 
with a considerably larger sample size of NAFLD patients and healthy populations of 
different ethnicities to test whether these effects apply to all ethnic groups. Moreover, 
it would be worthwhile to investigate whether there is a joint effect of these two SNPs 
as one study performed in Chinese Han population reported the strong additive 
effects of the risk alleles of PNPLA3 and TM6SF2 with an overall significance 
between the number of risk alleles and NAFLD (OR 1.64, 95%CI 1.34–2.01, 
P=1.4×10-6) (Wang et al., 2016). Furthermore, it would be interesting to test whether 
carriers of the PNPLA3 rs738409 variant show a different response compared to 
those with wild-type genotypes to drugs currently under investigation for treatment of 
NAFLD such as Elafibranor (Ratziu et al., 2016).  
The association of PNPLA3 and NAFLD-HCC demonstrated in this thesis may 
provide a useful tool that the PNPLA3 rs738409 genotyping, acting upon a broader 
multi-factorial risk assessment, to identify those NAFLD patients that are at higher 
risk of advanced NAFLD and possibly HCC development (particularly homozygous 
mutant, GG) or those are at low risk of less progressive NAFLD (homozygous wild-
type, CC). It seems very unlikely that this approach alone could predict or exclude 
the occurrence of HCC, but might lower the possibility of HCC by early life style 
interventions. Ideally, if genotyping data was available at the early stage of NAFLD, 
patients could be encouraged to modify their life style including diet and physical 
activity and the frequency of targeted surveillance could be individualised. Given the 
current knowledge that CVD is closely associated with NAFLD and is a very common 
cause of death in these patients (Adams et al., 2005; Ekstedt et al., 2006; Targher et 
al., 2007b; Rafiq et al., 2009; Soderberg et al., 2010; Treeprasertsuk et al., 2012; 
Zhou et al., 2012), the dual role of the TM6SF2 rs58452926 SNP cannot be ignored; 
the minor T-allele is associated with increased risk of NAFLD while the common C-
allele is associated with dyslipidaemia and cardiovascular risk, making targeted 
advice on the basis of this genotype more difficult. However, genotyping for these 
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two genetic risk factors should be considered further as a means of stratifying clinical 
care. 
The functions of both PNPLA3 and TM6SF2 remain elusive despite numerous 
studies already preformed especially for PNPLA3. In spite of this, positive 
associations have been detected and well replicated in genetic studies. Further 
studies on the roles of both proteins are needed with better cell culture models and 
well-designed experimental conditions. Our group is currently conducting a GWAS on 
additional biopsy-proven NAFLD samples from Northern Europe (EPoS: Elucidating 
Pathways of Steatohepatitis) to identify more SNPs associated with NAFLD. Use of 
this larger (approx. 2000 case) cohort may lead to the discovery of novel genetic risk 
factors. In the meantime, use of CRISPR/Cas9 to knock-in the SNPs of interest could 
provide higher targeting efficiency and the ability to facilitate multiplex genome 
editing to further investigate functional roles of PNPLA3 and TM6SF2. A better 
understanding of these roles may lead to novel therapeutic approaches to NAFLD 
management in the future. 
 
 
Table 7.1: Reanalysis focusing on clinical utility of PNPLA3 genotype testing in HCC risk 
prediction. 
Cohorts (n) Genotype 
Comparison 
Sensitivity Specificity PPV* NPV* 
NAFLD-HCC (100) 
vs. NAFLD Cohort 
(275) 
GG vs CC: 51% 79% 47% 82% 
CG/GG vs CC: 72% 45% 32% 82% 
NAFLD-HCC (100) 
vs. Background 
UK Popn(1476) 
GG vs CC: 51% 92% 28% 97% 
CG/GG vs CC: 72% 59% 10% 97% 
*PPV, positive predictive value; NPV, negative predictive value. PPV/NPV will alter according to the 
underlying prevalence of HCC in population assessed.  
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